[go: up one dir, main page]

WO2018104558A1 - Acylated glp-1/glp-2 dual agonists - Google Patents

Acylated glp-1/glp-2 dual agonists Download PDF

Info

Publication number
WO2018104558A1
WO2018104558A1 PCT/EP2017/082284 EP2017082284W WO2018104558A1 WO 2018104558 A1 WO2018104558 A1 WO 2018104558A1 EP 2017082284 W EP2017082284 W EP 2017082284W WO 2018104558 A1 WO2018104558 A1 WO 2018104558A1
Authority
WO
WIPO (PCT)
Prior art keywords
peg3
aib
isoglu
carboxy
hexadecanoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2017/082284
Other languages
French (fr)
Inventor
Bjarne Due Larsen
Jonathan Griffin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zealand Pharma AS
Original Assignee
Zealand Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma AS filed Critical Zealand Pharma AS
Publication of WO2018104558A1 publication Critical patent/WO2018104558A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to acylated compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1 ) and GLP-2 (glucagon-like peptide 2) receptors.
  • the compounds find use, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.
  • Human GLP-2 is a 33-amino-acid peptide with the following sequence: Hy-His-Ala-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-lle-Leu- Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-lle-Asn-Trp-Leu-lle-Gln-Thr-Lys-lle-Thr-Asp-OH (SEQ ID NO:1 ).
  • GLP-2 binds to a single G-protein-coupled receptor belonging to the class II glucagon secretin family. GLP-2 is co-secreted with GLP-1 , oxyntomodulin and glicentin, in response to nutrient ingestion.
  • Human GLP-1 is produced as a 30-amino acid peptide with the following sequence: Hy-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val- Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-lle-Ala-Trp-Leu-Val-Lys-Gly-Arg- Gly-NH 2 (SEQ ID NO:2).
  • GLP-2 has been reported to induce significant growth of the small intestinal mucosal epithelium via the stimulation of stem cell proliferation in the crypts, and by inhibition of apoptosis in the villi (Drucker et al., 1996, Proc. Natl. Acad. Sci. USA 93: 791 1 - 7916). GLP-2 also has growth effects on the colon. Furthermore, GLP-2 inhibits gastric emptying and gastric acid secretion (Wojdemann et al., 1999, J. Clin.
  • Endocrinol. Metab. 84: 2513-2517 enhances intestinal barrier function (Benjamin et al., 2000, Gut 47: 1 12-1 19), stimulates intestinal hexose transport via the upregulation of glucose transporters (Cheeseman, 1997, Am. J. Physiol. R1965-71 ), and increases intestinal blood flow (Guan et al., 2003, Gastroenterology, 125: 136-147).
  • GLP-1 has been described as a physiological incretin hormone and has thus been mostly reported to augment an insulin response after an oral intake of glucose or fat. It is, however, generally understood that GLP-1 lowers glucagon concentrations, has beneficial effects on inhibition of fast bowel movements (Tolessa et al., 1998, Dig. Dis. Sci. 43(10): 2284-90), and slows gastric emptying.
  • WO2013/164484 discloses GLP-2 analogues which comprise one or more substitutions compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use.
  • WO2016/066818 describes peptides having dual agonist activity at the GLP-1 and GLP-2 receptors, and proposes medical uses thereof. However, there remains a need for further compounds which combine effective agonist activities at both receptors.
  • the present invention relates to compounds which have agonist activity at the GLP-1 (glucagon-like peptide 1 ) and GLP-2 (glucagon-like peptide 2) receptors, e.g. as assessed in in vitro potency assays.
  • GLP-1 glucagon-like peptide 1
  • GLP-2 glucagon-like peptide 2
  • Such compounds are referred to in this specification as "GLP-1/GLP-2 dual agonists", or simply "dual agonists”.
  • the compounds of the present invention have activities of both GLP-1 (7-36) and GLP-2 (1 -33).
  • GLP-1 /GLP-2 dual agonist represented by the formula:
  • R 1 is hydrogen (Hy), C1-4 alkyl (e.g. methyl), acetyl, formyl, benzoyl or trifluoroacetyl;
  • R 2 is NH2 or OH;
  • X * is a peptide having the formula I:
  • X2 is G or Aib
  • X5 is S orT
  • X7 is S orT
  • X8 isS, ⁇ or ⁇ ;
  • X10 is L, V, M or ⁇
  • X11 is A; S or ⁇ ;
  • X16 is E, G, A or ⁇
  • X17 isQ, E, K, L or ⁇ ;
  • X19 is A, VorS;
  • X21 is L, D or E
  • X27 is I, H, Q, Y, ⁇ or ⁇ ;
  • X28 is Q, E, H, Y, L, K, RorA;
  • X29 is H, Q, Y, K or ⁇ ;
  • X33 is D, E or is absent
  • U is absent or a sequence of 1-15 residues each independently selected from K, k, E, A, T, I, Land ⁇ ;
  • the molecule contains a minimum of one and a maximum of two ⁇ , wherein each ⁇ is independently a residue of k, K, R, Orn, Dap or Dab in which the side chain is conjugated to a substituent having the formula -Z 1 or -Z 2 -Z 1 ,
  • Z 1 - is CH 3 -(CH 2 )io-22-(CO)- or HOOC-(CH 2 )io-22-(CO)-;
  • -Z S2 - is -(Peg3)m- where m is 1 , 2, or 3;
  • -Z S3 - is a peptide sequence of 1-6 amino acid units independently selected from the group consisting of A, L, S, T, Y, Q, D, E, K, k, R, H, F and G;
  • peptide X of the formulae provided here are numbered according to their linear position from N- to C-terminus in the amino acid chain.
  • ⁇ -Ala and 3-Aminopropanoyl are used interchangeably. It was found that by substituting the T in position 29 in a GLP-1/GLP-2 dual agonist with an amino acid selected from the group consisting of H, Y, Q, K and ⁇ , e.g. H, Y and Q, the potency on both the GLP-1 receptor and the GLP-2 receptor can be improved.
  • X2 is G or Aib
  • X5 is S or T
  • X8 is S, D or ⁇
  • X2 is Aib
  • X5 is S or T
  • X8 is S or D
  • X33 s D, E or is absent is absent. If X33 is absent, U may also be absent.
  • the invention further provides a GLP-1/GLP-2 dual agonist represented by the formula:
  • R 1 is hydrogen (Hy), C1-4 alkyl (e.g. methyl), acetyl, formyl, benzoyl or trifluoroacetyl;
  • R 2 is NH2 or OH;
  • X * is a peptide having the formula II:
  • X2 is G or Aib
  • X5 is S or T
  • X8 is S, D or ⁇
  • X10 is L or ⁇
  • X1 1 is A; S or ⁇ ;
  • X16 is E, G or ⁇
  • X17 is Q, E, K or ⁇
  • X19 is A or S
  • X27 is I, H, Q, Y or ⁇ ;
  • X28 is Q or A
  • X29 is H, Q, Y or ⁇ ;
  • U is absent or a sequence of 1 -15 residues independently selected from K, k and ⁇ ; the molecule contains one and only one ⁇ , wherein ⁇ is a residue of K, R, Orn, Dap or Dab in which the side chain is conjugated to a substituent having the formula -Z 1 or -Z 2 -Z 1 ,
  • Z 1 - is CH 3 -(CH 2 )io-22-(CO)- or HOOC-(CH 2 )io-22-(CO)-;
  • -Z 2 - is selected from -Z S1 -, -Z S1 -Z S2 -, -Z S2 -Z S1 , and Z S2 wherein
  • -Z S2 - is -(Peg3)m- where m is 1 , 2, or 3; or a pharmaceutically acceptable salt or solvate thereof.
  • U is absent or K1-15 (i.e. a sequence of 1- 15 Lys residues.
  • X27 is Q and X29 is H, Q or Y; orX27 is Q and X29 is H.
  • X2 is Aib. Additionally or alternatively, X 11 is A. Additionally or alternatively X17 is Q. Additionally or alternatively X19 is A orX27 is I.
  • X2 is Aib and X17 is Q;
  • X27 is I and X28 is Q;
  • X2 is Aib
  • X5 is S and X17 is Q
  • X27 is I, X28 is Q and X29 is H;
  • X8 is S and X16 is ⁇ ;
  • X8 is D, X10 is ⁇ and X29 is H;
  • X8 is D, X11 is ⁇ and X29 is H;
  • X2 is Aib
  • X5 is S
  • X17 is Q
  • X27 is I
  • X28 is Q
  • X29 is H
  • X2 is Aib
  • X8 is S
  • X17 is Q
  • X27 is I
  • X28 is Q
  • X29 is H
  • X2 is Aib
  • X8 is D
  • X17 is Q
  • X27 is I
  • X28 is Q
  • X29 is H
  • X2 is Aib
  • X8 is S
  • X16 is ⁇
  • X19 is A
  • X29 is H.
  • X* may be a peptide having the formula III:
  • X2 is G or Aib
  • X8 isS, D or ⁇
  • X10 is L, ⁇ ;
  • X16 isE, ⁇ or ⁇ ;
  • X17 is Q, E or K
  • X19 is A, VorS;
  • X21 is D or E
  • X27 is I or ⁇
  • X28 is Q, E or A
  • X29 isH,Q, ⁇ or ⁇ ;
  • X33 is D, E or absent.
  • X2 is Aib
  • X5 is S or T
  • X8 is S or D
  • X10 is L, ⁇ ;
  • X11 is A
  • X15 is D or E
  • X16 is E or ⁇
  • X17 is Q or E
  • X19 is A, VorS;
  • X21 is D or E
  • X28 is Q or E
  • X29 isH,Q, ⁇ or ⁇ ;
  • X33 is D, E or absent.
  • X * may be a peptide having the formula IV:
  • X2 is G or Aib
  • X5 is S or T
  • X8 is S, D or ⁇
  • X10 is L, ⁇ ;
  • X16 is E, G or ⁇ ; X17 is Q or K;
  • X19 is A or S
  • X27 is I or ⁇
  • X28 is Q or A
  • X29 is H, Q, Y or ⁇
  • X28 is Q and X29 is H, Q or Y; or X28 is Q and X29 is H It is desirable that X2 is Aib. Additionally or alternatively X 1 1 is A. Additionally or alternatively X17 is Q. Additionally or alternatively X19 is A and/or X27 is I.
  • residues and/or combinations of residues may also be included
  • X16 is ⁇
  • X2 is Aib and X17 is Q;
  • X27 is I and X28 is Q;
  • X8 is D and X10 is ⁇ ;
  • X8 is D and X1 1 is ⁇ ;
  • X8 is S and X16 is ⁇ ;
  • X8 is D, X10 is ⁇ and X29 is H;
  • X8 is D, X1 1 is ⁇ and X29 is H;
  • X8 is S, X16 is ⁇ and X29 is H;
  • X2 is Aib
  • X5 is S and X17 is Q
  • X27 is I, X28 is Q and X29 is H;
  • X2 is Aib
  • X5 is S
  • X17 is Q
  • X27 is I
  • X28 is Q
  • X29 is H
  • X2 is Aib
  • X8 is S
  • X17 is Q
  • X27 is I
  • X28 is Q
  • X29 is H
  • X2 is Aib
  • X8 is D
  • X17 is Q
  • X27 is I
  • X28 is Q
  • X29 is H
  • X2 is Aib
  • X8 is S
  • X16 is ⁇
  • X19 is A
  • X29 is H.
  • X2 is Aib
  • X8 is D
  • X10 is ⁇
  • X2 is Aib
  • X8 is D
  • X10 is ⁇
  • X16 is E and X24 is A;
  • X2 is Aib, X8 is D, X10 is ⁇ , X16 is E and X29 is H;
  • X2 is Aib
  • X5 is S
  • X8 is D
  • X10 is ⁇
  • X1 1 is A
  • X16 is E
  • X17 is Q
  • X24 is A
  • X2 is Aib
  • X5 is S
  • X8 is D
  • X10 is ⁇
  • X1 1 is A
  • X16 is E
  • X17 is Q
  • X16 is ⁇ , X19 is A and X29 is H;
  • X2 is Aib
  • X8 is S
  • X16 is ⁇
  • X19 is A and X29 is H;
  • X2 is Aib
  • X8 is S
  • X16 is ⁇
  • X19 is A and X29 is H;
  • X2 is Aib
  • X5 is S
  • X8 is S
  • X10 is L
  • X1 1 is A
  • X16 is ⁇
  • X17 is Q
  • X2 is Aib
  • X5 is S
  • X24 is A
  • X29 is H.
  • X2 is Aib
  • X8 is S
  • X16 is ⁇
  • X19 is S
  • X29 is Y;
  • X2 is Aib
  • X8 is D
  • X16 is E
  • X24 is A
  • X29 is ⁇
  • X2 is Aib
  • X5 is S
  • X16 is E
  • X24 is A
  • X29 is ⁇ ;
  • X8 is S
  • X16 is ⁇
  • X19 is S
  • X29 is Y.
  • the sequence of the dual agonist (e.g. peptide X * ) has no more than 5 amino acid changes, e.g. no more than 4, no more than 3, no more than 2 or no more than 1 change relative to the amino acid sequence
  • the peptide X * in any of formulae I to IV may have the sequence
  • the peptide X * in any of formulae I to IV may have the sequence
  • K * indicates a lysine residue in which the side chain is conjugated to the substituent Z 1 - or Z 1 -Z 2 -.
  • X * may be a peptide having the formula V
  • X2 is G or Aib
  • X8 is D or S
  • X16 is E or G; X17 isQor K;
  • X29 is H, Q, KorY.
  • X2 is Aib and X8 is D;
  • X2 is Aib, and X29 is H;
  • X2 is Aib and X16 is E;
  • X2 is Aib and X17 is Q, or
  • the sequence of the dual agonist (e.g. peptide X*) has no more than 5 amino acid changes, e.g. no more than 4, no more than 3, no more than 2 or no more than 1 change relative to the amino acid sequence
  • the peptide X* in formula V may have the sequence: wherein K* indicates a lysine residue in which the side chain is conjugated to the substituent Z 1 - or Z 1 -Z 2 -.
  • X* is a peptide having the formula VI:
  • X2 is G or Aib
  • X5 is S orT
  • X8 isS, ⁇ or ⁇ ;
  • X10 is Lor ⁇
  • X11 is A; S or ⁇ ;
  • X17 isQ, E, ⁇ or ⁇ ;
  • X19 is A or S
  • X27 is I, H, Q, Y or ⁇ ;
  • X28 is Q or A;
  • X29 is H, Q, Y or ⁇ ;
  • U is a sequence of 1-15 residues independently selected from K, k and ⁇ ;
  • the molecule contains a minimum of one and a maximum of two ⁇ , wherein each ⁇ is independently a residue of k, K, R, Orn, Dap or Dab in which the side chain is conjugated to a substituent having the formula -Z 1 or-Z 2 -Z 1 , and U contains at least one residue ⁇ .
  • X2 is Aib
  • X5 is S orT
  • X8 is S or D
  • X2 is Aib
  • X5 is S
  • X8 is S
  • X10 is Lor ⁇
  • X15 is D
  • X16 is E or ⁇
  • X19 is A
  • X21 is D; X27 is I;
  • X29 is H
  • the dual agonist or pharmaceutically acceptable salt or solvate thereof is a molecule which contains one and only one ⁇ at one position of sequence U.
  • the dual agonist contains two residues ⁇ , the other is located within X * .
  • the sequence of the dual agonist has no more than 5 amino acid changes, e.g. no more than 4, no more than 3, no more than 2 or no more than 1 change relative to the amino acid sequence
  • the sequence of the dual agonist has no more than 5 amino acid changes, e.g. no more than 4, no more than 3, no more than 2 or no more than 1 change relative to the amino acid sequence
  • the peptide X * -U in formula VI may have the sequence:
  • the peptide X * -U in formula VI may have the sequence:
  • K * indicates a lysine residue in which the side chain is conjugated to the substituent Z1 - or Z1 -Z2-.
  • ⁇ is a Lys residue whose side chain is conjugated to the substituent Z 1 - or Z 1 -Z 2 -.
  • Z 1 - is dodecanoyl, tetradecanoyl, hexadecanoyl, octadecanoyl or eicosanoyl.
  • Z 1 - alone or in combination with -Z 2 -, is
  • 17-carboxyheptadecanoyl i.e. HOOC-(CH 2 )i 6 -(CO)-;
  • 19-carboxynonadecanoyl i.e. HOOC-(CH 2 )i8-(CO)-;
  • Z 2 is absent.
  • Z 2 comprises Z S1 alone or in combination with Z S2 and/or Z S3 In such embodiments:
  • -Z S2 - when present, is -(Peg3) m - where m is 1 , 2, or 3;
  • -Z S3 - is a peptide sequence of 1 -6 amino acid units independently selected from the group consisting of A, L, S, T, Y, Q, D, E, K, k, R, H, F and G, such as the peptide sequence KEK.
  • Z 2 may have the formula -Z S1 -Z S3 -Z S2 -, where Z S1 is bonded to Z 1 and Z S2 is bonded to the side chain of the amino acid component of ⁇ .
  • -Z 2 - is:
  • -Z 2 - is:
  • Z 1 -Z 2 - is [17-carboxy-heptadecanoyl]-isoGlu).
  • ⁇ may be K([17-carboxy- heptadecanoyl]-isoGlu).
  • Z 1 -Z 2 - is:
  • U represents a peptide sequence of 1 -15 residues each independently selected from K (i.e. L-lysine), k (i.e. D-lysine) E (Glu), A (Ala), T (Thr), I (lie), L (Leu) and ⁇ .
  • U may be 1 -10 amino acids in length, 1 -7 amino acids in length, 3-7 amino acids in length, 1 -6 amino acids in length, or 3-6 amino acids in length.
  • U includes at least one charged amino acid (K, k or E) and preferably two or more charged amino acids. In some embodiments it includes at least 2 positively charged amino acids (K or k), or at least 1 positively charged amino acid (K or k) and at least one negatively charged amino acid (E). In some embodiments, all amino acid residues of U (except for ⁇ , if present) are charged.
  • U may be a chain of alternately positively and negatively charged amino acids.
  • U comprises residues selected only from K, k, E and ⁇ .
  • U comprises residues selected only from K, k, and ⁇ .
  • all residues may have an L- configuration or all may have a D-configuration.
  • Further examples include ki-i 5 , ki. 10 and ki- 7 , e.g. k3, k 4 , k 5 , k6 and k 7 , especially k 5 and k6.
  • peptide sequences U include kkkkkK, KKEEEK, KEK, EKEKEK, EkEkEk, AKAAEK, AKEKEK and ATILEK.
  • sequence U contains a residue ⁇
  • sequences U include ⁇ 1-14- ⁇ , ⁇ 1-9- ⁇ and ⁇ 1-6- ⁇ , e.g., ⁇ 2- ⁇ , ⁇ 3- ⁇ , ⁇ 4 - ⁇ , ⁇ 5 - ⁇ and ⁇ - ⁇ , especially ⁇ 4 - ⁇ and ⁇ 5 .- ⁇ .
  • Yet further examples include ki-i 4 - ⁇ , ki-g- ⁇ , and ki- ⁇ - ⁇ , e.g.
  • Yet further examples include kkkkk ⁇ , ⁇ , ⁇ , ⁇ , EkEkE ⁇ ⁇ , AKEKEH ⁇ and ⁇ . ⁇ .
  • the peptide sequence U may increase stability of the dual agonist, and may also prolong the in vivo half life of the dual agonist, especially when in combination with a substituent Z 1 or Z 1 Z 2 (i.e. when the peptide U contains a residue ⁇ ).
  • the dual agonist contains two residues ⁇
  • the ⁇ located within U may be the C-terminal residue of U.
  • the dual agonist may have the peptide backbone (excluding R 1 and R 2 groups):
  • R 1 is Hy and/or R 2 is OH.
  • the dual agonist may be:
  • Cpd 7 Hy-H[Aib]DGSFSSELATILD[K(Octadecanoyl-isoGlu)]QAARDFIAWLIQHKITD-OH;
  • Cpd 8 Hy-H[Aib]DGSFSDELATILDEQAARDFIAWLIQ[K(Dodecanoyl-[3-Aminopropanoyl])]KITD-OH; or
  • Cpd 9 Hy-H[Aib]DGSFSSELATILD[K(Hexadecanoyl-isoGlu)]QASRDFIAWLIQYKITD-OH.
  • the dual agonist may be
  • Cpd 10 Hy-H[Aib]DGSFSDEL[K(dodecanoyl-[3-aminopropanoyl])]TILDEQAARDFIAWLIQHKITD-OH; or Cpd 11 : Hy-H[Aib]DGSFSDEL[K(hexadecanoyl-[3-aminopropanoyl])]TILDEQAARDFIAWLIQHKITD-OH.
  • the dual agonist may be:
  • Cpd 12 Hy-H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDKKKKK[K(Hexadecanoyl-isoGlu)]- [NH2];
  • Cpd 15 Hy-H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDkkkkk[k([17-carboxy-Heptadecanoyl]- isoGlu)]-[NH2].
  • the dual agonist may be:
  • Hy-H[Aib]DGSFSSE [K(Hexadecanoyl-isoGlu)]ATILDEQAARDFIAWLIQHKITD-OH; Cpd. 43 Hy-H[Aib]DGSFSSE[K([19-Carboxy-nonadecanoyl]- isoGlu)]ATILDEQAARDFIAWLIQHKITD-OH;
  • the dual agonist may be in the form of a pharmaceutically acceptable salt or solvate, such as a pharmaceutically acceptable acid addition salt.
  • the invention also provides a composition comprising a dual agonist of the invention, or a pharmaceutically acceptable salt or solvate thereof, together with a carrier, excipient or vehicle.
  • the carrier may be a pharmaceutically acceptable carrier.
  • the composition may be a pharmaceutical composition.
  • the pharmaceutical composition may be formulated as a liquid suitable for administration by injection or infusion. It may be formulated to achieve slow release of the dual agonist.
  • the present invention further provides a dual agonist of the invention for use in therapy.
  • a dual agonist of the present invention for use as a medicament.
  • a dual agonist of the invention for use in a method of medical treatment.
  • the invention also provides a dual agonist of the invention for use in a method of increasing intestinal mass, improving intestinal function (especially intestinal barrier function), increasing intestinal blood flow, or repairing intestinal damage or dysfunction, e.g. damage to the intestinal epithelium.
  • the invention also provides a dual agonist of the invention for use in a method of prophylaxis or treatment of malabsorption, ulcers (e.g. peptic ulcers, Zollinger-Ellison Syndrome, drug-induced ulcers, and ulcers related to infections or other pathogens), short-bowel syndrome, cul-de-sac syndrome, inflammatory bowel disease (Crohns disease and ulcerative colitis), irritable bowel syndrome (IBS), pouchitis, celiac sprue (for example arising from gluten induced enteropathy or celiac disease), tropical sprue, hypogammaglobulinemic sprue, and mucositis or diarrhea induced by chemotherapy or radiation theraphy, low grade inflammation, metabolic endotoxemia, primary biliary cirrhosis, fatty liver disease (including parental nutrition associated gut atrophy, PNALD (Parenteral Nutrition-Associated Liver Disease), NAFLD (Non- Alcoholic Fatty Liver Disease) and NASH (Non-A
  • the invention also provides a dual agonist of the invention for use in a method of reducing or inhibiting weight gain, reducing gastric emptying or intestinal transit, reducing food intake, reducing appetite, or promoting weight loss.
  • the invention also provides a dual agonist of the invention for use in a method of prophylaxis or treatment of obesity, morbid obesity, obesity-linked gallbladder disease, obesity-induced sleep apnea, inadequate glucose control, glucose tolerance, dyslipidaemia (e.g. elevated LDL levels or reduced HDL/LDL ratio), diabetes (e.g. Type 2 diabetes, gestational diabetes), pre-diabetes, metabolic syndrome or hypertension.
  • dyslipidaemia e.g. elevated LDL levels or reduced HDL/LDL ratio
  • diabetes e.g. Type 2 diabetes, gestational diabetes
  • pre-diabetes e.g. Type 2 diabetes, gestational diabetes
  • the invention also provides a method of increasing intestinal mass, improving intestinal function (especially intestinal barrier function), increasing intestinal blood flow, or repairing intestinal damage or dysfunction in a subject in need thereof, the method comprising administering a dual agonist of the invention to the subject.
  • the invention also provides a method of prophylaxis or treatment of malabsorption, ulcers (e.g. peptic ulcers, Zollinger-Ellison Syndrome, drug-induced ulcers, and ulcers related to infections or other pathogens), short-bowel syndrome, cul-de-sac syndrome, inflammatory bowel disease (Crohns disease and ulcerative colitis), irritable bowel syndrome (IBS), pouchitis, celiac sprue (for example arising from gluten induced enteropathy or celiac disease), tropical sprue,
  • hypogammaglobulinemic sprue diarrhea, low grade inflammation, metabolic endotoxemia, primary biliary cirrhosis, hepatitis and/or fatty liver disease (including parental nutrition associated gut atrophy, PNALD (Parenteral Nutrition-Associated
  • the invention also provides a method of reducing or inhibiting weight gain, reducing gastric emptying or intestinal transit, reducing food intake, reducing appetite, or promoting weight loss in a subject in need thereof, the method comprising
  • the invention also provides a method of prophylaxis or treatment of obesity, morbid obesity, obesity-linked gallbladder disease, obesity-induced sleep apnea, inadequate glucose control, glucose tolerance, dyslipidaemia (e.g. elevated LDL levels or reduced HDL/LDL ratio), diabetes (e.g. Type 2 diabetes, gestational diabetes), pre- diabetes, metabolic syndrome or hypertension in a subject in need thereof, the method comprising administering a dual agonist of the invention to the subject.
  • obesity morbid obesity, obesity-linked gallbladder disease, obesity-induced sleep apnea, inadequate glucose control, glucose tolerance, dyslipidaemia (e.g. elevated LDL levels or reduced HDL/LDL ratio), diabetes (e.g. Type 2 diabetes, gestational diabetes), pre- diabetes, metabolic syndrome or hypertension in a subject in need thereof, the method comprising administering a dual agonist of the invention to the subject.
  • dyslipidaemia e.g. elevated LDL levels or reduced HDL/LDL ratio
  • diabetes
  • the invention also provides the use of a dual agonist of the invention in the preparation of a medicament for increasing intestinal mass, improving intestinal function (especially intestinal barrier function), increasing intestinal blood flow, or repairing intestinal damage or dysfunction, e.g. damage to the intestinal epithelium.
  • the invention also provides the use of a dual agonist of the invention in the preparation of a medicament for prophylaxis or treatment of malabsorption, ulcers (e.g. peptic ulcers, Zollinger-Ellison Syndrome, drug-induced ulcers, and ulcers related to infections or other pathogens), short-bowel syndrome, cul-de-sac syndrome, inflammatory bowel disease (Crohns disease and ulcerative colitis), irritable bowel syndrome (IBS), pouchitis, celiac sprue (for example arising from gluten induced enteropathy or celiac disease), tropical sprue,
  • ulcers e.g. peptic ulcers, Zollinger-Ellison Syndrome, drug-induced ulcers, and ulcers related to infections or other pathogens
  • short-bowel syndrome e.g. peptic ulcers, Zollinger-Ellison Syndrome, drug-induced ulcers, and ulcers related to infections or other pathogens
  • cul-de-sac syndrome e.
  • hypogammaglobulinemic sprue diarrhea, low grade inflammation, metabolic endotoxemia, primary biliary cirrhosis, fatty liver disease (including parental nutrition associated gut atrophy, PNALD (Parenteral Nutrition-Associated Liver Disease), NAFLD (Non-Alcoholic Fatty Liver Disease) and NASH (Non-Alcoholic
  • GVHD graft versus host disease
  • the invention also provides the use of a dual agonist of the invention in the preparation of a medicament for reducing or inhibiting weight gain, reducing gastric emptying or intestinal transit, reducing food intake, reducing appetite, or promoting weight loss.
  • the invention also provides the use of a dual agonist of the invention in the preparation of a medicament for prophylaxis or treatment of obesity, morbid obesity, obesity-linked gallbladder disease, obesity-induced sleep apnea, inadequate glucose control, glucose tolerance, dyslipidaemia (e.g. elevated LDL levels or reduced HDL/LDL ratio), diabetes (e.g. Type 2 diabetes, gestational diabetes), pre-diabetes, metabolic syndrome or hypertension.
  • a further aspect provides a therapeutic kit comprising a dual agonist, or a
  • patient may be used interchangeably and refer to either a human or a non-human animal.
  • mammals such as humans, primates, livestock animals (e.g., bovines and porcines), companion animals (e.g., canines and felines) and rodents (e.g., mice and rats).
  • solvate in the context of the present invention refers to a complex of defined stoichiometry formed between a solute (in casu, a peptide or
  • the solvent in this connection may, for example, be water, ethanol or another pharmaceutically acceptable, typically small-molecular organic species, such as, but not limited to, acetic acid or lactic acid.
  • a solvate is normally referred to as a hydrate.
  • agonist refers to a substance (ligand) that activates the receptor type in question.
  • oarmino acids such as sarcosine (Sar), norleucine (NIe), a-aminoisobutyric acid (Aib), 2,3-diaminopropanoic acid (Dap), 2,4-diaminobutanoic acid (Dab) and 2,5-diaminopentanoic acid (ornithine; Orn).
  • Sar sarcosine
  • NIe norleucine
  • Dap 2,3-diaminopropanoic acid
  • Dab 2,4-diaminobutanoic acid
  • 2,5-diaminopentanoic acid ornithine; Orn.
  • Such other oarmino acids may be shown in square brackets "[ ]" (e.g. "[Aib]”) when used in a general formula or sequence in the present specification, especially when the rest of the formula or sequence is shown using the
  • amino acid residues in peptides of the invention are of the L-configuration.
  • D-configuration amino acids may be incorporated.
  • an amino acid code written with a small letter represents the D- configuration of said amino acid, e.g. "k” represents the D-configuration of lysine (K).
  • sequences disclosed herein are sequences incorporating a "Hy-”moiety at the amino terminus (N-terminus) of the sequence, and either an "-OH” moiety or an "- NH2" moiety at the carboxy terminus (C-terminus) of the sequence.
  • a C- terminal "-OH" moiety may be substituted for a C-terminal "-NH2" moiety, and vice- versa.
  • Percent (%) amino acid sequence identity with respect to the GLP-2 polypeptide sequences is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in the wild-type (human) GLP-2 sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Sequence alignment can be carried out by the skilled person using techniques well known in the art, for example using publicly available software such as BLAST, BLAST2 or Align software. For examples, see Altschul et al., Methods in Enzymology 266: 460-480 (1996) or Pearson et al., Genomics 46: 24-36, 1997.
  • the dual agonist has at least one GLP-1 and at least one GLP-2 biological activity.
  • Exemplary GLP-1 physiological activities include reducing rate of intestinal transit, reducing rate of gastric emptying, reducing appetite, food intake or body weight, and improving glucose control and glucose tolerance.
  • Exemplary GLP-2 physiological activities include causing an increase in intestinal mass (e.g. of small intestine or colon), intestinal repair, and improving intestinal barrier function (i.e. reducing permeability of the intestine). These parameters can be assessed in in vivo assays in which the mass and the permeability of the intestine, or a portion thereof, is determined after a test animal has been treated with a dual agonist.
  • the dual agonists have agonist activity at the GLP-1 and GLP-2 receptors, e.g. the human GLP-1 and GLP-2 receptors.
  • EC50 values for in vitro receptor agonist activity may be used as a numerical measure of agonist potency at a given receptor.
  • An EC50 value is a measure of the concentration (e.g. mol/L) of a compound required to achieve half of that compound's maximal activity in a particular assay.
  • a compound having a numerical EC50 at a particular receptor which is lower than the EC50 of a reference compound in the same assay may be considered to have higher potency at that receptor than the reference compound.
  • the dual agonist has an EC50 at the GLP-1 receptor (e.g. the human GLP-1 receptor) which is below 18.5 nM, below 15.0 nM, below 10.0 nM, below 5.0 nM, below 1.1 nM, below 1.0, below 0.9 nM, below 0.8 nM, below 0.7 nM, below 0.6 nM, below 0.5 nM, below 0.4 nM, below 0.3 nM, below 0.2 nM, below 0.1 nM, below 0.09 nM, below 0.08 nM, below 0.07 nM, below 0.06 nM, below 0.05 nM, e.g. when assessed using the GLP-1 receptor potency assay described in the Examples below
  • the dual agonist has an EC50 at the GLP-1 receptor which is between 0.05 nM and 18.5 nM, between 0.06 nM and 0.9 nM, between 0.07 nM and 0.8 nM, between 0.08 nM and 0.85 nM, between 0.09 nM and 0.7 nM, between 0.1 nM and 0.65 nM, between 0.2 nM and 0.6 nM, between 0.23 nM and 0.59 nM between 0.3 nM and 0.55 nM, between 0.4 nM and 0.5 nM, between 0.07 nM and 0.35 nM, between 0.08 nM and 0.3 nM, between 0.09 nM and 0.25 nM, between 0.1 nM and 0.2 nM, between 0.13 nM and 0.95 nM, between 0.2 nM and 0.95 nM, between 0.3 nM and 0.96 nM, between 0.4 nM and 0.5 nM,
  • the dual agonist has an EC50 at the GLP-1 receptor which is below 1.0 nM, below 0.9 nM, below 0.8 nM, below 0.7 nM, below 0.6 nM, below 0.5 nM, below 0.4 nM, below 0.3 nM, below 0.2 nM, below 0.1 nM, below 0.09 nM, below 0.08 nM, below 0.07 nM, below 0.06 nM, below 0.05 nM, below 0.04 nM, below 0.03 nM, below 0.02 nM, below 0.01 nM, below 0.009 nM, e.g. when assessed using the GLP-1 receptor potency assay described in the Examples below.
  • the dual agonist has an EC50 at the GLP-1 receptor which is between 0.009 nM and 1.0 nM, between 0.009 nM and 0.9 nM, between 0.009 nM and 0.8 nM, between 0.009 nM and 0.7 nM, between 0.01 nM and 0.65 nM, between 0.02 nM and 0.6 nM, between 0.023 nM and 0.59 nM between 0.03 nM and 0.55 nM, between 0.04 nM and 0.5 nM, 0.01 nM and 0.5 nM, between 0.05 nM and 0.45 nM, between 0.06 nM and 0.4 nM, between 0.62 nM and 0.888 nM, between 0.07 nM and 0.35 nM, between 0.08 nM and 0.3 nM, between 0.09 nM and 0.25 nM, between 0.1 nM and 0.2 nM, between 0.13 nM and 0.95
  • the dual agonist has an EC50 at the GLP-1 receptor which is between 1 .001 nM and 10 nM, between 1 .01 nM and 10 nM, between 1.1 nM and 10 nM, between 1 .2 nM and 9.0 nM, between 1 .5 nM and 8.0 nM, between 1 .6 nM and 6.0 nM, between 1.7 nM and 5.0 nM, between 1 .8 nM and 2.0 nM, between 1.9 nM and 10.0 nM, between 2.0 nM and 9.5 nM, between 2.5 nM and 8.5 nM, between 3.0 nM and 7.5 nM, between 3.5 nM and 8.5 nM, between 4.0 nM and 5.0 nM, between 1.1 nM and 1 .9 nM, between 1.2 nM and 1.8 nM, between 1 .3 nM and 1 .7 nM,
  • the dual agonist has an EC50 at the GLP-1 receptor which is above 10.0 nM, above 10.01 nM, above 10.5 nM, above 1 1.0 nM, above 1 1 .5 nM, above 12.0 nM, above 12.5 nM, above 13.0 nM, above 13.5 nM, above 14.0 nM, above 14.5 nM, above 15 nM, above 15.5 nM, above 16 nM, above 20 nM, above 25 nM, above 50 nM, above 100 nM, above 200 nM, above 300 nM, above 400 nM, above 500 nM, e.g. when assessed using the GLP-1 receptor potency assay described in the Examples below.
  • the dual agonist has an EC50 at the GLP-1 receptor which is between 10.0 nM and 500 nM, between 12.0 nM and 400 nM, between 14.0 nM and 200 nM, between 15.0 nM and 100 nM, between 20 nM and 50 nM, between 30 nM and 40 nM, between 1 1 .0 nM and 75 nM, between 12.0 nM and 60 nM, between 13.0 nM and 50 nM, between 14.0 nM and 40 nM, between 12.0 nM and 13.0 nM, between
  • GLP-1 agonist activity may be derived by comparing the potency of a dual agonist with the potency of a known (or reference) GLP-1 agonist when both are measured in the same assay.
  • the relative potency at the GLP-1 receptor may be defined as:
  • the reference GLP-1 agonist may, for example, be human GLP-1 (7-37), liraglutide (NN221 1 ; Victoza), or Exendin-4, but is preferably liraglutide.
  • the relative potency will be between 0.001 and 100, e.g. between 0.001 and 10, between 0.001 and 5, between 0.001 and 1 , between 0.001 and 0.5, between 0.001 and 0.1 , between 0.001 and 0.05, between 0.001 and 0.01 or between 0.001 and 0.5; between 0.01 and 10, between 0.01 and 5, between 0.01 and 1 , between 0.01 and 0.5, between 0.01 and 0.1 , or between 0.01 and 0.05; between 0.05 and 10, between 0.05 and 5, between 0.05 and 1 , between 0.05 and 0.5, or between 0.05 and 0.1 ; between 0.1 and 10, between 0.1 and 5, between 0.1 and 1 , or between 0.1 and 0.5; between 0.5 and 10, between 0.5 and 5, or between 0.5 and 1 ; between 1 and 10, or between 1 and 5; or between 5 and 10.
  • the dual agonists described in the examples below may have a relative potency (using liraglutide as a reference) between 0.001 and 1 , between 0.001 and 0.5;
  • the dual agonists of the invention have higher potency at the GLP-1 receptor (e.g. the human GLP-1 receptor) than wild type human GLP-2 (hGLP-2 (1 - 33)) or [Gly2]-hGLP-2 (1 -33) (i.e. human GLP-2 having glycine at position 2, also known as teduglutide).
  • the relative potency of the dual agonists at the GLP-1 receptor compared to hGLP-2 (1 -33) or teduglutide is greater than 1 , typically greater than 5 or greater than 10, and may be up to 100, up to 500, or even higher.
  • the dual agonist has an EC50 at the GLP-2 receptor which is below 1.0 nM, below 0.9 nM, below 0.8 nM, below 0.7 nM, below 0.6 nM, below 0.5 nM, below 0.4 nM, below 0.3 nM, below 0.2 nM, below 0.1 nM, below 0.09 nM, below 0.08 nM, below 0.07 nM, below 0.06 nM, below 0.05 nM, below 0.04 nM, below 0.03 nM, below 0.02 nM, below 0.015, below 0.01 nM, below 0.009 nM, below 0.008 nM, below 0.007 nM, below 0.006 nM, or below 0.005 nM, below 0.003 nM, or below 0.002 nM, e.g. when assessed using the GLP-2 receptor potency assay described in the Examples below.
  • the dual agonist has an EC50 at the GLP-2 receptor which is between between 0.002 and 1 .0 nM, between 0.005 nM and 1.0 nM, between 0.006 nM and 0.9 nM, between 0.007 nM and 0.8 nM, between 0.008 nM and 0.85 nM, between 0.009 nM and 0.7 nM, between 0.01 nM and 0.65 nM, between 0.02 nM and 0.6 nM, between 0.023 nM and 0.59 nM between 0.03 nM and 0.55 nM, between 0.04 nM and 0.5 nM, between 0.05 nM and 0.45 nM, between 0.06 nM and 0.4 nM, between 0.62 nM and 0.888 nM, between 0.07 nM and 0.35 nM, between 0.08 nM and 0.3 nM, between 0.09 nM and 0.25 nM, between 0.1 nM
  • GLP-2 agonist activity may be derived by comparing the potency of a dual agonist with the potency of a known (or reference) GLP-2 agonist when both are measured in the same assay.
  • the relative potency at the GLP-2 receptor may be defined as:
  • a value of 1 indicates that the dual agonist and reference agonist have equal potency
  • a value of >1 indicates that the dual agonist has higher potency (i.e. lower EC50) than the reference agonist
  • a value of ⁇ 1 indicates that the dual agonist has lower potency (i.e. higher EC50) than the reference agonist.
  • the reference GLP-2 agonist may, for example, be human GLP-2(1 -33) or teduglutide ([Gly2]-hGLP-2 (1 -33)).
  • the relative potency will be between 0.001 and 100, e.g.
  • the dual agonists described in the examples below may have a relative potency (using teduglutide as a reference) a relative potency between 0.01 and 1 .5, between 0.01 and 1 , between 0.01 and 0.5, or between 0.01 and 0.1.
  • the dual agonists of the invention have higher potency at the GLP-2 receptor (e.g. the human GLP-2 receptor) than human GLP-1 (7-37), liraglutide
  • the relative potency of the dual agonists at the GLP-1 receptor compared to human GLP-1 (7-37), liraglutide (NN221 1 ; Victoza), or Exendin-4 is greater than 1 , typically greater than 5 or greater than 10, and may be up to 100, up to 500, or even higher.
  • the absolute potencies of the dual agonists at each receptor are much less important than the balance between the GLP-1 and GLP-2 agonist activities.
  • it is perfectly acceptable for the absolute GLP-1 or GLP-2 potency to be lower than that of known agonists at those receptors, as long as the dual agonist compound exerts acceptable relative levels of potency at both receptors. Any apparent deficiency in absolute potency can be compensated by an increased dose if required
  • the dual agonist of the present invention contains a residue ⁇ which comprises a residue of Lys, Arg, Orn, Dap or Dab in which the side chain is conjugated to a substituent Z 1 - or Z 1 -Z 2 - wherein Z 1 represents a moiety CH3-(CH2)io-22-(CO)- or HOOC-(CH2)io-22-(CO)- and Z 2 when present represents a spacer.
  • the spacer Z 2 is selected from
  • Z S1 is isoGlu, ⁇ -Ala, isoLys, or 4-aminobutanoyl
  • Z S2 is -(Peg3)m- where m is 1 , 2, or 3;
  • Z S3 - is a peptide sequence of 1 -6 amino acid units selected from the group consisting of A, L, S, T, Y, Q, D, E, K, k, R, H, F and G.
  • hydrocarbon chain of Z 1 binds albumin in the blood stream, thus shielding the dual agonists of the present invention from enzymatic degradation, which can enhance the half-life of the dual agonists.
  • half-life refers to the time taken for the
  • concentration of the GLP-1/GLP-2 dual agonist to reduce by 50%, in vivo, for example due to degradation of the dual agonist and/or clearance or sequestration of the dual agonist by natural mechanisms.
  • Increasing half-life and/or decreasing the clearance refers to increasing the time taken for the dual agonist to be eliminated from the body. For the dual agonists of the invention this entails an extended duration of
  • the pharmacokinetic properties of the dual agonists of the invention may suitably be determined in vivo in pharmacokinetic (PK) studies. Such studies are conducted to evaluate how pharmaceutical compounds are absorbed, distributed, and eliminated in the body, and how these processes affect the concentration of the compound in the body, over the course of time.
  • PK pharmacokinetic
  • the half-life of a GLP-1/GLP-2 dual agonist is increased if its functional activity persists, in vivo, for a longer period than e.g. the commercial available GLP-2 molecule or teduglutide.
  • the half-life of the dual agonist is increased by at least 2 fold, such as at least 3 fold, such as at least 4 fold, such as at least 6 fold, such as at least 7 fold, such as at least 10 fold, such as at least 15 fold, or such as at least 25 fold where terminal half-life (T1 ⁇ 2) in vivo in mice is determined after i.v. or s.c. administration.
  • the plasma terminal elimination half-life (T1 ⁇ 2) is determined as ln(2)/ ⁇ where ⁇ is the magnitude of the slope of the log linear regression of the log concentration versus time profile during the terminal phase, e.g. as described in Examples below.
  • the GLP-1/GLP-2 dual agonist has a half-life of at least 2 hours, such as at least 2.5 hours, such as at least 4 hours, such as at least 5 hours, such as at least 6 hours, such as at least 7 hours, such as at least 8 hours, such as at least 9 hours, such as at least 10 hours or more, where terminal half-life (T1 ⁇ 2) in vivo in mice is determined after i.v. or s.c. administration.
  • the plasma terminal elimination half-life (T1 ⁇ 2) is determined as ln(2)/ ⁇ where ⁇ is the magnitude of the slope of the log linear regression of the log concentration versus time profile during the terminal phase, e.g. as described in Examples below.
  • the substituent may also modulate the potency of the dual agonists, with respect to the GLP-2 receptor and/or the GLP-1 receptor.
  • the substituent Z 1 - or Z 1 -Z 2 - is conjugated to the functional group at the distal end of the side-chain from the alpha-carbon of the relevant amino acid residue.
  • the normal ability of the amino acid (Lys, Arg, Orn, Dab, Dap) side-chain in question to participate in interactions mediated by that functional group e.g. intra- and inter-molecular interactions
  • the overall properties of the dual agonist may be relatively insensitive to changes in the actual amino acid conjugated to the substituent.
  • any of the residues Lys, Arg, Orn, Dab, or Dap may be present at any position where ⁇ is permitted.
  • the amino acid to which the substituent is conjugated is Lys or Orn.
  • the moiety Z 1 may be covalently bonded to the functional group in the amino acid side-chain, or alternatively may be conjugated to the amino acid side-chain functional group via a spacer Z 2 .
  • conjugated is used here to describe the covalent attachment of one identifiable chemical moiety to another, and the structural relationship between such moieties. It should not be taken to imply any particular method of synthesis.
  • bonds between Z 1 , Z S1 , Z S2 , Z S3 and the amino acid side chain to which the substituent is bound are peptidic.
  • the units may be joined by amide condensation reactions.
  • Z 1 comprises a hydrocarbon chain having from 10 to 24 carbon (C) atoms, such as from 10 to 22 C atoms, e.g. from 10 to 20 C atoms. Preferably, it has at least 10 or at least 1 1 C atoms, and preferably it has 20 C atoms or fewer, e.g. 18 C atoms or fewer.
  • the hydrocarbon chain may contain 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms. For example, it may contain 18 or 20 carbon atoms.
  • Z 1 is a group selected from dodecanoyl, tetradecanoyl, hexadecanoyi, octadecanoyi and eicosanoyi, preferably hexadecanoyi, octadecanoyi or eicosanoyi, more preferably octadecanoyi or eicosanoyi.
  • Z 1 groups are derived from long-chain saturated ⁇ , ⁇ -dicarboxylic acids of formula HOOC-(CH2)i2-22-COOH, preferably from long-chain saturated ⁇ , ⁇ - dicarboxylic acids having an even number of carbon atoms in the aliphatic chain.
  • Z 1 may be:
  • 17-carboxyheptadecanoyl i.e. HOOC-(CH 2 )i 6 -(CO)-;
  • 19-carboxynonadecanoyl i.e. HOOC-(CH2)i8-(CO)-;
  • Z 1 may be conjugated to the amino acid side-chain by a spacer Z 2 .
  • the spacer is attached to Z 1 and to the amino acid side-chain.
  • the spacer Z 2 has the formula
  • -Z S2 - is -(Peg3)m- where m is 1 , 2, or 3;
  • S3 - is a peptide sequence of 1 -6 amino acid units independently selected from the group consisting of A (Ala), L (Leu), S (Ser), T (Thr), Y (Tyr), Q (Gin), D (Asp), E (Glu), K (L-Lys), k (D-Lys), R (Arg), H (His), F (Phe) and G (Gly).
  • isoGlu and “isoLys” indicate residues of amino acids which participate in bonds via their side chain carboxyl or amine functional groups. Thus isoGlu participates in bonds via its alpha amino and side chain carboxyl group, while isoLys participates via its carboxyl and side chain amino groups.
  • ⁇ -Glii and “isoGlu” are used interchangeably.
  • Peg3 is used to refer to an 8-amino-3,6-dioxaoctanoyl group.
  • Z S3 may, for example, be 3 to 6 amino acids in length, i.e. 3, 4, 5 or 6 amino acids in length.
  • the amino acids of Z S3 are independently selected from K, k, E, A, T, I and L, e.g. from K, k, E and A, e.g. from K, k and E.
  • Z S3 includes at least one charged amino acid (K, k, R or E, e.g. K, k or E) and preferably two or more charged amino acids. In some embodiments it includes at least 2 positively charged amino acids (K, k or R, especially K or k), or at least 1 positively charged amino acid (K, k or R, especially K or k) and at least one negatively charged amino acid (E). In some embodiments, all amino acid residues of Z S3 are charged. For example, Z S3 may be a chain of alternately positively and negatively charged amino acids.
  • Z S3 moieties examples include KEK, EKEKEK, kkkkkk, EkEkEk, AKAAEK,
  • -Z 2 - is -Z S1 - or -Z s1 -Z S2 -; in other words, -Z 2 - is selected from: isoGlu(Peg3) 0 - 3 ;
  • substituents Z 1 - include
  • -Z 2 - may be -Z S1 -, -Z S1 -Z S2 -, -Z S3 -Z S1 -, -Z S1 -Z S3 -, -Z S1 -Z S3 -Z S2 -, -Z S3 -Z S2 - Z S1 - or Z S3 -.
  • -Z 2 - may be selected from the group consisting of:
  • KEK (4-aminobutanoyl); isoGlu(KEK);
  • substituents Z 1 -Z 2 - include:
  • substituents Z1 -Z2 include:
  • More preferred substituents Z 1 -Z 2 - include:
  • ⁇ comprising different substituents (fatty acids, FA), conjugated to the amino acid side-chain, optionally by a spacer, are illustrated below:
  • the side chain of the Lys residue is covalently attached to the side-chain carboxyl group of the isoGlu spacer -Z2- (-Z S1 -) via an amide linkage.
  • hexadecanoyi group (Z 1 ) is covalently attached to the amino group of the isoGlu spacer via an amide linkage.
  • a dual agonist of the invention may be synthesized or produced in a number of ways, including for example, a method which comprises
  • the precursor peptide may be modified by introduction of one or more non- proteinogenic amino acids, e.g. Orn, Dap, or Dab, introduction of a lipophilic substituent Z1 or Z1 -Z2- at a residue ⁇ , introduction of the appropriate terminal groups R1 and R2, etc.
  • non-proteinogenic amino acids e.g. Orn, Dap, or Dab
  • introduction of a lipophilic substituent Z1 or Z1 -Z2- at a residue ⁇ introduction of the appropriate terminal groups R1 and R2, etc.
  • Expression is typically performed from a nucleic acid encoding the precursor peptide, which may be performed in a cell or a cell-free expression system comprising such a nucleic acid.
  • the nucleic acid fragments encoding the precursor peptide will normally be inserted in suitable vectors to form cloning or expression vectors.
  • the vectors can, depending on purpose and type of application, be in the form of plasmids, phages, cosmids, mini-chromosomes, or virus, but also naked DNA which is only expressed transiently in certain cells is an important vector.
  • Preferred cloning and expression vectors are capable of autonomous replication, thereby enabling high copy-numbers for the purposes of high-level expression or high-level replication for subsequent cloning.
  • an expression vector comprises the following features in the 5' ⁇ 3' direction and in operable linkage: a promoter for driving expression of the nucleic acid fragment, optionally a nucleic acid sequence encoding a leader peptide enabling secretion (to the extracellular phase or, where applicable, into the periplasma), the nucleic acid fragment encoding the precursor peptide, and optionally a nucleic acid sequence encoding a terminator. They may comprise additional features such as selectable markers and origins of replication. When operating with expression vectors in producer strains or cell lines it may be preferred that the vector is capable of integrating into the host cell genome. The skilled person is very familiar with suitable vectors and is able to design one according to their specific requirements.
  • the vectors of the invention are used to transform host cells to produce the precursor peptide.
  • Such transformed cells can be cultured cells or cell lines used for propagation of the nucleic acid fragments and vectors, and/or used for recombinant production of the precursor peptides.
  • Preferred transformed cells are micro-organisms such as bacteria [such as the species Escherichia (e.g. E. coli), Bacillus (e.g. Bacillus subtilis), Salmonella, or Mycobacterium (preferably non-pathogenic, e.g. M. bovis BCG), yeasts (e.g., Saccharomyces cerevisiae and Pichia pastoris), and protozoans.
  • the transformed cells may be derived from a multicellular organism, i.e. it may be fungal cell, an insect cell, an algal cell, a plant cell, or an animal cell such as a mammalian cell.
  • the transformed cell is capable of replicating the nucleic acid fragment of the invention.
  • Cells expressing the nucleic fragment can be used for small-scale or large-scale preparation of the peptides of the invention.
  • An aspect of the present invention relates to a composition comprising a dual agonist according to the invention, or a pharmaceutically acceptable salt or solvate thereof, together with a carrier.
  • the composition is a pharmaceutical composition and the carrier is a pharmaceutically acceptable carrier.
  • the present invention also relates to a pharmaceutical composition comprising a dual agonist according to the invention, or a salt or solvate thereof, together with a carrier, excipient or vehicle.
  • the dual agonist of the present invention may be formulated as compositions or pharmaceutical compositions prepared for storage or administration, and which comprise a therapeutically effective amount of a dual agonist of the present invention, or a salt or solvate thereof.
  • Suitable salts formed with bases include metal salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium or magnesium salts; ammonia salts and organic amine salts, such as those formed with morpholine, thiomorpholine, piperidine, pyrrolidine, a lower mono-, di- or tri-alkylamine (e.g., ethyl-tert-butyl-, diethyl-, diisopropyl-, triethyl-, tributyl- or dimethylpropylamine), or a lower mono-, di- or tri-(hydroxyalkyl)amine (e.g., mono-, di- or triethanolamine).
  • Internal salts may also be formed.
  • salts can be formed using organic or inorganic acids.
  • salts can be formed from the following acids: formic, acetic, propionic, butyric, valeric, caproic, oxalic, lactic, citric, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, phthalic, hydrochloric, hydrobromic, phosphoric, nitric, sulphuric, benzoic, carbonic, uric, methanesulphonic, naphthalenesulphonic, benzenesulphonic, toluenesulphonic, p-toluenesulphonic (i.e.
  • a pharmaceutical composition of the invention is one wherein the dual agonist is in the form of a pharmaceutically acceptable acid addition salt.
  • a "therapeutically effective amount" of a dual agonist compound or pharmaceutical composition thereof of the present invention will vary depending upon, inter alia, the age, weight and/or gender of the subject (patient) to be treated. Other factors that may be of relevance include the physical characteristics of the specific patient under consideration, the patient's diet, the nature of any concurrent medication, the particular compound(s) employed, the particular mode of administration, the desired pharmacological effect(s) and the particular therapeutic indication.
  • a therapeutically effective amount refers to an amount which reduces symptoms of a given condition or pathology, and preferably which normalizes physiological responses in an individual with that condition or pathology. Reduction of symptoms or normalization of physiological responses can be determined using methods routine in the art and may vary with a given condition or pathology.
  • a therapeutically effective amount of one or more dual agonists, or pharmaceutical compositions thereof is an amount which restores a measurable physiological parameter to substantially the same value (preferably to within 30%, more preferably to within 20%, and still more preferably to within 10% of the value) of the parameter in an individual without the condition or pathology in question.
  • such human doses of the active dual agonist may be between about 0.01 pmol/kg and 500 ⁇ /kg body weight, between about 0.01 pmol/kg and 300 ⁇ /kg body weight, between 0.01 pmol/kg and 100 ⁇ /kg body weight, between 0.1 pmol/kg and 50 ⁇ /kg body weight, between 1 pmol/kg and 10 ⁇ /kg body weight, between 5 pmol/kg and 5 ⁇ /kg body weight, between 10 pmol/kg and 1 ⁇ /kg body weight, between 50 pmol/kg and 0.1 ⁇ /kg body weight, between 100 pmol/kg and 0.01 ⁇ /kg body weight, between 0.001 ⁇ /kg and 0.5
  • the therapeutic dosing and regimen most appropriate for patient treatment will of course vary with the disease or condition to be treated, and according to the patient's weight and other parameters. Without wishing to be bound by any particular theory, it is expected that doses, in the ⁇ g/kg range, and shorter or longer duration or frequency of treatment may produce therapeutically useful results, such as a statistically significant increase particularly in small bowel mass.
  • the therapeutic regimen may include the administration of maintenance doses appropriate for preventing tissue regression that occurs following cessation of initial treatment.
  • the dosage sizes and dosing regimen most appropriate for human use may be guided by the results obtained by the present invention, and may be confirmed in properly designed clinical trials.
  • An effective dosage and treatment protocol may be determined by conventional means, starting with a low dose in laboratory animals and then increasing the dosage while monitoring the effects, and systematically varying the dosage regimen as well. Numerous factors may be taken into consideration by a clinician when determining an optimal dosage for a given subject. Such considerations are known to the skilled person.
  • the present invention provides a dual agonist of the invention for use as a medicament.
  • the present invention relates to a dual agonist of the invention for use in therapy.
  • GLP-2 induces significant growth of the small intestinal mucosal epithelium via the stimulation of stem cell proliferation in the crypts and inhibition of apoptosis on the villi (Drucker et al. Proc Natl Acad Sci U S A. 1996, 93:791 1 -6). GLP-2 also has growth effects on the colon. GLP-2 also inhibits gastric emptying and gastric acid secretion (Wojdemann et al. J Clin Endocrinol Metab. 1999, 84:2513-7), enhances intestinal barrier function (Benjamin et al.Gut.
  • GLP-2 has been shown to prevent or reduce mucosal epithelial damage in a wide number of preclinical models of gut injury, including chemotherapy-induced enteritis, ischemia-reperfusion injury, dextran sulfate-induced colitis and genetic models of inflammatory bowel disease (Sinclair and Drucker Physiology 2005: 357-65).
  • the GLP-2 analogue teduglutide (Gly2- hGLP-2) is approved for treatment of short bowel syndrome under the trade names Gattex and Revestive.
  • GLP-1 is a peptide hormone known for its important role in glucose homeostasis. When secreted from the gastrointestinal tract in response to nutrient ingestion, GLP-1 potentiates glucose-stimulated insulin secretion from the ⁇ -cells (Kim and Egan, 2008, Pharmacol. Rev. 470-512). Furthermore, GLP-1 or it analogues has been shown to increase somatostatin secretion and suppress glucagon secretion (Hoist JJ, 2007, Physiol Rev. 1409-1439).
  • GLP-1 is also known as a key regulator of appetite, food intake, and body weight. Moreover, GLP-1 can inhibit gastric emptying and gastrointestinal motility in both rodents and humans, most likely through GLP-1 receptors present in the gastrointestinal tract
  • GLP-1 seems to have insulin-like effects in major extrapancreatic tissues, participating in glucose homeostasis and lipid metabolism in tissues such as muscle, liver, and adipose tissues (Kim and Egan, 2008, Pharmacol. Rev. 470-512).
  • the dual agonist compounds of the present invention may be used to increase intestinal mass, improve intestinal function (especially intestinal barrier function), increase intestinal blood flow, or repair intestinal damage or dysfunction (whether structural or functional), e.g. damage to the intestinal epithelium. They may also be used in the prophylaxis or treatment of conditions which may be ameliorated by these effects, and in reducing the morbidity related to gastrointestinal damage.
  • gastrointestinal is used here to include the entire gastrointestinal tract, including oesophagus, stomach, small intestine (duodenum, jejunum, ileum) and large intestine (cecum, colon, rectum), but especially the small intestine and colon.
  • conditions in which the dual agonists may be of benefit include malabsorption, ulcers (which may be of any aetiology, e.g., peptic ulcers, Zollinger-Ellison Syndrome, drug-induced ulcers, and ulcers related to infections or other pathogens), short-bowel syndrome, cul-de-sac syndrome, inflammatory bowel disease (Crohn's disease and ulcerative colitis), irritable bowel syndrome (IBS), pouchitis, celiac sprue (for example arising from gluten induced enteropathy or celiac disease), tropical sprue,
  • hypogammaglobulinemic sprue and mucositis or diarrhea induced by chemotherapy or radiation therapy.
  • the dual agonists may also find use in certain conditions which do not primarily affect gastrointestinal tissue but which may be caused or exacerbated by factors arising from intestinal dysfunction.
  • impaired intestinal barrier function (which may be referred to as "leakiness" of the intestine or gut) can lead to transit of materials from the lumen of the gut directly into the bloodstream and thus to the kidney, lung and/or liver.
  • These materials may include food molecules such as fats, which contribute to conditions such as hepatitis and/or fatty liver diseases, including parenteral nutrition associated gut atrophy, PNALD (Parenteral Nutrition-Associated Liver Disease), NAFLD (Non-Alcoholic Fatty Liver Disease) and NASH (Non-Alcoholic Steatohepatitis).
  • food molecules such as fats, which contribute to conditions such as hepatitis and/or fatty liver diseases, including parenteral nutrition associated gut atrophy, PNALD (Parenteral Nutrition-Associated Liver Disease), NAFLD (Non-Alcoholic Fatty Liver Disease) and NASH (Non-Alcoholic Steatohepatitis).
  • the materials crossing into the bloodstream may also include pathogens such as bacteria, and toxins such as bacterial lipopolysaccharide (LPS), which may contribute to systemic inflammation (e.g. vascular inflammation).
  • pathogens such as bacteria
  • toxins such as bacterial lipopolysaccharide (LPS)
  • LPS bacterial lipopolysaccharide
  • Such inflammation is often referred to as “low grade inflammation” and is a contributing factor to the
  • pathogenesis of metabolic endotoxemia (a condition seen in both diabetes and obesity, discussed further below), primary biliary cirrhosis and hepatitis. Entry of pathogens to the bloodstream may also result in conditions such as necrotising enterocolitis.
  • Low grade inflammation is not characterised by the normal symptoms of acute inflammation such as pain, fever and redness, but can be detected via the presence of inflammatory markers in the blood, such as C-reactive protein and proinflammatory cytokines including TNF-alpha (tumour necrosis factor alpha).
  • the dual agonists may also find use in conditions which primarily affect other tissues but have gastrointestinal side-effects.
  • inflammatory conditions such as pancreatitis result in elevated levels of circulating inflammatory mediators which may in turn induce intestinal damage or intestinal dysfunction, such as impairment of barrier function.
  • intestinal damage or intestinal dysfunction such as impairment of barrier function.
  • this may lead to more severe systemic inflammatory conditions such as sepsis, or to surgical procedures or mechanical injuries (volvulus) where blood supply to the intestine is interrupted, ultimately leading to ischaemia-reperfusion injuries.
  • graft versus host disease may result in substantial tissue damage to the gastrointestinal tract, resulting in impaired barrier function and other side effects such as diarrhea.
  • GVHD graft versus host disease
  • prophylaxis or treatment of intestinal dysfunction or damage caused by or associated with GVHD as well as prophylaxis or treatment of side effects such as diarrhea caused by or associated with GVHD.
  • the dual agonist compounds described herein also find use, inter alia, in reducing or inhibiting weight gain, reducing rate of gastric emptying or intestinal transit, reducing food intake, reducing appetite, or promoting weight loss.
  • the effect on body weight may be mediated in part or wholly via reducing food intake, appetite or intestinal transit.
  • the dual agonists of the invention can be used for the prophylaxis or treatment of obesity, morbid obesity, obesity-linked gallbladder disease and obesity-induced sleep apnea.
  • the dual agonists of the invention may have a beneficial effect on glucose tolerance and/or glucose control. They may also be used to modulate (e.g. improve) circulating cholesterol levels, being capable of lowering circulating triglyceride or LDL levels, and increasing HDL/LDL ratio. Thus, they may be used for the prophylaxis or treatment of inadequate glucose control, glucose tolerance or dyslipidaemia (e.g. elevated LDL levels or reduced HDL/LDL ratio) and associated conditions, including diabetes (e.g. Type 2 diabetes, gestational diabetes), pre-diabetes, metabolic syndrome and hypertension.
  • diabetes e.g. Type 2 diabetes, gestational diabetes
  • pre-diabetes e.g. Type 2 diabetes, gestational diabetes
  • metabolic syndrome e.g. Type 2 diabetes, gestational diabetes
  • Effects on body weight may be therapeutic or cosmetic.
  • the dual agonist activity of the compounds described herein may be particularly beneficial in many of the conditions described, as the two activities may complement one another.
  • malabsorption is a condition arising from abnormality in the absorption of water and/or food nutrients, such as amino acids, sugars, fats, vitamins or minerals, via the gastrointestinal (Gl) tract, leading to malnutrition and/or dehydration.
  • Malabsorption may be a result of physical (e.g. traumatic) or chemical damage to the intestinal tract.
  • Dual agonists as described in this specification may be capable of improving intestinal barrier function, reducing gastric empting, and increasing intestinal absorption while at the same time normalising intestinal transit time. This would not only help patients to increase the absorption of nutrients and liquid, but would also alleviate patients' social problems related to meal- stimulated bowel movements.
  • intestinal function and metabolic disorders may be closely inter-related, with each contributing to the development or symptoms of the other.
  • obesity is linked with low grade inflammation (sometimes designated “obesity-linked inflammation”). It is also generally recognised that obesity (along with other syndromes) causes an increased vascular permeability which allows pathogens and toxins such as LPS to enter the cell wall of the intestinal tract and thereby initiate inflammation.
  • pathogens and toxins such as LPS
  • the changes that result from the inflammatory response are essentially the same regardless of the cause and regardless of where the insult arises.
  • the inflammatory response may be acute (short lived) or chronic (longer lasting).
  • mice e.g., obese mice (ob/ob and db/db mice) have a disrupted mucosal barrier function and exhibit increased low-grade inflammation
  • LPS lipopolysaccharide
  • ME metabolic endotoxemia
  • the inflammatory process may also play a role in causing metabolic dysfunction in obese individuals, such as insulin resistance and other metabolic disturbances.
  • the dual agonist compounds of the invention may be particularly useful for prophylaxis or treatment of low grade inflammation, especially in obese or overweight individuals, exerting beneficial effects via the GLP-1 agonist component of their activity and/or the GLP-2 component of their activity.
  • the therapeutic efficacy of treatment with a dual agonist of the invention may be monitored by enteric biopsy to examine the villus morphology, by biochemical assessment of nutrient absorption, by non-invasive determination of intestinal permeability, by patient weight gain, or by amelioration of the symptoms associated with these conditions.
  • a therapeutic kit comprising a dual agonist of the invention, or a pharmaceutically acceptable salt or solvate thereof.
  • Peptides were synthesized batchwise on a peptide synthesiser, such as a CEM Liberty Peptide Synthesizer or a Symphony X Synthesizer, according to solid phase peptide synthetic procedures using 9-fluorenylmethyloxycarbonyl (Fmoc) as N-o amino protecting group and suitable common protection groups for side-chain functionalities.
  • a peptide synthesiser such as a CEM Liberty Peptide Synthesizer or a Symphony X Synthesizer
  • polymeric support based resins such as e.g. TentaGelTM
  • the synthesizer was loaded with resin that prior to usage was swelled in DMF.
  • the coupling solutions were transferred to the reaction vessels in the following order: amino acid (4 equiv.), HATU (4 equiv.) and DIPEA (8 equiv.).
  • the coupling time was 10 min at room temperature (RT) unless otherwise stated.
  • the resin was washed with DMF (5 x 0,5 min). In case of repeated couplings the coupling time was in all cases 45 min at RT.
  • Fmoc deprotection was performed for 2,5 minutes using 40% piperidine in DMF and repeated using the same conditions.
  • the resin was washed with DMF (5 x 0,5 min).
  • a suitable trifunctional amino acid with an orthogonal side-chain protecting group according to Fmoc methodology is introduced at the position of the acylation.
  • the N- terminal of the growing peptide chain is then Boc-protected using B0C2O or alternatively by using an N-a-Boc-protected amino acid in the last coupling.
  • the orthogonal side chain protecting group is selectively cleaved using a suitable deprotection reagent.
  • the lipophilic moiety is then coupled directly to the free side-chain functionality or alternatively via a linker in between according to suitable coupling protocols.
  • the dried peptide resin was treated with TFA and suitable scavengers for
  • the crude peptide was purified by preparative reverse phase HPLC using a conventional HPLC apperatus, such as a Gilson GX-281 with 331/332 pump combination ' , for binary gradient application equipped with a column, such as 5 x 25 cm Gemini NX 5u C18 1 10A column, and a fraction collector using a flow 20-40 ml/min with a suitable gradient of buffer A (0.1 % Fomic acid, aq.) or A (0.1 % TFA, aq.) and buffer B (0.1 % Formic acid, 90% MeCN, aq.) or B (0.1 % TFA, 90% MeCN, aq.). Fractions were analyzed by analytical HPLC and MS and selected fractions were pooled and lyophilized. The final product was characterized by HPLC and MS. Analytical HPLC
  • Peptides of the present invention act as both GLP-1 and GLP-2 agonists and thus activate the GLP-1 receptor and GLP-2 receptor, respectively.
  • One useful in vitro assay for measuring GLP-1 receptor (GLP-1 R) and GLP-2 receptor (GLP-2 R) activation is quantification of cAMP, i.e. 3'-5'-cyclic adenosine monophosphate, which is a second messenger essential in many biological processes, and one of the most ubiquitous mechanisms for regulating cellular functions.
  • cAMP AlphaScreen ® assay from Perkin Elmer which has been used to quantify the cAMP response upon GLP-1 and GLP-2 receptor activation in HEK293 cells stably expressing GLP-1 R or GLP-2 R.
  • Test compounds eliciting an increase in the intracellular level of cAMP can be tested in these assays and the response normalized relative to a positive and negative control (vehicle) to calculate the EC50 and maximal response from the concentration - response curve using the 4- parameter logistic (4PL) nonlinear model for curve fitting.
  • mice Males with a body weight of approximately 25 g were given either a single subcutaneous (s.c.) bolus or a single intravenous (i.v.) bolus of each peptide to be tested.
  • s.c. subcutaneous
  • i.v. intravenous
  • the dosing vehicle was either a phosphate buffer containing mannitol (pH 7.5) or a phosphate buffer containing NaCI (pH 7.4).
  • Plasma terminal elimination half-life T1 ⁇ 2 was determined as ⁇ (2)/ ⁇ where Iz is the magnitude of the slope of the log linear regression of the log concentration versus time profile during the terminal phase.
  • Suitable protected Fmoc-amino acids were coupled as described above using HATU as coupling reagent. All couplings were performed at R.T.
  • a pseudoproline were used: in position 6 and 7 Fmoc-Phe-Ser(psi Me,Mepro)-OH. Acylation in position 16 was obtained according to the side-chain acylation procedure described above. The pseudoproline was coupled according to the standard procedure described above for Fmoc-amino acids.
  • the peptide-resin was washed with EtOH (3 x 10 ml) and Et20 (3 x 10 ml) and dried to constant weight at room temperature (r.t).
  • the peptide was cleaved from the resin by treatment with TFA TIS/H 2 0 (95/2,5/2,5; 40 ml, 2 h; r.t.).
  • the volume of the filtrate was reduced and the crude peptide was precipitated after addition of diethylether.
  • the crude peptide precipitate was washed several times with diethylether and finally dried to constant weight at room temperature yield 710 mg crude peptide product (purity -40%).
  • the crude peptide was purified by preparative reverse phase HPLC using a Gilson GX-281with 331/332 pump combination for binary gradient application equipped with a 5 x 25 cm Gemini NX 5u C18 1 1 OA, column and a fraction collector and run at 35 ml/min with a gradient of buffer A (0.1 % TFA, aq.) and buffer B (0.1 % TFA, 90% MeCN, aq.) gradient from 30%B to 70%B in 47 min.
  • the cDNA encoding the human glucagon-like peptide 1 receptor (GLP-1 R) was cloned from the cDNA BC1 12126
  • the DNA encoding the GLP-1 -R was amplified by PCR using primers encoding terminal restriction sites for subcloning. The 5'-end primers additionally encoded a near Kozak consensus sequence to ensure efficient translation. The fidelity of the DNA encoding the GLP-1 -R was confirmed by DNA sequencing.
  • the PCR products encoding the GLP-1 -R were subcloned into a mammalian expression vector containing a neomycin (G418) resistance marker.
  • the mammalian expression vectors encoding the GLP-1 -R were transfected into HEK293 cells by a standard calcium phosphate transfection method.
  • the hGLP2-R was purchased from MRC-geneservice, Babraham, Cambridge as an Image clone: 5363415 (1 1924-117).
  • primers for subcloning were obtained from DNA-Technology, Risskov, Denmark.
  • the 5' and 3' primers used for the PCR reaction include terminal restriction sites for cloning and the context of the 5' primer is modified to a Kozak consensus without changing the sequence of the product encoded by the ORF.
  • a standard PCR reaction was run using Image clone 5363415 (1 1924-117) as a template with the above mentioned primers and Polymerase Herculase II Fusion in a total vol. of 50 ⁇ .
  • the generated PCR product was purified using GFX PCR and Gel band purification kit, digested with restriction enzymes and cloned into the mammalian expression vector using Rapid DNA Ligation Kit. Ligation reaction was transformed to XL10 Gold Ultracompetent cells and colonies were picked for DNA production using Endofree Plasmid maxi kit. Subsequent sequence analysis was conducted by MWG Eurofins, Germany. The clone was confirmed to be the hGLP-2 (1 -33) receptor, splice variant rs17681684.
  • HEK293 cells were transfected using the Lipofectamine PLUS transfection method. The day before transfection, HEK293 cells were seeded in two T75 flasks at a density of 2x10 6 cells / T75 flask in cell culturing medium without antibiotics. On the day of transfection, cells were washed with 1x DPBS and medium was replaced with Optimem to a volume of 5 mL / T75 flask before addition of Lipofectamine-plasmid complexes were added gently and drop wise to the cells in T75 flasks and replaced with growth medium after 3 hours and again to growth medium supplemented with 50C ⁇ g/ml_ G418 after 24 hours. Following 4 weeks in G418 selection, clones were picked and tested in a functional GLP-2 receptor potency assay as described below. One clone was selected for use in compound profiling. GLP-1R and GLP-2 receptor potency assays
  • the cAMP AlphaScreen ® assay from Perkin Elmer was used to quantitate the cAMP response to activation of the GLP1 and GLP2 receptor, respectively.
  • Exendin-4 was used as reference compound for GLP1 receptor activation and Teduglutide as reference compound for GLP2 receptor activation.
  • Data from test compounds eliciting an increase in the intracellular level of cAMP were normalized relative to the positive and negative control (vehicle) to calculate the ECso and maximal response from the concentration response curve. The results are listed in Table 2.1.
  • Example 3 Pharmacokinetics of selected compounds in mice dosed with a single administration The purpose of this study was to determine the half-life (T1 ⁇ 2) and clearance of the GLP-1/GLP-2 dual agonist after s.c. and i.v. administration to mice.
  • mice Males with a body weight of approximately 25 g were given either a single subcutaneous (s.c.) bolus or a single intravenous (i.v.) bolus of each peptide to be tested.
  • s.c. subcutaneous
  • i.v. intravenous
  • Selected compounds were administered either s.c. or i.v., 150 nmol/kg, and blood samples were drawn at 10 min, 30 min, 2, 4, 8, 16, 24, 36, 48 and 72 hours post-dose following s.c. administration or 10 min, 30 min, 2, 4, 8, 16, 24, 36 and 48 hours post- dose following i.v. administration. Blood samples were drawn by orbital bleeding.
  • the dosing vehicle was 50 mM Histidine pH 6 and 200 mM Mannitol.
  • mice were drawn, i.e. 20 mice were included for each compound s.c. and 18 mice for each compound i.v.
  • the mice were euthanized immediately after blood sampling by cervical dislocation.
  • Plasma samples were analyzed after either solid phase extraction (SPE) or precipitation by liquid chromatography mass spectrometry (LC-MS/MS).
  • Mean plasma concentrations were used for calculation of the pharmacokinetic parameters using the non-compartmental approach in Phoenix WinNonlin 7.0.
  • Plasma terminal elimination half-life (T1 ⁇ 2) was determined as ⁇ (2)/ ⁇ where ⁇ is the magnitude of the slope of the log linear regression of the log concentration versus time profile during the terminal phase.
  • T ma x is the post-dose time where the maximal plasma concentration was observed. See tables 3.1 . and 3.2.
  • mice Normal chow-fed C57BL/6J male mice were used. The mice were kept in standard housing conditions, light-, temperature-, and humidity-controlled room (12:12 h light- dark cycle, with lights on at 06.00-18.00 h; 20-22°C; 50-80% relative humidity). Each dosing group consisted of 6 animals. Mice were dosed once daily (compound 18 and compound 21 , or twice daily (compound 22) with 250 nmol/kg, or vehicle for 3 days (day 0-day 2) via subcutaneous administration. Mice were fasted and blood glucose levels measured after a single s.c. injection with peptides. Animals were sacrificed on day 3 after final dosing on day 2, and small intestinal wet weights were measured.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to compounds having agonist activity at the GLP-1 (glucagon- like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors. The compounds find use, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.

Description

ACYLATED GLP-1/GLP-2 DUAL AGONISTS
Field of the Invention
The present invention relates to acylated compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1 ) and GLP-2 (glucagon-like peptide 2) receptors. The compounds find use, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.
Background to the Invention
Intestinal tissue is responsible for the production of both human glucagon-like peptide 1 (GLP-1 (7-36)) and human glucagon-like peptide 2 (GLP-2 (1 -33)) as they are produced by the same cells. Human GLP-2 is a 33-amino-acid peptide with the following sequence: Hy-His-Ala-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-lle-Leu- Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-lle-Asn-Trp-Leu-lle-Gln-Thr-Lys-lle-Thr-Asp-OH (SEQ ID NO:1 ). It is derived from specific posttranslational processing of proglucagon in the enteroendocrine L cells of the intestine and in specific regions of the brainstem. GLP-2 binds to a single G-protein-coupled receptor belonging to the class II glucagon secretin family. GLP-2 is co-secreted with GLP-1 , oxyntomodulin and glicentin, in response to nutrient ingestion. Human GLP-1 is produced as a 30-amino acid peptide with the following sequence: Hy-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val- Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-lle-Ala-Trp-Leu-Val-Lys-Gly-Arg- Gly-NH2 (SEQ ID NO:2).
GLP-2 has been reported to induce significant growth of the small intestinal mucosal epithelium via the stimulation of stem cell proliferation in the crypts, and by inhibition of apoptosis in the villi (Drucker et al., 1996, Proc. Natl. Acad. Sci. USA 93: 791 1 - 7916). GLP-2 also has growth effects on the colon. Furthermore, GLP-2 inhibits gastric emptying and gastric acid secretion (Wojdemann et al., 1999, J. Clin.
Endocrinol. Metab. 84: 2513-2517), enhances intestinal barrier function (Benjamin et al., 2000, Gut 47: 1 12-1 19), stimulates intestinal hexose transport via the upregulation of glucose transporters (Cheeseman, 1997, Am. J. Physiol. R1965-71 ), and increases intestinal blood flow (Guan et al., 2003, Gastroenterology, 125: 136-147).
GLP-1 has been described as a physiological incretin hormone and has thus been mostly reported to augment an insulin response after an oral intake of glucose or fat. It is, however, generally understood that GLP-1 lowers glucagon concentrations, has beneficial effects on inhibition of fast bowel movements (Tolessa et al., 1998, Dig. Dis. Sci. 43(10): 2284-90), and slows gastric emptying. WO2013/164484 discloses GLP-2 analogues which comprise one or more substitutions compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use.
WO2016/066818 describes peptides having dual agonist activity at the GLP-1 and GLP-2 receptors, and proposes medical uses thereof. However, there remains a need for further compounds which combine effective agonist activities at both receptors.
All patents, published patent applications and non-patent publications cited herein are expressly incorporated herein by reference in their entirety. Summary of the Invention
Broadly, the present invention relates to compounds which have agonist activity at the GLP-1 (glucagon-like peptide 1 ) and GLP-2 (glucagon-like peptide 2) receptors, e.g. as assessed in in vitro potency assays. Such compounds are referred to in this specification as "GLP-1/GLP-2 dual agonists", or simply "dual agonists". Thus, the compounds of the present invention have activities of both GLP-1 (7-36) and GLP-2 (1 -33).
In a first aspect, there is provided a GLP-1 /GLP-2 dual agonist represented by the formula:
R1-X*-U-R2
wherein:
R1 is hydrogen (Hy), C1-4 alkyl (e.g. methyl), acetyl, formyl, benzoyl or trifluoroacetyl; R2 is NH2 or OH;
X* is a peptide having the formula I:
H-X2-DG-X5-F-X7-X8-E-X10-X1 1 -TIL-X15-X16-X17-A-X19-X20-X21 -FIAWL-X27- X28-X29-KIT-X33 (I)
wherein:
X2 is G or Aib; X5 is S orT;
X7 is S orT;
X8 isS, ΌorΨ;
X10 is L, V, M orΨ;
X11 is A; S orΨ;
X15isDorE;
X16 is E, G, A or Ψ;
X17 isQ, E, K, L or Ψ;
X19 is A, VorS;
X20isRorK;
X21 is L, D or E;
X27 is I, H, Q, Y, ΚorΨ;
X28 is Q, E, H, Y, L, K, RorA;
X29 is H, Q, Y, K or Ψ;
X33 is D, E or is absent;
U is absent or a sequence of 1-15 residues each independently selected from K, k, E, A, T, I, Land Ψ;
the molecule contains a minimum of one and a maximum of two Ψ, wherein each Ψ is independently a residue of k, K, R, Orn, Dap or Dab in which the side chain is conjugated to a substituent having the formula -Z1 or -Z2-Z1,
wherein
Z1- is CH3-(CH2)io-22-(CO)- or HOOC-(CH2)io-22-(CO)-; and
-Z2- is selected from
Figure imgf000004_0002
Figure imgf000004_0001
-ZS1- is isoGlu, β-Ala, isoLys, or 4-aminobutanoyl;
-ZS2- is -(Peg3)m- where m is 1 , 2, or 3; and
-ZS3- is a peptide sequence of 1-6 amino acid units independently selected from the group consisting of A, L, S, T, Y, Q, D, E, K, k, R, H, F and G;
or a pharmaceutically acceptable salt or solvate thereof.
The various amino acid positions in peptide X of the formulae provided here are numbered according to their linear position from N- to C-terminus in the amino acid chain. the present context, β-Ala and 3-Aminopropanoyl are used interchangeably. It was found that by substituting the T in position 29 in a GLP-1/GLP-2 dual agonist with an amino acid selected from the group consisting of H, Y, Q, K and Ψ, e.g. H, Y and Q, the potency on both the GLP-1 receptor and the GLP-2 receptor can be improved.
In some embodiments of formula I
X2 is G or Aib;
X5 is S or T;
X8 is S, D or Ψ;
X10 s Ι-orΨ;
X11 s A; S or Ψ;
X15 s D or E;
X16 sE, Gor<+>;
X17 sQ, E, K or Ψ;
X19 s A, V or S;
X21 s D or E;
X27 si, H, Q, Y or Ψ;
X28 s Q, E or A;
X29 sH,Q, Yor<+>;and
X33 s D, E or is absent.
In further embodiments of formula I:
X2 is Aib;
X5 is S or T;
X8 is S or D;
X10 s Ι-orΨ;
X11 s A or Ψ;
X15 s D or E;
X16 s Ε or Ψ;
X17 s Q or E;
X19 s A, V or S;
X21 s D or E;
X27 si;
X28 s Q or E;
X29 sH,Q, Yor<+>;and
X33 s D, E or is absent. If X33 is absent, U may also be absent.
The invention further provides a GLP-1/GLP-2 dual agonist represented by the formula:
R1-X*-U-R2
wherein:
R1 is hydrogen (Hy), C1-4 alkyl (e.g. methyl), acetyl, formyl, benzoyl or trifluoroacetyl; R2 is NH2 or OH;
X* is a peptide having the formula II:
Figure imgf000006_0001
wherein:
X2 is G or Aib;
X5 is S or T;
X8 is S, D or Ψ;
X10 is L or Ψ;
X1 1 is A; S or Ψ;
X16 is E, G or Ψ;
X17 is Q, E, K or Ψ;
X19 is A or S;
X27 is I, H, Q, Y or Ψ;
X28 is Q or A;
X29 is H, Q, Y or Ψ;
U is absent or a sequence of 1 -15 residues independently selected from K, k and Ψ; the molecule contains one and only one Ψ, wherein Ψ is a residue of K, R, Orn, Dap or Dab in which the side chain is conjugated to a substituent having the formula -Z1 or -Z2-Z1,
wherein
Z1- is CH3-(CH2)io-22-(CO)- or HOOC-(CH2)io-22-(CO)-; and
-Z2- is selected from -ZS1-, -ZS1-ZS2-, -ZS2-ZS1, and ZS2 wherein
-ZS1- is isoGlu, β-Ala, isoLys, or 4-aminobutanoyl;
-ZS2- is -(Peg3)m- where m is 1 , 2, or 3; or a pharmaceutically acceptable salt or solvate thereof.
In some embodiments of formulae I and II, U is absent or K1-15 (i.e. a sequence of 1- 15 Lys residues. In some embodiments of formulae I and II, X27 is Q and X29 is H, Q or Y; orX27 is Q and X29 is H.
It is desirable that X2 is Aib. Additionally or alternatively, X 11 is A. Additionally or alternatively X17 is Q. Additionally or alternatively X19 is A orX27 is I.
In even further embodiments of formula I
Χ16is Ψ;
X2 is Aib and X17 is Q;
X27 is I and X28 is Q;
X2 is Aib, X5 is S and X17 is Q,
X27 is I, X28 is Q and X29 is H;
X8isDandX10is Ψ;
X8 isDandXH is Ψ;
X8 is S and X16 is Ψ;
X8 is D, X10 is Ψ and X29 is H;
X8 is D, X11 is Ψ and X29 is H;
X8isS, X16is ΨandX29isH;
X2 is Aib, X5 is S, X17 is Q, X27 is I, X28 is Q and X29 is H;
X2 is Aib, X8 is S, X17 is Q, X27 is I, X28 is Q and X29 is H;
X2 is Aib, X8 is D, X17 is Q, X27 is I, X28 is Q and X29 is H; or
X2 is Aib, X8 is S, X16 is Ψ, X19 is A and X29 is H. X* may be a peptide having the formula III:
Figure imgf000007_0001
wherein:
X2 is G or Aib;
X5isSorT;
X8 isS, D orΨ;
X10 is L, Ψ;
X11 is A or S; X15 is D or E;
X16 isE, ΘorΨ;
X17 is Q, E or K;
X19 is A, VorS;
X21 is D or E;
X27 is I or Ψ;
X28 is Q, E or A;
X29 isH,Q, ΥorΨ;
X33 is D, E or absent.
In certain embodiments of formula III
X2 is Aib;
X5 is S or T;
X8 is S or D;
X10 is L, Ψ;
X11 is A;
X15 is D or E;
X16 is E orΨ;
X17 is Q or E;
X19 is A, VorS;
X21 is D or E;
X27 is I;
X28 is Q or E;
X29 isH,Q, ΥorΨ;
X33 is D, E or absent.
In embodiments of formulae I or II, X* may be a peptide having the formula IV:
Figure imgf000008_0001
wherein:
X2 is G or Aib;
X5 is S or T;
X8 is S, D orΨ;
X10 is L, Ψ;
X11 isAorS;
X16 is E, G orΨ; X17 is Q or K;
X19 is A or S;
X27 is I or Ψ;
X28 is Q or A;
X29 is H, Q, Y or Ψ
In some embodiments of formulae III or IV, X28 is Q and X29 is H, Q or Y; or X28 is Q and X29 is H It is desirable that X2 is Aib. Additionally or alternatively X 1 1 is A. Additionally or alternatively X17 is Q. Additionally or alternatively X19 is A and/or X27 is I.
In further embodiments, the following residues and/or combinations of residues may also be included
X16 is Ψ;
X2 is Aib and X17 is Q;
X27 is I and X28 is Q;
X8 is D and X10 is Ψ;
X8 is D and X1 1 is Ψ;
X8 is S and X16 is Ψ;
X8 is D, X10 is Ψ and X29 is H;
X8 is D, X1 1 is Ψ and X29 is H;
X8 is S, X16 is Ψ and X29 is H;
X2 is Aib, X5 is S and X17 is Q,
X27 is I, X28 is Q and X29 is H;
X2 is Aib, X5 is S, X17 is Q, X27 is I, X28 is Q and X29 is H;
X2 is Aib, X8 is S, X17 is Q, X27 is I, X28 is Q and X29 is H;
X2 is Aib, X8 is D, X17 is Q, X27 is I, X28 is Q and X29 is H; or
X2 is Aib, X8 is S, X16 is Ψ, X19 is A and X29 is H.
In further embodiments, the following combinations of residues may also be included X2 is Aib, X8 is D, X10 is Ψ,
X2 is Aib, X8 is D, X10 is Ψ, X16 is E and X24 is A;
X2 is Aib, X8 is D, X10 is Ψ, X16 is E and X29 is H;
X2 is Aib, X5 is S, X8 is D, X10 is Ψ, X1 1 is A, X16 is E, X17 is Q and X24 is A; X2 is Aib, X5 is S, X8 is D, X10 is Ψ, X1 1 is A, X16 is E, X17 is Q, X24 is A and X29 is H;
X16 is Ψ, X19 is A and X29 is H;
X2 is Aib, X8 is S, X16 is Ψ, X19 is A and X29 is H;
X2 is Aib, X8 is S, X16 is Ψ, X19 is A and X29 is H;
X2 is Aib, X5 is S, X8 is S, X10 is L, X1 1 is A, X16 is Ψ, X17 is Q, X24 is A and X29 is H; or
X2 is Aib, X5 is S, X24 is A and X29 is H.
In other embodiments, the following combinations of residues may also be included
X2 is Aib, X8 is S, X16 is Ψ, X19 is S and X29 is Y;
X2 is Aib, X8 is D, X16 is E, X24 is A, and X29 is Ψ;
X2 is Aib, X5 is S, X16 is E, X24 is A and X29 is Ψ; or
X8 is S, X16 is Ψ, X19 is S and X29 is Y.
In some embodiments, the sequence of the dual agonist (e.g. peptide X*) has no more than 5 amino acid changes, e.g. no more than 4, no more than 3, no more than 2 or no more than 1 change relative to the amino acid sequence
Figure imgf000010_0001
The peptide X* in any of formulae I to IV may have the sequence
Figure imgf000010_0002
Figure imgf000011_0001
The peptide X* in any of formulae I to IV may have the sequence
Figure imgf000011_0002
wherein K* indicates a lysine residue in which the side chain is conjugated to the substituent Z1- or Z1-Z2-.
In embodiments of formulae I or II, X* may be a peptide having the formula V
Figure imgf000011_0003
wherein:
X2 is G or Aib;
X8 is D or S;
X16 is E or G; X17 isQor K;
X29 is H, Q, KorY.
In other embodiments, the following combinations of residues may also be included
X2 is Aib and X8 is D;
X2 is Aib, and X29 is H;
X2 is Aib and X16 is E;
X2 is Aib and X17 is Q, or
X16isEandX17isQ.
In some embodiments, the sequence of the dual agonist (e.g. peptide X*) has no more than 5 amino acid changes, e.g. no more than 4, no more than 3, no more than 2 or no more than 1 change relative to the amino acid sequence
Figure imgf000012_0001
The peptide X* in formula V may have the sequence
Figure imgf000012_0002
The peptide X* in formula V may have the sequence:
Figure imgf000012_0003
wherein K* indicates a lysine residue in which the side chain is conjugated to the substituent Z1- or Z1-Z2-.
In certain embodiments of the invention, X* is a peptide having the formula VI:
Figure imgf000012_0004
wherein:
X2 is G or Aib;
X5 is S orT;
X8 isS, ΌorΨ;
X10 is Lor Ψ;
X11 is A; S orΨ;
X16isE, ΰorΨ;
X17 isQ, E, ΚorΨ;
X19 is A or S;
X27 is I, H, Q, Y or Ψ; X28 is Q or A;
X29 is H, Q, Y or Ψ;
U is a sequence of 1-15 residues independently selected from K, k and Ψ;
the molecule contains a minimum of one and a maximum of two Ψ, wherein each Ψ is independently a residue of k, K, R, Orn, Dap or Dab in which the side chain is conjugated to a substituent having the formula -Z1 or-Z2-Z1, and U contains at least one residue Ψ.
In some embodiments of formula VI
X2 is Aib;
X5 is S orT;
X8 is S or D;
X10 s Ι,orΨ;
X11 S ΑorΨ;
X15 s D or E;
X16 s ΕorΨ;
X17 s Q or E;
X19 s A, V or S;
X21 s D or E;
X27 si;
X28 s Q or E;
X29 sH,Q, ΥorΨ;
X33 s D or E.
In further embodiments of formula VI
X2 is Aib;
X5 is S;
X8 is S;
X10 is Lor Ψ;
X11 isA;
X15 is D;
X16 is E orΨ;
X17 isQorE;
X19 is A;
X21 is D; X27 is I;
X28 is Q;
X29 is H;
X33 is D.
In some embodiments, the dual agonist or pharmaceutically acceptable salt or solvate thereof is a molecule which contains one and only one Ψ at one position of sequence U. When the dual agonist contains two residues Ψ, the other is located within X*.
In some embodiments, the sequence of the dual agonist has no more than 5 amino acid changes, e.g. no more than 4, no more than 3, no more than 2 or no more than 1 change relative to the amino acid sequence
Figure imgf000014_0001
In some embodiments, the sequence of the dual agonist has no more than 5 amino acid changes, e.g. no more than 4, no more than 3, no more than 2 or no more than 1 change relative to the amino acid sequence
Figure imgf000014_0002
The peptide X*-U in formula VI may have the sequence:
Figure imgf000014_0003
Figure imgf000015_0001
The peptide X*-U in formula VI may have the sequence:
Figure imgf000015_0002
wherein K* indicates a lysine residue in which the side chain is conjugated to the substituent Z1 - or Z1 -Z2-.
In some embodiments, Ψ is a Lys residue whose side chain is conjugated to the substituent Z1- or Z1-Z2-.
In some embodiments, Z1-, alone or in combination with -Z2-, is dodecanoyl, tetradecanoyl, hexadecanoyl, octadecanoyl or eicosanoyl.
In some embodiments, Z1-, alone or in combination with -Z2-, is
13-carboxytridecanoyl, i.e. HOOC-(CH2)i2-(CO)-;
15-carboxypentadecanoyl, i.e. HOOC-(CH2)i4-(CO)-;
17-carboxyheptadecanoyl, i.e. HOOC-(CH2)i6-(CO)-;
19-carboxynonadecanoyl, i.e. HOOC-(CH2)i8-(CO)-; or
21 -carboxyheneicosanoyl, i.e. HOOC-(CH2)20-(CO)-.
In some embodiments Z2 is absent.
In some embodiments, Z2 comprises ZS1 alone or in combination with ZS2 and/or ZS3 In such embodiments:
-ZS1- is isoGlu, β-Ala, isoLys, or 4-aminobutanoyl;
-ZS2-, when present, is -(Peg3)m- where m is 1 , 2, or 3; and
-ZS3- is a peptide sequence of 1 -6 amino acid units independently selected from the group consisting of A, L, S, T, Y, Q, D, E, K, k, R, H, F and G, such as the peptide sequence KEK.
Z2 may have the formula -ZS1-ZS3-ZS2-, where ZS1 is bonded to Z1 and ZS2 is bonded to the side chain of the amino acid component of Ψ.
Thus, in some embodiments, -Z2- is:
isoGlu(Peg3)o-3;
3-Ala(Peg3)0-3;
isoLys(Peg3)o-3; or
4-aminobutanoyl(Peg3)o-3.
In further embodiments, -Z2- is:
isoGlu-KEK-(Peg3)o-3. Specific examples of the substituent Z1-Z2- are set out below. In some embodiments, Z1-Z2- is [17-carboxy-heptadecanoyl]-isoGlu). For example, Ψ may be K([17-carboxy- heptadecanoyl]-isoGlu).
In some embodiments, Z1-Z2 - is:
[17-carboxy-heptadecanoyl]-[3-Aminopropanoyl]-;
Hexadecanoyl-[3-aminopropanoyl]-;
[17-carboxy-heptadecanoyl]-isoGlu-;
[19-carboxy-nonadecanoyl]-isoGlu-;
[19-Carboxy-nonadecanoyl]-isoGlu-KEK-;
[19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3-;
[19-Carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3-;
[19-Carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3-Peg3-;
Dodecanoyl-[3-Aminopropanoyl]-;
Eicosanoyl-[3-Aminopropanoyl]-;
Hexadecanoyl-[3-Aminopropanoyl]-;
Hexadecanoyl-isoGlu- Hexadecanoyl-isoLys-; or
Octadecanoyl-[3-Aminopropanoyl]-.
In some embodiments K([17-carboxy-heptadecanoyl]-[3-Aminopropanoyl]);
K(Hexadecanoyl-[3-aminopropanoyl]);
K([17-carboxy-heptadecanoyl]-isoGlu);
K([19-carboxy-nonadecanoyl]-isoGlu);
K([19-Carboxy-nonadecanoyl]-isoGlu-KEK);
K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3);
K([19-Carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3);
K([19-Carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3-Peg3);
K(Dodecanoyl-[3-Aminopropanoyl]);
K(Eicosanoyl-[3-Aminopropanoyl]);
K(Hexadecanoyl-[3-Aminopropanoyl]);
K(Hexadecanoyl-isoGlu);
K(Hexadecanoyl-isoLys); or
K(Octadecanoyl-[3-Aminopropanoyl]).
When present, U represents a peptide sequence of 1 -15 residues each independently selected from K (i.e. L-lysine), k (i.e. D-lysine) E (Glu), A (Ala), T (Thr), I (lie), L (Leu) and Ψ. For example, U may be 1 -10 amino acids in length, 1 -7 amino acids in length, 3-7 amino acids in length, 1 -6 amino acids in length, or 3-6 amino acids in length. Typically U includes at least one charged amino acid (K, k or E) and preferably two or more charged amino acids. In some embodiments it includes at least 2 positively charged amino acids (K or k), or at least 1 positively charged amino acid (K or k) and at least one negatively charged amino acid (E). In some embodiments, all amino acid residues of U (except for ψ, if present) are charged. For example, U may be a chain of alternately positively and negatively charged amino acids.
In certain embodiments, U comprises residues selected only from K, k, E and Ψ.
In certain embodiments, U comprises residues selected only from K, k, and Ψ. When U comprises only lysine residues (whether K or k), all residues may have an L- configuration or all may have a D-configuration. Examples include K1-15, KMO and Ki. 7, e.g., K3, K4, K5, Κβ and K7, especially K5 and Κβ. Further examples include ki-i5, ki. 10 and ki-7, e.g. k3, k4, k5, k6 and k7, especially k5 and k6.
Further examples of peptide sequences U include kkkkkK, KKEEEK, KEK, EKEKEK, EkEkEk, AKAAEK, AKEKEK and ATILEK.
In any case, one of those residues may be exchanged for Ψ. Where the sequence U contains a residue Ψ, it may be desirable that the C-terminal residue of U is Ψ. Thus, further examples of sequences U include Κ1-14-Ψ, Κ1-9-Ψ and Κ1-6-Ψ, e.g., Κ2-Ψ, Κ3-Ψ, Κ4-Ψ, Κ5-Ψ and Κβ-Ψ, especially Κ4-Ψ and Κ5.-Ψ. Yet further examples include ki-i4- Ψ, ki-g-Ψ, and ki-β-Ψ, e.g. kz-Ψ, ks-Ψ, k-Ψ, ks-Ψ and ke-Ψ especially Ι¾-Ψ and ks-Ψ. Yet further examples include kkkkkΨ, ΚΚΕΕΕΨ, ΚΕΨ, ΕΚΕΚΕΨ, EkEkEΨ ΑΚΑΑΕΨ, AKEKEH^ and ΑΤΙΙ.ΕΨ.
Without wishing to be bound by theory, it is believed that the peptide sequence U may increase stability of the dual agonist, and may also prolong the in vivo half life of the dual agonist, especially when in combination with a substituent Z1 or Z1Z2 (i.e. when the peptide U contains a residue ψ).
Where U contains a residue Ψ, that Ψ is typically the C-terminal residue of U.
When the dual agonist contains two residues Ψ, it may be desirable that one Ψ is located within X* and one within U. As set out above, the Ψ located within U may be the C-terminal residue of U.
The dual agonist may have the peptide backbone (excluding R1 and R2 groups):
Cpd 1 H[Aib]DGSFSDE[K(Dodecanoyl-[3-
Aminopropanoyl])]ATILDEQAARDFIAWLIQHKITD;
Cpd 2 H[Aib]DGSFSDE[K(Hexadecanoyl-[3-
Aminopropanoyl])]ATILDEQAARDFIAWLIQHKITD;
Cpd 3 H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]- isoGlu)]QAARDFIAWLIQHKITD;
Cpd 4 H[Aib]DGSFSSELATILD[K(Hexadecanoyl-isoGlu)]QASRDFIAWLIQHKITD;
H[Aib]DGSFSSELATILD[K(Hexadecanoyl-isoGlu)]QAARDFIAWLIQQKITD;
Cpd 6 H[Aib]DGSFSSELATILD[K(Hexadecanoyl-isoGlu)]QAARDFIAWLIQHKITD; Cpd 7 H[Aib]DGSFSSELATILD[K(Octadecanoyl-isoGlu)]QAARDFIAWLIQHKITD;
Cpd 8 H[Aib]DGSFSDELATILDEQAARDFIAWLIQ[K(Dodecanoyl-[3-
Aminopropanoyl])]KITD;
Cpd 9 H[Aib]DGSFSSELATILD[K(Hexadecanoyl-isoGlu)]QASRDFIAWLIQYKITD;
Cpd 10 H[Aib]DGSFSDEL[K(dodecanoyl-[3- aminopropanoyl])]TILDEQAARDFIAWLIQHKITD;
Cpd 1 1 H[Aib]DGSFSDEL[K(hexadecanoyl-[3- aminopropanoyl])]TILDEQAARDFIAWLIQHKITD;
Cpd 12 H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDKKKKK[K(Hexadecanoyl- isoGlu)];
Cpd 13 H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDkkkkk[k(19-carboxy-
Nonadecanoyl]-isoGlu)];
Cpd 14 H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDkkkkk[k(Hexadecanoyl- isoGlu)];
Cpd 15 H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDkkkkk[k([17-carboxy-
Heptadecanoyl]-isoGlu)];
Cpd 16 H[Aib]DGSFSSELATILD[K(Hexadecanoyl-isoGlu)]QAVRDFIAWLIQHKITD;
Cpd 17 H[Aib]DGSFSSELATILD[K([19-carboxy-nonadecanoyl]- isoGlu)]QAARDFIAWLIQHKITD;
Cpd 18 H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]-[3-
Aminopropanoyl])]QAARDFIAWLIQHKITD;
Cpd 19 H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDkkkkk[k(Hexadecanoyl-[3- aminopropanoyl])];
Cpd 20 H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDkkkkk[k(Hexadecanoyl- isoLys)];
Cpd 21 H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]-[3-
Aminopropanoyl])]QAARDFIAWLIQHKITDkkkkk[K(Hexadecanoyl-[3- aminopropanoyl])];
Cpd 22 H[Aib]DGSFSSE[K(Hexadecanoyl-[3-
Aminopropanoyl])]ATILDEQAARDFIAWLIQHKITDkkkkk[k(Hexadecanoyl-[3- aminopropanoyl])];
Cpd 23 H[Aib]DGSFSDE[K(Octadecanoyl-[3-
Aminopropanoyl])]ATILDEQAARDFIAWLIQHKITD;
Cpd 24 H[Aib]DGSFSDE[K(Eicosanoyl-[3-
Aminopropanoyl])]ATILDEQAARDFIAWLIQHKITD;
Cpd 25 H[Aib]DGSFSSE[K(Dodecanoyl-[3-
Aminopropanoyl])]ATILDEQAARDFIAWLIQHKITD;
Cpd 26 H[Aib]DGSFSSE[K(Hexadecanoyl-[3-
Aminopropanoyl])]ATILDEQAARDFIAWLIQHKITD;
Cpd 27 H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDkkkkk[k(Octadecanoyl-[3- aminopropanoyl])];
Cpd 28 H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDkkkkk[k(Eicosanoyl-[3- aminopropanoyl])];
Cpd 29 H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDEKEKE[K(Hexadecanoyl- isoGlu)];
Cpd 30 H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDKKEEE[K(Hexadecanoyl- isoGlu)];
Cpd 31 H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDAKAAE[K(Hexadecanoyl- isoGlu)];
Cpd 32 H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDAKEKE[K(Hexadecanoyl- isoGlu)];
Cpd 33 H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDATILE[K(Hexadecanoyl- isoGlu)];
Cpd 34 H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDEKEKE[K([19-Carboxy- nonadecanoyl]-isoGlu)];
Cpd 35 H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDEKEKE[K([19-Carboxy- nonadecanoyl]-isoGlu-Peg3-Peg3)];
Cpd 36 H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDEKEKE[K([19-Carboxy- nonadecanoyl]-isoGlu-Peg3-Peg3-Peg3)];
Cpd 37 H[Aib]DGSFSSE[K(Hexadecanoyl- isoGlu)]ATILDEQAARDFIAWLIQHKITDEKEKE[K(Hexadecanoyl-isoGlu)]; Cpd 38 H[Aib]DGSFSSE[K(Hexadecanoyl- isoGlu)]ATILDEQAARDFIAWLIQHKITDEKEKE[K([19-Carboxy-nonadecanoyl]- isoGlu)];
Cpd 39 H[Aib]DGSFSSELATILD[K([19-Carboxy-nonadecanoyl]-isoGlu-Peg3-
Peg3)]QAARDFIAWLIQHKITD;
Cpd 40 H[Aib]DGSFSSELATILD[K([19-Carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3-
Peg3)]QAARDFIAWLIQHKITD;
Cpd 41 H[Aib]DGSFSDE[K(Hexadecanoyl-isoGlu)]ATILDEQAARDFIAWLIQHKITD;
Cpd 42 H[Aib]DGSFSSE[K(Hexadecanoyl-isoGlu)]ATILDEQAARDFIAWLIQHKITD;
Cpd 43 H[Aib]DGSFSSE[K([19-Carboxy-nonadecanoyl]- isoGlu)]ATILDEQAARDFIAWLIQHKITD;
Cpd 44 H[Aib]DGSFSSE[K([19-Carboxy-nonadecanoyl]-isoGlu-
KEK)]ATILDEQAARDFIAWLIQHKITD;
Cpd 45 H[Aib]DGSFSSE[K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]ATILDEQAARDFIAWLIQHKITD;
Cpd 46 H[Aib]DGSFSSELATILD[K([19-Carboxy-nonadecanoyl]-isoGlu-
KEK)]QAARDFIAWLIQHKITD;
Cpd 47 H[Aib]DGSFSSELATILD[K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]QAARDFIAWLIQHKITD;
Cpd 48 H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]- isoGlu)]QAARDFIAWLIQHKIT;
Cpd 49 H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]- isoGlu)]EAARDFIAWLIQHKITD;
Cpd 50 H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]- isoGlu)]QAARDFIAWLIEHKITD;
Cpd 51 H[Aib]DGSFSSELATILDEEAARDFIAWLIQHKITDkkkkk[k([17-carboxy-
Heptadecanoyl]-isoGlu)];
Cpd 52 H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]- isoGlu)]QAARDFIAWLIQHKITE;
Cpd 53 H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]- isoGlu)]QAAREFIAWLIQHKITD;
Cpd 54 H[Aib]DGSFSSELATILE[K([17-carboxy-heptadecanoyl]- isoGlu)]QAARDFIAWLIQHKITD;
Cpd 55 H[Aib]DGSFSSELATILE[K([17-carboxy-heptadecanoyl]- isoGlu)]QAAREFIAWLIQHKITE;
Cpd 56 H[Aib]DGSFSSELATILE[K([17-carboxy-heptadecanoyl]- isoGlu)]QAAREFIAWLIQHKITD;
Cpd 57 H[Aib]DGTFSSELATILD[K([17-carboxy-heptadecanoyl]- isoGlu)]QAARDFIAWLIQHKITD; or
Cpd 58 H[Aib]DGSFSSELATILD[K([19-Carboxy-nonadecanoyl]- isoGlu)]QAARDFIAWLIQHKITDEKEKE[K(Hexadecanoyl-isoGlu)]. In some embodiments R1 is Hy and/or R2 is OH.
The dual agonist may be:
Cpd 1 : Hy-H[Aib]DGSFSDE[K(Dodecanoyl-[3-Aminopropanoyl])]ATILDEQAARDFIAWLIQHKITD-OH;
Cpd 2: Hy-H[Aib]DGSFSDE[K(Hexadecanoyl-[3-Aminopropanoyl])]ATILDEQAARDFIAWLIQHKITD-OH;
Cpd 3: Hy-H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLIQHKITD-OH;
Cpd 4: Hy-H[Aib]DGSFSSELATILD[K(Hexadecanoyl-isoGlu)]QASRDFIAWLIQHKITD-OH;
Cpd 5: Hy-H[Aib]DGSFSSELATILD[K(Hexadecanoyl-isoGlu)]QAARDFIAWLIQQKITD-OH;
Cpd 6: Hy-H[Aib]DGSFSSELATILD[K(Hexadecanoyl-isoGlu)]QAARDFIAWLIQHKITD-OH;
Cpd 7: Hy-H[Aib]DGSFSSELATILD[K(Octadecanoyl-isoGlu)]QAARDFIAWLIQHKITD-OH;
Cpd 8: Hy-H[Aib]DGSFSDELATILDEQAARDFIAWLIQ[K(Dodecanoyl-[3-Aminopropanoyl])]KITD-OH; or
Cpd 9: Hy-H[Aib]DGSFSSELATILD[K(Hexadecanoyl-isoGlu)]QASRDFIAWLIQYKITD-OH.
The dual agonist may be
Cpd 10: Hy-H[Aib]DGSFSDEL[K(dodecanoyl-[3-aminopropanoyl])]TILDEQAARDFIAWLIQHKITD-OH; or Cpd 11 : Hy-H[Aib]DGSFSDEL[K(hexadecanoyl-[3-aminopropanoyl])]TILDEQAARDFIAWLIQHKITD-OH. The dual agonist may be:
Cpd 12: Hy-H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDKKKKK[K(Hexadecanoyl-isoGlu)]- [NH2];
Cpd 13: Hy-H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDkkkkk[k(19-carboxy-Nonadecanoyl]- isoGlu)]-[NH2];
Cpd 14: Hy-H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDkkkkk[k(Hexadecanoyl-isoGlu)]- [NH2]; or
Cpd 15: Hy-H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDkkkkk[k([17-carboxy-Heptadecanoyl]- isoGlu)]-[NH2].
The dual agonist may be:
Cpd. 16
Hy-H[Aib]DGSFSSELATILD[K(Hexadecanoyl-isoGlu)]QAVRDFIAWLIQHKITD-OH; Cpd. 17 Hy-H[Aib]DGSFSSELATILD[K([19-carboxy-nonadecanoyl]- isoGlu)]QAARDFIAWLIQHKITD-OH;
Cpd. 18 Hy-H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]-[3-
Aminopropanoyl])]QAARDFIAWLIQHKITD-OH;
Cpd. 19 Hy-H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDkkkkk[k(Hexadecanoyl-[3- aminopropanoyl])]-[NH2];
Cpd. 20 Hy-H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDkkkkk[k(Hexadecanoyl-isoLys)]-
[NH2];
Cpd. 21 Hy-H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]-[3-
Aminopropanoyl])]QAARDFIAWLIQHKITDkkkkk[K(Hexadecanoyl-[3-aminopropanoyl])]- [NH2];
Cpd. 22 Hy-H[Aib]DGSFSSE[K(Hexadecanoyl-[3-
Aminopropanoyl])]ATILDEQAARDFIAWLIQHKITDkkkkk[k(Hexadecanoyl-[3- aminopropanoyl])]-[NH2];
Cpd. 23 Hy-H[Aib]DGSFSDE[K(Octadecanoyl-[3- Aminopropanoyl])]ATILDEQAARDFIAWLIQHKITD-OH;
Cpd. 24 Hy-H[Aib]DGSFSDE[K(Eicosanoyl-[3-
Aminopropanoyl])]ATILDEQAARDFIAWLIQHKITD-OH;
Cpd. 25 Hy-H[Aib]DGSFSSE[K(Dodecanoyl-[3-
Aminopropanoyl])]ATILDEQAARDFIAWLIQHKITD-OH;
Cpd. 26 Hy-H[Aib]DGSFSSE[K(Hexadecanoyl-[3-
Aminopropanoyl])]ATILDEQAARDFIAWLIQHKITD-OH;
Cpd. 27 Hy-H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDkkkkk[k(Octadecanoyl-[3- aminopropanoyl])]-[NH2];
Cpd. 28 Hy-H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDkkkkk[k(Eicosanoyl-[3- aminopropanoyl])]-[NH2];
Cpd. 29 Hy-H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDEKEKE[K(Hexadecanoyl-isoGlu)]-
[NH2];
Cpd. 30 Hy-H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDKKEEE[K(Hexadecanoyl-isoGlu)]- [NH2];
Cpd. 31 Hy-H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDAKAAE[K(Hexadecanoyl-isoGlu)]- [NH2];
Cpd. 32 Hy-H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDAKEKE[K(Hexadecanoyl-isoGlu)]- [NH2];
Cpd. 33 Hy-H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDATILE[K(Hexadecanoyl-isoGlu)]- [NH2];
Cpd. 34 Hy-H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDEKEKE[K([19-Carboxy- nonadecanoyl]-isoGlu)]-[NH2];
Cpd. 35 Hy-H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDEKEKE[K([19-Carboxy- nonadecanoyl]-isoGlu-Peg3-Peg3)]-[NH2];
Cpd. 36 Hy-H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDEKEKE[K([19-Carboxy- nonadecanoyl]-isoGlu-Peg3-Peg3-Peg3)]-[NH2];
Cpd. 37 Hy-H[Aib]DGSFSSE[K(Hexadecanoyl- isoGlu)]ATILDEQAARDFIAWLIQHKITDEKEKE[K(Hexadecanoyl-isoGlu)]-[NH2];
Cpd. 38 Hy-H[Aib]DGSFSSE[K(Hexadecanoyl- isoGlu)]ATILDEQAARDFIAWLIQHKITDEKEKE[K([19-Carboxy-nonadecanoyl]-isoGlu)]-
[NH2];
Cpd. 39 Hy-H[Aib]DGSFSSELATILD[K([19-Carboxy-nonadecanoyl]-isoGlu-Peg3-
Peg3)]QAARDFIAWLIQHKITD-0H;
Cpd. 40 Hy-H[Aib]DGSFSSELATILD[K([19-Carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3-
Peg3)]QAARDFIAWLIQHKITD-0H;
Cpd. 41
Hy-H[Aib]DGSFSDE[K(Hexadecanoyl-isoGlu)]ATILDEQAARDFIAWLIQHKITD-OH;
Cpd. 42
Hy-H[Aib]DGSFSSE[K(Hexadecanoyl-isoGlu)]ATILDEQAARDFIAWLIQHKITD-OH; Cpd. 43 Hy-H[Aib]DGSFSSE[K([19-Carboxy-nonadecanoyl]- isoGlu)]ATILDEQAARDFIAWLIQHKITD-OH;
Cpd. 44 Hy-H[Aib]DGSFSSE[K([19-Carboxy-nonadecanoyl]-isoGlu-
KEK)]ATILDEQAARDFIAWLIQHKITD-OH;
Cpd. 45 Hy-H[Aib]DGSFSSE[K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]ATILDEQAARDFIAWLIQHKITD-0H;
Cpd. 46 Hy-H[Aib]DGSFSSELATILD[K([19-Carboxy-nonadecanoyl]-isoGlu-
KEK)]QAARDFIAWLIQHKITD-OH;
Cpd. 47 Hy-H[Aib]DGSFSSELATILD[K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]QAARDFIAWLIQHKITD-0H;
Cpd. 48 Hy-H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]- isoGlu)]QAARDFIAWLIQHKIT-OH;
Cpd. 49 Hy-H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]- isoGlu)]EAARDFIAWLIQHKITD-OH;
Cpd. 50 Hy-H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]- isoGlu)]QAARDFIAWLIEHKITD-OH;
Cpd. 51 Hy-H[Aib]DGSFSSELATILDEEAARDFIAWLIQHKITDkkkkk[k([17-carboxy-
Heptadecanoyl]-isoGlu)]-[NH2];
Cpd. 52 Hy-H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]- isoGlu)]QAARDFIAWLIQHKITE-OH; Cpd. 53 Hy-H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]- isoGlu)]QAAREFIAWLIQHKITD-OH;
Cpd. 54 Hy-H[Aib]DGSFSSELATILE[K([17-carboxy-heptadecanoyl]- isoGlu)]QAARDFIAWLIQHKITD-OH;
Cpd. 55 Hy-H[Aib]DGSFSSELATILE[K([17-carboxy-heptadecanoyl]- isoGlu)]QAAREFIAWLIQHKITE-OH;
Cpd. 56 Hy-H[Aib]DGSFSSELATILE[K([17-carboxy-heptadecanoyl]- isoGlu)]QAAREFIAWLIQHKITD-OH;
Cpd. 57 Hy-H[Aib]DGTFSSELATILD[K([17-carboxy-heptadecanoyl]- isoGlu)]QAARDFIAWLIQHKITD-OH; or
Cpd. 58 Hy-H[Aib]DGSFSSELATILD[K([19-Carboxy-nonadecanoyl]- isoGlu)]QAARDFIAWLIQHKITDEKEKE[K(Hexadecanoyl-isoGlu)]-[NH2].
The dual agonist may be in the form of a pharmaceutically acceptable salt or solvate, such as a pharmaceutically acceptable acid addition salt.
The invention also provides a composition comprising a dual agonist of the invention, or a pharmaceutically acceptable salt or solvate thereof, together with a carrier, excipient or vehicle. The carrier may be a pharmaceutically acceptable carrier.
The composition may be a pharmaceutical composition. The pharmaceutical composition may be formulated as a liquid suitable for administration by injection or infusion. It may be formulated to achieve slow release of the dual agonist. The present invention further provides a dual agonist of the invention for use in therapy. In yet another aspect there is provided a dual agonist of the present invention for use as a medicament. Also provided is a dual agonist of the invention for use in a method of medical treatment.
The invention also provides a dual agonist of the invention for use in a method of increasing intestinal mass, improving intestinal function (especially intestinal barrier function), increasing intestinal blood flow, or repairing intestinal damage or dysfunction, e.g. damage to the intestinal epithelium.
The invention also provides a dual agonist of the invention for use in a method of prophylaxis or treatment of malabsorption, ulcers (e.g. peptic ulcers, Zollinger-Ellison Syndrome, drug-induced ulcers, and ulcers related to infections or other pathogens), short-bowel syndrome, cul-de-sac syndrome, inflammatory bowel disease (Crohns disease and ulcerative colitis), irritable bowel syndrome (IBS), pouchitis, celiac sprue (for example arising from gluten induced enteropathy or celiac disease), tropical sprue, hypogammaglobulinemic sprue, and mucositis or diarrhea induced by chemotherapy or radiation theraphy, low grade inflammation, metabolic endotoxemia, primary biliary cirrhosis, fatty liver disease (including parental nutrition associated gut atrophy, PNALD (Parenteral Nutrition-Associated Liver Disease), NAFLD (Non- Alcoholic Fatty Liver Disease) and NASH (Non-Alcoholic Steatohepatitis)), or gastrointestinal side-effects of inflammatory conditions such as pancreatitis.
The invention also provides a dual agonist of the invention for use in a method of reducing or inhibiting weight gain, reducing gastric emptying or intestinal transit, reducing food intake, reducing appetite, or promoting weight loss.
The invention also provides a dual agonist of the invention for use in a method of prophylaxis or treatment of obesity, morbid obesity, obesity-linked gallbladder disease, obesity-induced sleep apnea, inadequate glucose control, glucose tolerance, dyslipidaemia (e.g. elevated LDL levels or reduced HDL/LDL ratio), diabetes (e.g. Type 2 diabetes, gestational diabetes), pre-diabetes, metabolic syndrome or hypertension.
The invention also provides a method of increasing intestinal mass, improving intestinal function (especially intestinal barrier function), increasing intestinal blood flow, or repairing intestinal damage or dysfunction in a subject in need thereof, the method comprising administering a dual agonist of the invention to the subject.
The invention also provides a method of prophylaxis or treatment of malabsorption, ulcers (e.g. peptic ulcers, Zollinger-Ellison Syndrome, drug-induced ulcers, and ulcers related to infections or other pathogens), short-bowel syndrome, cul-de-sac syndrome, inflammatory bowel disease (Crohns disease and ulcerative colitis), irritable bowel syndrome (IBS), pouchitis, celiac sprue (for example arising from gluten induced enteropathy or celiac disease), tropical sprue,
hypogammaglobulinemic sprue, diarrhea, low grade inflammation, metabolic endotoxemia, primary biliary cirrhosis, hepatitis and/or fatty liver disease (including parental nutrition associated gut atrophy, PNALD (Parenteral Nutrition-Associated
Liver Disease), NAFLD (Non-Alcoholic Fatty Liver Disease) and NASH (Non-Alcoholic Steatohepatitis)), or gastrointestinal side-effects of inflammatory conditions such as pancreatitis in a subject in need thereof, the method comprising administering a dual agonist of the invention to the subject. The invention also provides a method of reducing or inhibiting weight gain, reducing gastric emptying or intestinal transit, reducing food intake, reducing appetite, or promoting weight loss in a subject in need thereof, the method comprising
administering a dual agonist of the invention to the subject. The invention also provides a method of prophylaxis or treatment of obesity, morbid obesity, obesity-linked gallbladder disease, obesity-induced sleep apnea, inadequate glucose control, glucose tolerance, dyslipidaemia (e.g. elevated LDL levels or reduced HDL/LDL ratio), diabetes (e.g. Type 2 diabetes, gestational diabetes), pre- diabetes, metabolic syndrome or hypertension in a subject in need thereof, the method comprising administering a dual agonist of the invention to the subject.
The invention also provides the use of a dual agonist of the invention in the preparation of a medicament for increasing intestinal mass, improving intestinal function (especially intestinal barrier function), increasing intestinal blood flow, or repairing intestinal damage or dysfunction, e.g. damage to the intestinal epithelium.
The invention also provides the use of a dual agonist of the invention in the preparation of a medicament for prophylaxis or treatment of malabsorption, ulcers (e.g. peptic ulcers, Zollinger-Ellison Syndrome, drug-induced ulcers, and ulcers related to infections or other pathogens), short-bowel syndrome, cul-de-sac syndrome, inflammatory bowel disease (Crohns disease and ulcerative colitis), irritable bowel syndrome (IBS), pouchitis, celiac sprue (for example arising from gluten induced enteropathy or celiac disease), tropical sprue,
hypogammaglobulinemic sprue, diarrhea, low grade inflammation, metabolic endotoxemia, primary biliary cirrhosis, fatty liver disease (including parental nutrition associated gut atrophy, PNALD (Parenteral Nutrition-Associated Liver Disease), NAFLD (Non-Alcoholic Fatty Liver Disease) and NASH (Non-Alcoholic
Steatohepatitis)), or gastrointestinal side-effects of inflammatory conditions such as pancreatitis pancreatitis or graft versus host disease (GVHD).
The invention also provides the use of a dual agonist of the invention in the preparation of a medicament for reducing or inhibiting weight gain, reducing gastric emptying or intestinal transit, reducing food intake, reducing appetite, or promoting weight loss.
The invention also provides the use of a dual agonist of the invention in the preparation of a medicament for prophylaxis or treatment of obesity, morbid obesity, obesity-linked gallbladder disease, obesity-induced sleep apnea, inadequate glucose control, glucose tolerance, dyslipidaemia (e.g. elevated LDL levels or reduced HDL/LDL ratio), diabetes (e.g. Type 2 diabetes, gestational diabetes), pre-diabetes, metabolic syndrome or hypertension. A further aspect provides a therapeutic kit comprising a dual agonist, or a
pharmaceutically acceptable salt or solvate thereof, according to the invention.
Detailed Description of the Invention
Unless otherwise defined herein, scientific and technical terms used in this application shall have the meanings that are commonly understood by those of ordinary skill in the art. Generally, nomenclature used in connection with, and techniques of, chemistry, molecular biology, cell and cancer biology, immunology, microbiology, pharmacology, and protein and nucleic acid chemistry, described herein, are those well known and commonly used in the art.
All patents, published patent applications and non-patent publications referred to in this application are specifically incorporated by reference herein. In case of conflict, the present specification, including its specific definitions, will control.
Each embodiment of the invention described herein may be taken alone or in combination with one or more other embodiments of the invention. Definitions
Unless specified otherwise, the following definitions are provided for specific terms which are used in the present written description.
Throughout this specification, the word "comprise", and grammatical variants thereof, such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or component, or group of integers or components, but not the exclusion of any other integer or component, or group of integers or components.
The singular forms "a," "an," and "the" include the plurals unless the context clearly dictates otherwise.
The term "including" is used to mean "including but not limited to". "Including" and "including but not limited to" may be used interchangeably.
The terms "patient", "subject" and "individual" may be used interchangeably and refer to either a human or a non-human animal. These terms include mammals such as humans, primates, livestock animals (e.g., bovines and porcines), companion animals (e.g., canines and felines) and rodents (e.g., mice and rats).
The term "solvate" in the context of the present invention refers to a complex of defined stoichiometry formed between a solute (in casu, a peptide or
pharmaceutically acceptable salt thereof according to the invention) and a solvent. The solvent in this connection may, for example, be water, ethanol or another pharmaceutically acceptable, typically small-molecular organic species, such as, but not limited to, acetic acid or lactic acid. When the solvent in question is water, such a solvate is normally referred to as a hydrate.
The term "agonist" as employed in the context of the invention refers to a substance (ligand) that activates the receptor type in question.
Throughout the present description and claims the conventional three-letter and one- letter codes for naturally occurring amino acids are used, i.e.
A (Ala), G (Gly), L (Leu), I (lie), V (Val), F (Phe), W (Trp), S (Ser), T (Thr), Y (Tyr), N (Asn), Q (Gin), D (Asp), E (Glu), K (Lys), R (Arg), H (His), M (Met), C (Cys) and P (Pro);
as well as generally accepted three-letter codes for other oarmino acids, such as sarcosine (Sar), norleucine (NIe), a-aminoisobutyric acid (Aib), 2,3-diaminopropanoic acid (Dap), 2,4-diaminobutanoic acid (Dab) and 2,5-diaminopentanoic acid (ornithine; Orn). Such other oarmino acids may be shown in square brackets "[ ]" (e.g. "[Aib]") when used in a general formula or sequence in the present specification, especially when the rest of the formula or sequence is shown using the single letter code.
Unless otherwise specified, amino acid residues in peptides of the invention are of the L-configuration. However, D-configuration amino acids may be incorporated. In the present context, an amino acid code written with a small letter represents the D- configuration of said amino acid, e.g. "k" represents the D-configuration of lysine (K).
Among sequences disclosed herein are sequences incorporating a "Hy-"moiety at the amino terminus (N-terminus) of the sequence, and either an "-OH" moiety or an "- NH2" moiety at the carboxy terminus (C-terminus) of the sequence. In such cases, and unless otherwise indicated, a "Hy-" moiety at the N-terminus of the sequence in question indicates a hydrogen atom [i.e. R1 = hydrogen = Hy in the general formulas; corresponding to the presence of a free primary or secondary amino group at the N- terminus], while an "-OH" or an "-NH2" moiety at the C-terminus of the sequence indicates a hydroxy group [e.g. R2 = OH in general formulas; corresponding to the presence of a carboxy (COOH) group at the C-terminus] or an amino group [e.g. R2 = [NH2] in the general formulas; corresponding to the presence of an amido (CONH2) group at the C-terminus], respectively. In each sequence of the invention, a C- terminal "-OH" moiety may be substituted for a C-terminal "-NH2" moiety, and vice- versa. "Percent (%) amino acid sequence identity" with respect to the GLP-2 polypeptide sequences is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in the wild-type (human) GLP-2 sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Sequence alignment can be carried out by the skilled person using techniques well known in the art, for example using publicly available software such as BLAST, BLAST2 or Align software. For examples, see Altschul et al., Methods in Enzymology 266: 460-480 (1996) or Pearson et al., Genomics 46: 24-36, 1997.
The percentage sequence identities used herein in the context of the present invention may be determined using these programs with their default settings. More generally, the skilled worker can readily determine appropriate parameters for determining alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
Dual agonists of the invention
In accordance with the present invention, the dual agonist has at least one GLP-1 and at least one GLP-2 biological activity. Exemplary GLP-1 physiological activities include reducing rate of intestinal transit, reducing rate of gastric emptying, reducing appetite, food intake or body weight, and improving glucose control and glucose tolerance. Exemplary GLP-2 physiological activities include causing an increase in intestinal mass (e.g. of small intestine or colon), intestinal repair, and improving intestinal barrier function (i.e. reducing permeability of the intestine). These parameters can be assessed in in vivo assays in which the mass and the permeability of the intestine, or a portion thereof, is determined after a test animal has been treated with a dual agonist.
The dual agonists have agonist activity at the GLP-1 and GLP-2 receptors, e.g. the human GLP-1 and GLP-2 receptors. EC50 values for in vitro receptor agonist activity may be used as a numerical measure of agonist potency at a given receptor. An EC50 value is a measure of the concentration (e.g. mol/L) of a compound required to achieve half of that compound's maximal activity in a particular assay. A compound having a numerical EC50 at a particular receptor which is lower than the EC50 of a reference compound in the same assay may be considered to have higher potency at that receptor than the reference compound. GLP-1 activity
In some embodiments, the dual agonist has an EC50 at the GLP-1 receptor (e.g. the human GLP-1 receptor) which is below 18.5 nM, below 15.0 nM, below 10.0 nM, below 5.0 nM, below 1.1 nM, below 1.0, below 0.9 nM, below 0.8 nM, below 0.7 nM, below 0.6 nM, below 0.5 nM, below 0.4 nM, below 0.3 nM, below 0.2 nM, below 0.1 nM, below 0.09 nM, below 0.08 nM, below 0.07 nM, below 0.06 nM, below 0.05 nM, e.g. when assessed using the GLP-1 receptor potency assay described in the Examples below
In some embodiments, the dual agonist has an EC50 at the GLP-1 receptor which is between 0.05 nM and 18.5 nM, between 0.06 nM and 0.9 nM, between 0.07 nM and 0.8 nM, between 0.08 nM and 0.85 nM, between 0.09 nM and 0.7 nM, between 0.1 nM and 0.65 nM, between 0.2 nM and 0.6 nM, between 0.23 nM and 0.59 nM between 0.3 nM and 0.55 nM, between 0.4 nM and 0.5 nM, between 0.07 nM and 0.35 nM, between 0.08 nM and 0.3 nM, between 0.09 nM and 0.25 nM, between 0.1 nM and 0.2 nM, between 0.13 nM and 0.95 nM, between 0.2 nM and 0.95 nM, between 0.3 nM and 0.96 nM, between 0.4 nM and 0.5 nM, between 0.5 nM and 1 .0 nM, between 0.6 nM and 1.0 nM, between 0.7 nM and 1.0 nM, between 0.8 nM and 1 .0 nM, e.g. when assessed using the GLP-1 receptor potency assay described in the Examples below In some embodiments, the dual agonist has an EC50 at the GLP-1 receptor which is below 1.0 nM, below 0.9 nM, below 0.8 nM, below 0.7 nM, below 0.6 nM, below 0.5 nM, below 0.4 nM, below 0.3 nM, below 0.2 nM, below 0.1 nM, below 0.09 nM, below 0.08 nM, below 0.07 nM, below 0.06 nM, below 0.05 nM, below 0.04 nM, below 0.03 nM, below 0.02 nM, below 0.01 nM, below 0.009 nM, e.g. when assessed using the GLP-1 receptor potency assay described in the Examples below.
In some embodiments, the dual agonist has an EC50 at the GLP-1 receptor which is between 0.009 nM and 1.0 nM, between 0.009 nM and 0.9 nM, between 0.009 nM and 0.8 nM, between 0.009 nM and 0.7 nM, between 0.01 nM and 0.65 nM, between 0.02 nM and 0.6 nM, between 0.023 nM and 0.59 nM between 0.03 nM and 0.55 nM, between 0.04 nM and 0.5 nM, 0.01 nM and 0.5 nM, between 0.05 nM and 0.45 nM, between 0.06 nM and 0.4 nM, between 0.62 nM and 0.888 nM, between 0.07 nM and 0.35 nM, between 0.08 nM and 0.3 nM, between 0.09 nM and 0.25 nM, between 0.1 nM and 0.2 nM, between 0.13 nM and 0.95 nM, between 0.2 nM and 0.95 nM, between 0.3 nM and 0.96 nM, between 0.4 nM and 0.5 nM, between 0.5 nM and 1 .0 nM, between 0.6 nM and 1.0 nM, between 0.7 nM and 1.0 nM, between 0.8 nM and
I .0 nM, e.g. when assessed using the GLP-1 receptor potency assay described in the Examples below
In some embodiments, the dual agonist has an EC50 at the GLP-1 receptor which is between 1 .001 nM and 10 nM, between 1 .01 nM and 10 nM, between 1.1 nM and 10 nM, between 1 .2 nM and 9.0 nM, between 1 .5 nM and 8.0 nM, between 1 .6 nM and 6.0 nM, between 1.7 nM and 5.0 nM, between 1 .8 nM and 2.0 nM, between 1.9 nM and 10.0 nM, between 2.0 nM and 9.5 nM, between 2.5 nM and 8.5 nM, between 3.0 nM and 7.5 nM, between 3.5 nM and 8.5 nM, between 4.0 nM and 5.0 nM, between 1.1 nM and 1 .9 nM, between 1.2 nM and 1.8 nM, between 1 .3 nM and 1 .7 nM, between 1 .4 nM and 1 .6 nM, between 1 .2 nM and 1 .7 nM, between 1 .1 nM and 1 .7 nM, e.g. when assessed using the GLP-1 receptor potency assay described in the Examples below
In some embodiments, the dual agonist has an EC50 at the GLP-1 receptor which is above 10.0 nM, above 10.01 nM, above 10.5 nM, above 1 1.0 nM, above 1 1 .5 nM, above 12.0 nM, above 12.5 nM, above 13.0 nM, above 13.5 nM, above 14.0 nM, above 14.5 nM, above 15 nM, above 15.5 nM, above 16 nM, above 20 nM, above 25 nM, above 50 nM, above 100 nM, above 200 nM, above 300 nM, above 400 nM, above 500 nM, e.g. when assessed using the GLP-1 receptor potency assay described in the Examples below.
In some embodiments, the dual agonist has an EC50 at the GLP-1 receptor which is between 10.0 nM and 500 nM, between 12.0 nM and 400 nM, between 14.0 nM and 200 nM, between 15.0 nM and 100 nM, between 20 nM and 50 nM, between 30 nM and 40 nM, between 1 1 .0 nM and 75 nM, between 12.0 nM and 60 nM, between 13.0 nM and 50 nM, between 14.0 nM and 40 nM, between 12.0 nM and 13.0 nM, between
I I .0 nM and 13.5 nM, e.g. when assessed using the GLP-1 receptor potency assay described in the Examples below.
An alternative measure of GLP-1 agonist activity may be derived by comparing the potency of a dual agonist with the potency of a known (or reference) GLP-1 agonist when both are measured in the same assay. Thus the relative potency at the GLP-1 receptor may be defined as:
[EC5o(reference agonist)] / [ECso(dual agonist)]. Thus a value of 1 indicates that the dual agonist and reference agonist have equal potency, a value of >1 indicates that the dual agonist has higher potency (i.e. lower EC50) than the reference agonist, and a value of <1 indicates that the dual agonist has lower potency (i.e. higher EC50) than the reference agonist. The reference GLP-1 agonist may, for example, be human GLP-1 (7-37), liraglutide (NN221 1 ; Victoza), or Exendin-4, but is preferably liraglutide.
Typically the relative potency will be between 0.001 and 100, e.g. between 0.001 and 10, between 0.001 and 5, between 0.001 and 1 , between 0.001 and 0.5, between 0.001 and 0.1 , between 0.001 and 0.05, between 0.001 and 0.01 or between 0.001 and 0.5; between 0.01 and 10, between 0.01 and 5, between 0.01 and 1 , between 0.01 and 0.5, between 0.01 and 0.1 , or between 0.01 and 0.05; between 0.05 and 10, between 0.05 and 5, between 0.05 and 1 , between 0.05 and 0.5, or between 0.05 and 0.1 ; between 0.1 and 10, between 0.1 and 5, between 0.1 and 1 , or between 0.1 and 0.5; between 0.5 and 10, between 0.5 and 5, or between 0.5 and 1 ; between 1 and 10, or between 1 and 5; or between 5 and 10.
The dual agonists described in the examples below may have a relative potency (using liraglutide as a reference) between 0.001 and 1 , between 0.001 and 0.5;
between 0.01 and 0.1 , or between 0.01 and 0.05.
By contrast, the dual agonists of the invention have higher potency at the GLP-1 receptor (e.g. the human GLP-1 receptor) than wild type human GLP-2 (hGLP-2 (1 - 33)) or [Gly2]-hGLP-2 (1 -33) (i.e. human GLP-2 having glycine at position 2, also known as teduglutide). Thus, the relative potency of the dual agonists at the GLP-1 receptor compared to hGLP-2 (1 -33) or teduglutide is greater than 1 , typically greater than 5 or greater than 10, and may be up to 100, up to 500, or even higher.
GLP-2 activity
In some embodiments, the dual agonist has an EC50 at the GLP-2 receptor which is below 1.0 nM, below 0.9 nM, below 0.8 nM, below 0.7 nM, below 0.6 nM, below 0.5 nM, below 0.4 nM, below 0.3 nM, below 0.2 nM, below 0.1 nM, below 0.09 nM, below 0.08 nM, below 0.07 nM, below 0.06 nM, below 0.05 nM, below 0.04 nM, below 0.03 nM, below 0.02 nM, below 0.015, below 0.01 nM, below 0.009 nM, below 0.008 nM, below 0.007 nM, below 0.006 nM, or below 0.005 nM, below 0.003 nM, or below 0.002 nM, e.g. when assessed using the GLP-2 receptor potency assay described in the Examples below.
In some embodiments, the dual agonist has an EC50 at the GLP-2 receptor which is between between 0.002 and 1 .0 nM, between 0.005 nM and 1.0 nM, between 0.006 nM and 0.9 nM, between 0.007 nM and 0.8 nM, between 0.008 nM and 0.85 nM, between 0.009 nM and 0.7 nM, between 0.01 nM and 0.65 nM, between 0.02 nM and 0.6 nM, between 0.023 nM and 0.59 nM between 0.03 nM and 0.55 nM, between 0.04 nM and 0.5 nM, between 0.05 nM and 0.45 nM, between 0.06 nM and 0.4 nM, between 0.62 nM and 0.888 nM, between 0.07 nM and 0.35 nM, between 0.08 nM and 0.3 nM, between 0.09 nM and 0.25 nM, between 0.1 nM and 0.2 nM, between 0.13 nM and 0.95 nM, between 0.2 nM and 0.95 nM, between 0.3 nM and 0.96 nM, between 0.4 nM and 0.5 nM, between 0.5 nM and 1 .0 nM, between 0.6 nM and 1 .1 nM, between 0.7 nM and 1.2 nM, between 0.8 nM and 1 .0 nM, e.g. when assessed using the GLP-2 receptor potency assay described in the Examples below.
An alternative measure of GLP-2 agonist activity may be derived by comparing the potency of a dual agonist with the potency of a known (or reference) GLP-2 agonist when both are measured in the same assay. Thus the relative potency at the GLP-2 receptor may be defined as:
[EC5o(reference agonist)] / [ECso(dual agonist)].
Thus a value of 1 indicates that the dual agonist and reference agonist have equal potency, a value of >1 indicates that the dual agonist has higher potency (i.e. lower EC50) than the reference agonist, and a value of <1 indicates that the dual agonist has lower potency (i.e. higher EC50) than the reference agonist.
The reference GLP-2 agonist may, for example, be human GLP-2(1 -33) or teduglutide ([Gly2]-hGLP-2 (1 -33)). Typically the relative potency will be between 0.001 and 100, e.g. between 0.001 and 10, between 0.001 and 5, between 0.001 and 1 , between 0.001 and 0.5, between 0.001 and 0.1 , between 0.001 and 0.05, or between 0.001 and 0.01 ; between 0.01 and 10, between 0.01 and 5, between 0.01 and 1 , between 0.01 and 0.5, between 0.01 and 0.1 , or between 0.01 and 0.05; between 0.05 and 10, between 0.05 and 5, between 0.05 and 1 , between 0.05 and 0.5, or between 0.05 and 0.1 ; between 0.04 and 10, between 0.04 and 5, between 0.04 and 1 , between 0.04 and 0.5, between 0.04 and 0.3 or between 0.04 and 0.1 ; between 0.1 and 10, between 0.1 and 5, between 0.1 and 1 , or between 0.1 and 0.5; between 0.5 and 10, between 0.5 and 5, or between 0.5 and 1 ; between 1 and 10, or between 1 and 5; or between 5 and 10.
The dual agonists described in the examples below may have a relative potency (using teduglutide as a reference) a relative potency between 0.01 and 1 .5, between 0.01 and 1 , between 0.01 and 0.5, or between 0.01 and 0.1.
By contrast, the dual agonists of the invention have higher potency at the GLP-2 receptor (e.g. the human GLP-2 receptor) than human GLP-1 (7-37), liraglutide
(NN221 1 ; Victoza), or Exendin-4. Thus, the relative potency of the dual agonists at the GLP-1 receptor compared to human GLP-1 (7-37), liraglutide (NN221 1 ; Victoza), or Exendin-4 is greater than 1 , typically greater than 5 or greater than 10, and may be up to 100, up to 500, or even higher. It will be understood that the absolute potencies of the dual agonists at each receptor are much less important than the balance between the GLP-1 and GLP-2 agonist activities. Thus it is perfectly acceptable for the absolute GLP-1 or GLP-2 potency to be lower than that of known agonists at those receptors, as long as the dual agonist compound exerts acceptable relative levels of potency at both receptors. Any apparent deficiency in absolute potency can be compensated by an increased dose if required
Substituents
The dual agonist of the present invention contains a residue Ψ which comprises a residue of Lys, Arg, Orn, Dap or Dab in which the side chain is conjugated to a substituent Z1- or Z1-Z2- wherein Z1 represents a moiety CH3-(CH2)io-22-(CO)- or HOOC-(CH2)io-22-(CO)- and Z2 when present represents a spacer. The spacer Z2 is selected from
Figure imgf000034_0001
Figure imgf000034_0002
ZS1 is isoGlu, β-Ala, isoLys, or 4-aminobutanoyl;
ZS2 is -(Peg3)m- where m is 1 , 2, or 3; and
ZS3- is a peptide sequence of 1 -6 amino acid units selected from the group consisting of A, L, S, T, Y, Q, D, E, K, k, R, H, F and G.
Without wishing to be bound by theory, it is believed that the hydrocarbon chain of Z1 binds albumin in the blood stream, thus shielding the dual agonists of the present invention from enzymatic degradation, which can enhance the half-life of the dual agonists.
In the present context, the term "half-life," refers to the time taken for the
concentration of the GLP-1/GLP-2 dual agonist to reduce by 50%, in vivo, for example due to degradation of the dual agonist and/or clearance or sequestration of the dual agonist by natural mechanisms. Increasing half-life and/or decreasing the clearance refers to increasing the time taken for the dual agonist to be eliminated from the body. For the dual agonists of the invention this entails an extended duration of
pharmacological effect. The pharmacokinetic properties of the dual agonists of the invention may suitably be determined in vivo in pharmacokinetic (PK) studies. Such studies are conducted to evaluate how pharmaceutical compounds are absorbed, distributed, and eliminated in the body, and how these processes affect the concentration of the compound in the body, over the course of time.
Thus, the half-life of a GLP-1/GLP-2 dual agonist is increased if its functional activity persists, in vivo, for a longer period than e.g. the commercial available GLP-2 molecule or teduglutide. In some embodiments, the half-life of the dual agonist is increased by at least 2 fold, such as at least 3 fold, such as at least 4 fold, such as at least 6 fold, such as at least 7 fold, such as at least 10 fold, such as at least 15 fold, or such as at least 25 fold where terminal half-life (T½) in vivo in mice is determined after i.v. or s.c. administration. The plasma terminal elimination half-life (T½) is determined as ln(2)/ λζ where λζ is the magnitude of the slope of the log linear regression of the log concentration versus time profile during the terminal phase, e.g. as described in Examples below.
In some embodiments, the GLP-1/GLP-2 dual agonist has a half-life of at least 2 hours, such as at least 2.5 hours, such as at least 4 hours, such as at least 5 hours, such as at least 6 hours, such as at least 7 hours, such as at least 8 hours, such as at least 9 hours, such as at least 10 hours or more, where terminal half-life (T½) in vivo in mice is determined after i.v. or s.c. administration. The plasma terminal elimination half-life (T½) is determined as ln(2)/ λζ where λζ is the magnitude of the slope of the log linear regression of the log concentration versus time profile during the terminal phase, e.g. as described in Examples below.
The substituent may also modulate the potency of the dual agonists, with respect to the GLP-2 receptor and/or the GLP-1 receptor.
The substituent Z1- or Z1-Z2- is conjugated to the functional group at the distal end of the side-chain from the alpha-carbon of the relevant amino acid residue. The normal ability of the amino acid (Lys, Arg, Orn, Dab, Dap) side-chain in question to participate in interactions mediated by that functional group (e.g. intra- and inter-molecular interactions) may therefore be reduced or completely eliminated by the presence of the substituent. Thus, the overall properties of the dual agonist may be relatively insensitive to changes in the actual amino acid conjugated to the substituent.
Consequently, it is believed that any of the residues Lys, Arg, Orn, Dab, or Dap may be present at any position where Ψ is permitted. However, in certain embodiments, it may be advantageous that the amino acid to which the substituent is conjugated is Lys or Orn. The moiety Z1 may be covalently bonded to the functional group in the amino acid side-chain, or alternatively may be conjugated to the amino acid side-chain functional group via a spacer Z2.
The term "conjugated" is used here to describe the covalent attachment of one identifiable chemical moiety to another, and the structural relationship between such moieties. It should not be taken to imply any particular method of synthesis.
The bonds between Z1, ZS1, ZS2, ZS3 and the amino acid side chain to which the substituent is bound (collectively referred to herein as Ψ) are peptidic. In other words, the units may be joined by amide condensation reactions.
Z1 comprises a hydrocarbon chain having from 10 to 24 carbon (C) atoms, such as from 10 to 22 C atoms, e.g. from 10 to 20 C atoms. Preferably, it has at least 10 or at least 1 1 C atoms, and preferably it has 20 C atoms or fewer, e.g. 18 C atoms or fewer. For example, the hydrocarbon chain may contain 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms. For example, it may contain 18 or 20 carbon atoms. In some embodiments, Z1 is a group selected from dodecanoyl, tetradecanoyl, hexadecanoyi, octadecanoyi and eicosanoyi, preferably hexadecanoyi, octadecanoyi or eicosanoyi, more preferably octadecanoyi or eicosanoyi.
Alternative Z1 groups are derived from long-chain saturated α,ω-dicarboxylic acids of formula HOOC-(CH2)i2-22-COOH, preferably from long-chain saturated α,ω- dicarboxylic acids having an even number of carbon atoms in the aliphatic chain. For example, Z1 may be:
13-carboxytridecanoyl, i.e. HOOC-(CH2)i2-(CO)-;
15-carboxypentadecanoyl, i.e. HOOC-(CH2)i4-(CO)-;
17-carboxyheptadecanoyl, i.e. HOOC-(CH2)i6-(CO)-;
19-carboxynonadecanoyl, i.e. HOOC-(CH2)i8-(CO)-; or
21 -carboxyheneicosanoyl, i.e. HOOC-(CH2)2o-(CO)-.
As mentioned above, Z1 may be conjugated to the amino acid side-chain by a spacer Z2. When present, the spacer is attached to Z1 and to the amino acid side-chain.
The spacer Z2 has the formula
Figure imgf000036_0001
Figure imgf000036_0002
-ZS1- is isoGlu, β-Ala, isoLys, or 4-aminobutanoyl;
-ZS2- is -(Peg3)m- where m is 1 , 2, or 3; and
-ZS3- is a peptide sequence of 1 -6 amino acid units independently selected from the group consisting of A (Ala), L (Leu), S (Ser), T (Thr), Y (Tyr), Q (Gin), D (Asp), E (Glu), K (L-Lys), k (D-Lys), R (Arg), H (His), F (Phe) and G (Gly).
The terms "isoGlu" and "isoLys" indicate residues of amino acids which participate in bonds via their side chain carboxyl or amine functional groups. Thus isoGlu participates in bonds via its alpha amino and side chain carboxyl group, while isoLys participates via its carboxyl and side chain amino groups. In the context of the present specification, the terms "γ-Glii" and "isoGlu" are used interchangeably.
The term Peg3 is used to refer to an 8-amino-3,6-dioxaoctanoyl group.
ZS3 may, for example, be 3 to 6 amino acids in length, i.e. 3, 4, 5 or 6 amino acids in length.
In some embodiments, the amino acids of ZS3 are independently selected from K, k, E, A, T, I and L, e.g. from K, k, E and A, e.g. from K, k and E.
Typically ZS3 includes at least one charged amino acid (K, k, R or E, e.g. K, k or E) and preferably two or more charged amino acids. In some embodiments it includes at least 2 positively charged amino acids (K, k or R, especially K or k), or at least 1 positively charged amino acid (K, k or R, especially K or k) and at least one negatively charged amino acid (E). In some embodiments, all amino acid residues of ZS3 are charged. For example, ZS3 may be a chain of alternately positively and negatively charged amino acids.
Examples of ZS3 moieties include KEK, EKEKEK, kkkkkk, EkEkEk, AKAAEK,
AKEKEK and ATILEK.
Without being bound by theory, it is believed that the incorporation of ZS3 into the linker between the fatty acid chain and the peptide backbone may increase the half- life of the dual agonist by enhancing its affinity for serum albumin.
In some embodiments, -Z2- is -ZS1- or -Zs1-ZS2-; in other words, -Z2- is selected from: isoGlu(Peg3)0-3;
3- Ala(Peg3)0-3;
isoLys(Peg3)o-3; and
4- aminobutanoyl(Peg3)o-3.
Thus, certain examples of substituents Z1- include
[Dodecanoyl], [Tetradecanoyl], [Hexadecanoyl], [Octadecanoyl], [Eicosanoyl],
[13-Carboxy-tridecanoyl], [15-Carboxy-pentadecanoyl], [17-Carboxy-heptadecanoyl], [19-Carboxy-nonadecanoyl], [21 -carboxy-heneicosanoyl].
More broadly, -Z2- may be -ZS1-, -ZS1-ZS2-, -ZS3-ZS1-, -ZS1-ZS3-, -ZS1-ZS3-ZS2-, -ZS3-ZS2- ZS1- or ZS3-. Thus, -Z2- may be selected from the group consisting of:
isoGlu(Peg3)0-3;
3- Ala(Peg3)0-3;
isoLys(Peg3)0-3;
4- aminobutanoyl(Peg3)o-3; isoGlu(KEK)(Peg3)0-3;
3-Ala(KEK)(Peg3)0-3;
isoLys(KEK)(Peg3)0-3;
4-aminobutanoyl(KEK)(Peg3)o-3; KEK(isoGlu);
KEK(β-Ala);
KEK(isoLys);
KEK(4-aminobutanoyl); isoGlu(KEK);
β- Ala(KEK);
isoLys(KEK);
4- aminobutanoyl(KEK);
KEK(isoGlu)(Peg3)0-3;
KEK(β-Ala)(Peg3)0-3;
KEK(isoLys)(Peg3)0-3; and
KEK(4-aminobutanoyl)(Peg3)o-3.
Certain examples of substituents Z1-Z2- include:
[Dodecanoyl]-isoGlu, [Tetradecanoyl]-isoGlu, [Hexadecanoyl]-isoGlu, [Octadecanoyl]- isoGlu, [Eicosanoyl]-isoGlu,
[Hexadecanoyl]-βAla, [Octadecanoyl]-βAla, [Eicosanoyl]-βAla, [Tetradecanoyl]-βAla, [Dodecanoyl]-βAla,
[Dodecanoyl]-isoGlu-Peg3, [Tetradecanoyl]-isoGlu-Peg3, [Hexadecanoyl]-isoGlu- Peg3, [Octadecanoyl]-isoGlu-Peg3, [Eicosanoyl]-isoGlu-Peg3,
[DodecanoyI]- βAla-Peg3, [TetradecanoyI]- βAla-Peg3, [HexadecanoyI]- βAla-Peg3, [OctadecanoyI]- βAla-Peg3, [EicosanoyI]- βAla-Peg3,
[Dodecanoyl]-isoGlu-Peg3-Peg3, [Tetradecanoyl]-isoGlu-Peg3-Peg3,
[Hexadecanoyl]-isoGlu-Peg3-Peg3, [Octadecanoyl]-isoGlu-Peg3-Peg3, [Eicosanoyl]- isoGlu-Peg3-Peg3,
[DodecanoyI]- βAla-Peg3-Peg3, [TetradecanoyI]- βAla-Peg3-Peg3, [Hexadecanoyl]- βAla-Peg3-Peg3, [OctadecanoyI]- βAla-Peg3-Peg3, [EicosanoyI]- βAla-Peg3-Peg3,
[Dodecanoyl]-isoGlu-Peg3-Peg3-Peg3, [Tetradecanoyl]-isoGlu-Peg3-Peg3-Peg3, [Hexadecanoyl]-isoGlu-Peg3-Peg3-Peg3, [Octadecanoyl]-isoGlu-Peg3-Peg3-Peg3, [Eicosanoyl]-isoGlu-Peg3-Peg3-Peg3,
[DodecanoyI]- βAla-Peg3-Peg3-Peg3, [TetradecanoyI]- βAla-Peg3-Peg3-Peg3,
[HexadecanoyI]- βAla-Peg3-Peg3-Peg3, [OctadecanoyI]- βAla-Peg3-Peg3-Peg3, [EicosanoyI]- βAla-Peg3-Peg3-Peg3, [Dodecanoyl]-isoLys, [Tetradecanoyl]-isoLys, [Hexadecanoyl]-isoLys, [Octadecanoyl]- isoLys, [Eicosanoyl]-isoLys,
[Hexadecanoyl]-[4-aminobutanoyl], [Octadecanoyl]-[4-aminobutanoyl], [Eicosanoyl]- [4-aminobutanoyl], [Tetradecanoyl]-[4-aminobutanoyl], [Dodecanoyl]-[4- aminobutanoyl],
[Dodecanoyl]-isoLys-Peg3, [Tetradecanoyl]-isoLys-Peg3, [Hexadecanoyl]-isoLys- Peg3, [Octadecanoyl]-isoLys-Peg3, [Eicosanoyl]-isoLys-Peg3,
[Dodecanoyl]-[4-aminobutanoyl]-Peg3, [Tetradecanoyl]- [4-aminobutanoyl]-Peg3, [Hexadecanoyl]-[4-aminobutanoyl]-Peg3, [Octadecanoyl]-[4-aminobutanoyl]-Peg3, [Eicosanoyl]-[4-aminobutanoyl]-Peg3,
[Dodecanoyl]-isoLys-Peg3-Peg3, [Tetradecanoyl]-isoLys-Peg3-Peg3,
[Hexadecanoyl]-isoLys-Peg3-Peg3, [Octadecanoyl]-isoLys-Peg3-Peg3, [Eicosanoyl]- isoLys-Peg3-Peg3,
[Dodecanoyl]-[4-aminobutanoyl]-Peg3-Peg3, [Tetradecanoyl]-[4-aminobutanoyl]- Peg3-Peg3, [Hexadecanoyl]-[4-aminobutanoyl]-Peg3-Peg3, [Octadecanoyl]-[4- aminobutanoyl]-Peg3-Peg3, [Eicosanoyl]-[4-aminobutanoyl]-Peg3-Peg3,
[Dodecanoyl]-isoLys-Peg3-Peg3-Peg3, [Tetradecanoyl]-isoLys-Peg3-Peg3-Peg3, [Hexadecanoyl]-isoLys-Peg3-Peg3-Peg3, [Octadecanoyl]-isoLys-Peg3-Peg3-Peg3, [Eicosanoyl]-isoLys-Peg3-Peg3-Peg3,
[Dodecanoyl]-[4-aminobutanoyl]-Peg3-Peg3-Peg3, [Tetradecanoyl]-[4- aminobutanoyl]-Peg3-Peg3-Peg3, [Hexadecanoyl]-[4-aminobutanoyl]-Peg3-Peg3- Peg3, [Octadecanoyl]-[4-aminobutanoyl]-Peg3-Peg3-Peg3, [Eicosanoyl]-[4- aminobutanoyl]-Peg3-Peg3-Peg3,
[13-carboxy-tridecanoyl]-isoGlu, [15-carboxy-Pentadecanoyl]-isoGlu, [17-carboxy- Heptadecanoyl]-isoGlu, [19-carboxy-Nonadecanoyl]-isoGlu, [21 -carboxy- heneicosanoyl]-isoGlu,
[17-carboxy-Heptadecanoyl]-βAla, [19-carboxy-Nonadecanoyl]-βAla, [21 -carboxy- heneicosanoyl]-βAla, [15-carboxy-Pentadecanoyl]-βAla, [13-carboxy-tridecanoyl]- βAla,
[13-carboxy-tridecanoyl]-isoGlu-Peg3, [15-carboxy-Pentadecanoyl]-isoGlu-Peg3, [17- carboxy-Heptadecanoyl]-isoGlu-Peg3, [19-carboxy-Nonadecanoyl]-isoGlu-Peg3, [21 - carboxy-heneicosanoyl]-isoGlu-Peg3, [13-carboxy-tridecanoyl]- βAla-Peg3, [15-carboxy-Pentadecanoyl]- βAla-Peg3, [17- carboxy-Heptadecanoyl]- βAla-Peg3, [19-carboxy-Nonadecanoyl]- βAla-Peg3, [21 - carboxy-heneicosanoyl]- βAla-Peg3,
[13-carboxy-tridecanoyl]-isoGlu-Peg3-Peg3, [15-carboxy-Pentadecanoyl]-isoGlu- Peg3-Peg3, [17-carboxy-Heptadecanoyl]-isoGlu-Peg3-Peg3, [19-carboxy-
Nonadecanoyl]-isoGlu-Peg3-Peg3, [21 -carboxy-heneicosanoyl]-isoGlu-Peg3-Peg3,
[13-carboxy-tridecanoyl]- βAla-Peg3-Peg3, [15-carboxy-Pentadecanoyl]- βAla-Peg3- Peg3, [17-carboxy-Heptadecanoyl]- βAla-Peg3-Peg3, [19-carboxy-Nonadecanoyl]- βAla-Peg3-Peg3, [21 -carboxy-heneicosanoyl]- βAla-Peg3-Peg3,
[13-carboxy-tridecanoyl]-isoGlu-Peg3-Peg3-Peg3, [15-carboxy-Pentadecanoyl]- isoGlu-Peg3-Peg3-Peg3, [17-carboxy-Heptadecanoyl]-isoGlu-Peg3-Peg3-Peg3, [19- carboxy-Nonadecanoyl]-isoGlu-Peg3-Peg3-Peg3, [21 -carboxy-heneicosanoyl]-isoGlu- Peg3-Peg3-Peg3,
[13-carboxy-tridecanoyl]- βAla-Peg3-Peg3-Peg3, [15-carboxy-Pentadecanoyl]- βAla- Peg3-Peg3-Peg3, [17-carboxy-Heptadecanoyl]- βAla-Peg3-Peg3-Peg3, [19-carboxy- Nonadecanoyl]- βAla-Peg3-Peg3-Peg3, [21 -carboxy-heneicosanoyl]- βAla-Peg3- Peg3-Peg3,
[13-carboxy-tridecanoyl]-isoLys, [15-carboxy-Pentadecanoyl]-isoLys, [17-carboxy- Heptadecanoyl]-isoLys, [19-carboxy-Nonadecanoyl]-isoLys, [21 -carboxy- heneicosanoyl]-isoLys,
[17-carboxy-Heptadecanoyl]-[4-aminobutanoyl], [19-carboxy-Nonadecanoyl]-[4- aminobutanoyl], [21 -carboxy-heneicosanoyl]-[4-aminobutanoyl], [15-carboxy- Pentadecanoyl]-[4-aminobutanoyl], [13-carboxy-tridecanoyl]-[4-aminobutanoyl],
[13-carboxy-tridecanoyl]-isoLys-Peg3, [15-carboxy-Pentadecanoyl]-isoLys-Peg3, [17- carboxy-Heptadecanoyl]-isoLys-Peg3, [19-carboxy-Nonadecanoyl]-isoLys-Peg3, [21 - carboxy-heneicosanoyl]-isoLys-Peg3,
[13-carboxy-tridecanoyl]-[4-aminobutanoyl]-Peg3, [15-carboxy-Pentadecanoyl]- [4- aminobutanoyl]-Peg3, [17-carboxy-Heptadecanoyl]-[4-aminobutanoyl]-Peg3,
[19-carboxy-Nonadecanoyl]- βAla-Peg3, [21 -carboxy-heneicosanoyl]- βAla-Peg3, [13-carboxy-tridecanoyl]-isoLys-Peg3-Peg3, [15-carboxy-Pentadecanoyl]-isoLys- Peg3-Peg3, [17-carboxy-Heptadecanoyl]-isoLys-Peg3-Peg3, [19-carboxy- Nonadecanoyl]-isoLys-Peg3-Peg3, [21 -carboxy-heneicosanoyl]-isoLys-Peg3-Peg3, [13-carboxy-tridecanoyl]-[4-aminobutanoyl]-Peg3-Peg3, [15-carboxy-Pentadecanoyl]- [4-aminobutanoyl]-Peg3-Peg3, [17-carboxy-Heptadecanoyl]-[4-aminobutanoyl]-Peg3- Peg3, [19-carboxy-Nonadecanoyl]-[4-aminobutanoyl]-Peg3-Peg3, [21 -carboxy- heneicosanoyl]-[4-aminobutanoyl]-Peg3-Peg3,
[13-carboxy-tridecanoyl]-isoLys-Peg3-Peg3-Peg3, [15-carboxy-Pentadecanoyl]- isol_ys-Peg3-Peg3-Peg3, [17-carboxy-Heptadecanoyl]-isoLys-Peg3-Peg3-Peg3, [19- carboxy-Nonadecanoyl]-isoLys-Peg3-Peg3-Peg3, [21 -carboxy-heneicosanoyl]-isol_ys- Peg3-Peg3-Peg3,
[13-carboxy-tridecanoyl]-[4-aminobutanoyl]-Peg3-Peg3-Peg3, [15-carboxy- Pentadecanoyl]-[4-aminobutanoyl]-Peg3-Peg3-Peg3, [17-carboxy-Heptadecanoyl]-[4- aminobutanoyl]-Peg3-Peg3-Peg3, [19-carboxy-Nonadecanoyl]-[4-aminobutanoyl]- Peg3-Peg3-Peg3 and [21 -carboxy-heneicosanoyl]-[4-aminobutanoyl]-Peg3-Peg3- Peg3.
Further examples of substituents Z1 -Z2 include:
[Dodecanoyl]-isoLys, [Tetradecanoyl]-isoLys, [Hexadecanoyl]-isoLys, [Octadecanoyl]- isoLys, [Eicosanoyl]-isoLys,
[Hexadecanoyl]-[4-aminobutanoyl], [Octadecanoyl]-[4-aminobutanoyl], [Eicosanoyl]- [4-aminobutanoyl], [Tetradecanoyl]-[4-aminobutanoyl], [Dodecanoyl]-[4- aminobutanoyl],
[Hexadecanoyl]-KEK, [OctadecanoyI]- KEK, [EicosanoyI]- KEK, [TetradecanoyI]- KEK, [Dodecanoyl]- KEK,
[Dodecanoyl]-Peg3, [Tetradecanoyl]-Peg3, [Hexadecanoyl]-Peg3,
[Octadecanoyl]-Peg3, [Eicosanoyl]-Peg3,
[Dodecanoyl]-Peg3-Peg3, [Tetradecanoyl]-Peg3-Peg3,
[Hexadecanoyl]-Peg3-Peg3, [Octadecanoyl]-Peg3-Peg3, [Eicosanoyl]-Peg3-Peg3,
[Dodecanoyl]-Peg3-Peg3-Peg3, [Tetradecanoyl]-Peg3- Peg3-Peg3, [Hexadecanoyl]-Peg3-Peg3-Peg3, [Octadecanoyl]- Peg3-Peg3-Peg3, [Eicosanoyl]-Peg3-Peg3-Peg3,
Dodecanoyl]-isoLys-Peg3, [Tetradecanoyl]-isoLys-Peg3, [Hexadecanoyl]-isoLys- Peg3, [Octadecanoyl]-isoLys-Peg3, [Eicosanoyl]-isoLys-Peg3, [Dodecanoyl]-[4-aminobutanoyl]-Peg3, [Tetradecanoyl]- [4-aminobutanoyl]-Peg3, [Hexadecanoyl]-[4-aminobutanoyl]-Peg3, [Octadecanoyl]-[4-aminobutanoyl]-Peg3, [Eicosanoyl]-[4-aminobutanoyl]-Peg3,
[Dodecanoyl]-KEK-Peg3, [Tetradecanoyl]-KEK-Peg3, [Hexadecanoyl]-KEK-Peg3, [Octadecanoyl]-KEK-Peg3, [Eicosanoyl]-KEK-Peg3,
[Dodecanoyl]-isoLys-Peg3-Peg3, [Tetradecanoyl]-isoLys-Peg3-Peg3,
[Hexadecanoyl]-isoLys-Peg3-Peg3, [Octadecanoyl]-isoLys-Peg3-Peg3, [Eicosanoyl]- isoLys-Peg3-Peg3,
[Dodecanoyl]-[4-aminobutanoyl]-Peg3-Peg3, [Tetradecanoyl]-[4-aminobutanoyl]- Peg3-Peg3, [Hexadecanoyl]-[4-aminobutanoyl]-Peg3-Peg3, [Octadecanoyl]-[4- aminobutanoyl]-Peg3-Peg3, [Eicosanoyl]-[4-aminobutanoyl]-Peg3-Peg3,
[Dodecanoyl]-KEK-Peg3-Peg3, [Tetradecanoyl]-KEK-Peg3-Peg3, [Hexadecanoyl]- KEK-Peg3-Peg3, [Octadecanoyl]- KEK -Peg3-Peg3, [Eicosanoyl]- KEK -Peg3-Peg3,
[Dodecanoyl]-isoLys-Peg3-Peg3-Peg3, [Tetradecanoyl]-isoLys-Peg3-Peg3-Peg3, [Hexadecanoyl]-isoLys-Peg3-Peg3-Peg3, [Octadecanoyl]-isoLys-Peg3-Peg3-Peg3, [Eicosanoyl]-isoLys-Peg3-Peg3-Peg3,
[Dodecanoyl]-[4-aminobutanoyl]-Peg3-Peg3-Peg3, [Tetradecanoyl]-[4- aminobutanoyl]-Peg3-Peg3-Peg3, [Hexadecanoyl]-[4-aminobutanoyl]-Peg3-Peg3- Peg3, [Octadecanoyl]-[4-aminobutanoyl]-Peg3-Peg3-Peg3, [Eicosanoyl]-[4- aminobutanoyl]-Peg3-Peg3-Peg3,
[Dodecanoyl]-KEK-Peg3-Peg3-Peg3, [Tetradecanoyl]-KEK-Peg3-Peg3-Peg3,
[Hexadecanoyl]-KEK-Peg3-Peg3-Peg3, [Octadecanoyl]-KEK-Peg3-Peg3-Peg3, [Eicosanoyl]-KEK-Peg3-Peg3-Peg3,
[Dodecanoyl]-isoGlu-KEK-Peg3, [Tetradecanoyl]-isoGlu-KEK-Peg3, [Hexadecanoyl]- isoGlu-KEK-Peg3, [Octadecanoyl]-isoGlu-KEK-Peg3, [Eicosanoyl]-isoGlu-KEK-Peg3,
[Dodecanoyl]-[4-aminobutanoyl]-KEK-Peg3, [Tetradecanoyl]-[4-aminobutanoyl]-KEK- Peg3, [Hexadecanoyl]-[4-aminobutanoyl]-KEK-Peg3, [Octadecanoyl]-[4- aminobutanoyl]-KEK-Peg3, [Eicosanoyl]-[4-aminobutanoyl]-KEK-Peg3,
[Dodecanoyl]-isoLys-KEK-Peg3, [Tetradecanoyl]-isoLys-KEK-Peg3, [Hexadecanoyl]- isoLys-KEK-Peg3, [Octadecanoyl]-isoLys-KEK-Peg3, [Eicosanoyl]-isoLys-KEK-Peg3,
[Dodecanoyl]-βAla-KEK-Peg3, [Tetradecanoyl]-βAla-KEK-Peg3, [Hexadecanoyl]- βAla-KEK-Peg3, [Octadecanoyl]-βAla-KEK-Peg3, [Eicosanoyl]-βAla-KEK-Peg3, [Dodecanoyl]-isoGlu-KEK-Peg3-Peg3, [Tetradecanoyl]-isoGlu-KEK-Peg3-Peg3, [Hexadecanoyl]-isoGlu-KEK-Peg3-Peg3, [Octadecanoyl]-isoGlu-KEK-Peg3-Peg3, [Eicosanoyl]-isoGlu-KEK-Peg3-Peg3,
[Dodecanoyl]-βAla-KEK-Peg3-Peg3, [Tetradecanoyl]-βAla-KEK-Peg3-Peg3,
[Hexadecanoyl]-βAla-KEK-Peg3-Peg3, [Octadecanoyl]-βAla-KEK-Peg3-Peg3,
[Eicosanoyl]-βAla-KEK-Peg3-Peg3,
[Dodecanoyl]-isoLys-KEK-Peg3-Peg3, [Tetradecanoyl]-isoLys-KEK-Peg3-Peg3, [Hexadecanoyl]-isoLys-KEK-Peg3-Peg3, [Octadecanoyl]-isoLys-KEK-Peg3-Peg3, [Eicosanoyl]-isoLys-KEK-Peg3-Peg3,
[Dodecanoyl]-[4-aminobutanoyl]-KEK-Peg3-Peg3, [Tetradecanoyl]-[4-aminobutanoyl]- KEK-Peg3-Peg3, [Hexadecanoyl]-[4-aminobutanoyl]-KEK-Peg3-Peg3,
[Octadecanoyl]-[4-aminobutanoyl]-KEK-Peg3-Peg3, [Eicosanoyl]-[4-aminobutanoyl]- KEK-Peg3-Peg3,
[Dodecanoyl]-isoGlu-KEK-Peg3-Peg3-Peg3, [Tetradecanoyl]-isoGlu-KEK-Peg3-Peg3- Peg3, [Hexadecanoyl]-isoGlu-KEK-Peg3-Peg3-Peg3, [Octadecanoyl]-isoGlu-KEK- Peg3-Peg3-Peg3, [Eicosanoyl]-isoGlu-KEK-Peg3-Peg3-Peg3,
[Dodecanoyl]- βAla-KEK-Peg3-Peg3-Peg3, [Tetradecanoyl]- βAla-KEK-Peg3-Peg3- Peg3, [HexadecanoyI]- βAla-KEK-Peg3-Peg3-Peg3, [OctadecanoyI]- βAla-KEK-Peg3- Peg3-Peg3, [Eicosanoyl]- βAla-KEK-Peg3-Peg3-Peg3,
[Dodecanoyl]-isoLys-KEK-Peg3-Peg3-Peg3, [Tetradecanoyl]-isoLys-KEK-Peg3-Peg3- Peg3, [Hexadecanoyl]-isoLys-KEK-Peg3-Peg3-Peg3, [Octadecanoyl]-isoLys-KEK- Peg3-Peg3-Peg3, [Eicosanoyl]-isoLys-KEK-Peg3-Peg3-Peg3,
[Dodecanoyl]-[4-aminobutanoyl]-KEK-Peg3-Peg3-Peg3, [Tetradecanoyl]-[4- aminobutanoyl]-KEK-Peg3-Peg3-Peg3, [Hexadecanoyl]-[4-aminobutanoyl]-KEK- Peg3-Peg3-Peg3, [Octadecanoyl]-[4-aminobutanoyl]-KEK-Peg3-Peg3-Peg3,
[Eicosanoyl]-[4-aminobutanoyl]-KEK-Peg3-Peg3-Peg3,
[Dodecanoyl]-KEK-isoGlu-Peg3, [Tetradecanoyl]-KEK-isoGlu-Peg3, [Hexadecanoyl]- KEK-isoGlu-Peg3, [Octadecanoyl]-KEK-isoGlu-Peg3, [Eicosanoyl]-KEK-isoGlu-Peg3,
[Dodecanoyl]-KEK-βAla-Peg3, [Tetradecanoyl]-KEK-βAla-Peg3, [Hexadecanoyl]- KEK-βAla-Peg3, [Octadecanoyl]-KEK-βAla-Peg3, [Eicosanoyl]-KEK-βAla-Peg3,
[Dodecanoyl]-KEK-[4-aminobutanoyl]-Peg3, [Tetradecanoyl]-KEK-[4-aminobutanoyl]- Peg3, [Hexadecanoyl]-KEK-[4-aminobutanoyl]-Peg3, [Octadecanoyl]-KEK-[4- aminobutanoyl]-Peg3, [Eicosanoyl]-KEK-[4-aminobutanoyl]-Peg3, [Dodecanoyl]-KEK-isoLys-Peg3, [Tetradecanoyl]-KEK-isoLys-Peg3, [Hexadecanoyl]- KEK-isoLys-Peg3, [Octadecanoyl]-KEK-isoLys-Peg3, [Eicosanoyl]-KEK-isoLys-Peg3,
[Dodecanoyl]-KEK-isoGlu-Peg3-Peg3, [Tetradecanoyl]-KEK-isoGlu-Peg3-Peg3, [Hexadecanoyl]-KEK-isoGlu-Peg3-Peg3, [Octadecanoyl]-KEK-isoGlu-Peg3-Peg3, [Eicosanoyl]-KEK-isoGlu-Peg3-Peg3,
[Dodecanoyl]-KEK-βAla-Peg3-Peg3, [Tetradecanoyl]-KEK-βAla-Peg3-Peg3,
[Hexadecanoyl]-KEK-βAla-Peg3-Peg3, [Octadecanoyl]-KEK-βAla-Peg3-Peg3,
[Eicosanoyl]-βAla-KEK-Peg3-Peg3,
[Dodecanoyl]-KEK-[4-aminobutanoyl]-Peg3-Peg3, [Tetradecanoyl]-KEK-[4- aminobutanoyl]-Peg3-Peg3, [Hexadecanoyl]-KEK-[4-aminobutanoyl]-Peg3-Peg3, [Octadecanoyl]-KEK-[4-aminobutanoyl]-Peg3-Peg3, [Eicosanoyl]-KEK-[4- aminobutanoyl]-Peg3-Peg3,
[Dodecanoyl]-KEK-isoLys-Peg3-Peg3, [Tetradecanoyl]-KEK-isoLys-Peg3-Peg3, [Hexadecanoyl]-KEK-isoLys-Peg3-Peg3, [Octadecanoyl]-KEK-isoLys-Peg3-Peg3, [Eicosanoyl]-KEK-isoLys-Peg3-Peg3,
[Dodecanoyl]-KEK-isoGlu-Peg3-Peg3-Peg3, [Tetradecanoyl]-KEK-isoGlu-Peg3-Peg3- Peg3, [Hexadecanoyl]-KEK-isoGlu-Peg3-Peg3-Peg3, [Octadecanoyl]-KEK-isoGlu- Peg3-Peg3-Peg3, [Eicosanoyl]-KEK-isoGlu-Peg3-Peg3-Peg3,
[Dodecanoyl]-KEK-βAla-Peg3-Peg3-Peg3, [Tetradecanoyl]KEK-βAla-Peg3-Peg3- Peg3, [HexadecanoyI]- βAla-KEK-Peg3-Peg3-Peg3, [Octadecanoyl]-KEK-βAla-Peg3- Peg3-Peg3, [Eicosanoyl]-KEK-βAla-Peg3-Peg3-Peg3,
[Dodecanoyl]-KEK-[4-aminobutanoyl]-Peg3-Peg3-Peg3, [Tetradecanoyl]-KEK-[4- aminobutanoyl]-Peg3-Peg3-Peg3, [Hexadecanoyl]-KEK-[4-aminobutanoyl]-Peg3- Peg3-Peg3, [Octadecanoyl]-KEK-[4-aminobutanoyl]-Peg3-Peg3-Peg3, [Eicosanoyl]- KEK-[4-aminobutanoyl]-Peg3-Peg3-Peg3,
[Dodecanoyl]-KEK-isoLys-Peg3-Peg3-Peg3, [Tetradecanoyl]-KEK-isoLys-Peg3-Peg3- Peg3, [Hexadecanoyl]-KEK-isoLys-Peg3-Peg3-Peg3, [Octadecanoyl]-KEK-isoLys- Peg3-Peg3-Peg3, [Eicosanoyl]-KEK-isoLys-Peg3-Peg3-Peg3,
[13-carboxy-tridecanoyl]-isoGlu, [15-carboxy-Pentadecanoyl]-isoGlu, [17-carboxy- Heptadecanoyl]-isoGlu, [19-carboxy-Nonadecanoyl]-isoGlu, [21 -carboxy-hen21 - carboxy-heneicosanoyl]-isoGlu, [17-carboxy-Heptadecanoyl]-βAla, [19-carboxy-Nonadecanoyl]-βAla, [21 -carboxy- heneicosanoyl]-βAla, [15-carboxy-Pentadecanoyl]-βAla, [13-carboxy-tridecanoyl]- βAla,
[13-carboxy-tridecanoyl]-isoLys, [15-carboxy-Pentadecanoyl]-isoLys, [17-carboxy- Heptadecanoyl]-isoLys, [19-carboxy-Nonadecanoyl]-isoLys, [21 -carboxy- heneicosanoyl]-isoLys,
[17-carboxy-Heptadecanoyl]-[4-aminobutanoyl], [19-carboxy-Nonadecanoyl]-[4- aminobutanoyl], [21 -carboxy-heneicosanoyl]-[4-aminobutanoyl], [15-carboxy- Pentadecanoyl]-[4-aminobutanoyl], [13-carboxy-tridecanoyl]-[4-aminobutanoyl], [17-carboxy-Heptadecanoyl]-KEK, [19-carboxy-Nonadecanoyl]- KEK, [21 -carboxy- heneicosanoyl]- KEK, [15-carboxy-Pentadecanoyl]- KEK, [13-carboxy-tridecanoyl]- KEK,
[13-carboxy-tridecanoyl]-Peg3, [15-carboxy-Pentadecanoyl]-Peg3, [17-carboxy- Heptadecanoyl]-Peg3, [19-carboxy-Nonadecanoyl]-Peg3, [21 -carboxy- heneicosanoyl]-Peg3,
[13-carboxy-tridecanoyl]-Peg3-Peg3, [15-carboxy-Pentadecanoyl]-Peg3-Peg3,
[17-carboxy-Heptadecanoyl]-Peg3-Peg3, [19-carboxy-Nonadecanoyl]-Peg3- Peg3, [21 -carboxy-heneicosanoyl]-Peg3-Peg3,
[13-carboxy-tridecanoyl]-Peg3-Peg3-Peg3, [15-carboxy-Pentadecanoyl]-Peg3- Peg3-Peg3, [17-carboxy-Heptadecanoyl]-Peg3-Peg3-Peg3, [19-carboxy-
Nonadecanoyl]-Peg3-Peg3-Peg3, [21 -carboxy-heneicosanoyl]-Peg3-Peg3-Peg3,
[13-carboxy-tridecanoyl]-isoGlu-Peg3, [15-carboxy-Pentadecanoyl]-isoGlu-Peg3, [17- carboxy-Heptadecanoyl]-isoGlu-Peg3, [19-carboxy-Nonadecanoyl]-isoGlu-Peg3, [21 - carboxy-heneicosanoyl]-isoGlu-Peg3,
[13-carboxy-tridecanoyl]- βAla-Peg3, [15-carboxy-Pentadecanoyl]- βAla-Peg3, [17- carboxy-Heptadecanoyl]- βAla-Peg3, [19-carboxy-Nonadecanoyl]- βAla-Peg3, [21 - carboxy-heneicosanoyl]- βAla-Peg3,
[13-carboxy-tridecanoyl]-isoLys-Peg3, [15-carboxy-Pentadecanoyl]-isoLys-Peg3, [17- carboxy-Heptadecanoyl]-isoLys-Peg3, [19-carboxy-Nonadecanoyl]-isoLys-Peg3, [21 - carboxy-heneicosanoyl]-isoLys-Peg3,
[13-carboxy-tridecanoyl]-[4-aminobutanoyl]-Peg3, [15-carboxy-Pentadecanoyl]- [4- aminobutanoyl]-Peg3, [17-carboxy-Heptadecanoyl]-[4-aminobutanoyl]-Peg3, [19- carboxy-Nonadecanoyl]-[4-aminobutanoyl]-Peg3, [21 -carboxy-heneicosanoyl]-[4- aminobutanoyl]-Peg3,
[13-carboxy-tridecanoyl]-KEK-Peg3, [15-carboxy-Pentadecanoyl]-KEK-Peg3, [17- carboxy-Heptadecanoyl]-KEK-Peg3, [19-carboxy-Nonadecanoyl]-KEK-Peg3, [21 - carboxy-heneicosanoyl]-KEK-Peg3,
[13-carboxy-tridecanoyl]-isoGlu-Peg3-Peg3, [15-carboxy-Pentadecanoyl]-isoGlu- Peg3-Peg3, [17-carboxy-Heptadecanoyl]-isoGlu-Peg3-Peg3, [19-carboxy- Nonadecanoyl]-isoGlu-Peg3-Peg3, [21 -carboxy-heneicosanoyl]-isoGlu-Peg3-Peg3, [13-carboxy-tridecanoyl]- βAla-Peg3-Peg3, [15-carboxy-Pentadecanoyl]- βAla-Peg3- Peg3, [17-carboxy-Heptadecanoyl]- βAla-Peg3-Peg3, [19-carboxy-Nonadecanoyl]- βAla-Peg3-Peg3, [21 -carboxy-heneicosanoyl]- βAla-Peg3-Peg3,
[13-carboxy-tridecanoyl]-isoLys-Peg3-Peg3, [15-carboxy-Pentadecanoyl]-isol_ys- Peg3-Peg3, [17-carboxy-Heptadecanoyl]-isoLys-Peg3-Peg3, [19-carboxy- Nonadecanoyl]-isoLys-Peg3-Peg3, [21 -carboxy-heneicosanoyl]-isoLys-Peg3-Peg3,
[13-carboxy-tridecanoyl]-[4-aminobutanoyl]-Peg3-Peg3, [15-carboxy-Pentadecanoyl]- [4-aminobutanoyl]-Peg3-Peg3, [17-carboxy-Heptadecanoyl]-[4-aminobutanoyl]-Peg3- Peg3, [19-carboxy-Nonadecanoyl]-[4-aminobutanoyl]-Peg3-Peg3, [21 -carboxy- heneicosanoyl]-[4-aminobutanoyl]-Peg3-Peg3,
[13-carboxy-tridecanoyl]-KEK-Peg3-Peg3, [15-carboxy-Pentadecanoyl]-KEK-Peg3- Peg3, [17-carboxy-Heptadecanoyl]- KEK-Peg3-Peg3, [19-carboxy-Nonadecanoyl]- KEK -Peg3-Peg3, [21 -carboxy-heneicosanoyl]- KEK -Peg3-Peg3,
[13-carboxy-tridecanoyl]-isoGlu-Peg3-Peg3-Peg3, [15-carboxy-Pentadecanoyl]- isoGlu-Peg3-Peg3-Peg3, [17-carboxy-Heptadecanoyl]-isoGlu-Peg3-Peg3-Peg3, [19- carboxy-Nonadecanoyl]-isoGlu-Peg3-Peg3-Peg3, [21 -carboxy-heneicosanoyl]-isoGlu- Peg3-Peg3-Peg3,
[13-carboxy-tridecanoyl]- βAla-Peg3-Peg3-Peg3, [15-carboxy-Pentadecanoyl]- βAla- Peg3-Peg3-Peg3, [17-carboxy-Heptadecanoyl]- βAla-Peg3-Peg3-Peg3, [19-carboxy- Nonadecanoyl]- βAla-Peg3-Peg3-Peg3, [21 -carboxy-heneicosanoyl]- βAla-Peg3- Peg3-Peg3,
[13-carboxy-tridecanoyl]-isoLys-Peg3-Peg3-Peg3, [15-carboxy-Pentadecanoyl]- isoLys-Peg3-Peg3-Peg3, [17-carboxy-Heptadecanoyl]-isoLys-Peg3-Peg3-Peg3, [19- carboxy-Nonadecanoyl]-isoLys-Peg3-Peg3-Peg3, [21 -carboxy-heneicosanoyl]-isoLys- Peg3-Peg3-Peg3,
[13-carboxy-tridecanoyl]-[4-aminobutanoyl]-Peg3-Peg3-Peg3, [15-carboxy- Pentadecanoyl]-[4-aminobutanoyl]-Peg3-Peg3-Peg3, [17-carboxy-Heptadecanoyl]-[4- aminobutanoyl]-Peg3-Peg3-Peg3, [19-carboxy-Nonadecanoyl]-[4-aminobutanoyl]- Peg3-Peg3-Peg3, [21 -carboxy-heneicosanoyl]-[4-aminobutanoyl]-Peg3-Peg3-Peg3,
[13-carboxy-tridecanoyl]- KEK-Peg3-Peg3-Peg3, [15-carboxy-Pentadecanoyl]-KEK- Peg3-Peg3-Peg3, [17-carboxy-Heptadecanoyl]-KEK-Peg3-Peg3-Peg3, [19-carboxy- Nonadecanoyl]-KEK-Peg3-Peg3-Peg3, [21 -carboxy-heneicosanoyl]-KEK-Peg3-Peg3- Peg3,
[13-carboxy-tridecanoyl]-isoGlu-KEK-Peg3, [15-carboxy-Pentadecanoyl]-isoGlu-KEK- Peg3, [17-carboxy-Heptadecanoyl]-isoGlu-KEK-Peg3, [19-carboxy-Nonadecanoyl]- isoGlu-KEK-Peg3, [21 -carboxy-heneicosanoyl]-isoGlu-KEK-Peg3,
[13-carboxy-tridecanoyl]-[4-aminobutanoyl]-KEK-Peg3, [15-carboxy-Pentadecanoyl]- [4-aminobutanoyl]-KEK-Peg3, [17-carboxy-Heptadecanoyl]-[4-aminobutanoyl]-KEK- Peg3, [19-carboxy-Nonadecanoyl]-[4-aminobutanoyl]-KEK-Peg3, [21 -carboxy- heneicosanoyl]-[4-aminobutanoyl]-KEK-Peg3,
[13-carboxy-tridecanoyl]-isoLys-KEK-Peg3, [15-carboxy-Pentadecanoyl]-isoLys-KEK- Peg3, [17-carboxy-Heptadecanoyl]-isoLys-KEK-Peg3, [19-carboxy-Nonadecanoyl]- isoLys-KEK-Peg3, [21 -carboxy-heneicosanoyl]-isoLys-KEK-Peg3,
[13-carboxy-tridecanoyl]-βAla-KEK-Peg3, [15-carboxy-Pentadecanoyl]-βAla-KEK- Peg3, [17-carboxy-Heptadecanoyl]-βAla-KEK-Peg3, [19-carboxy-Nonadecanoyl]- βAla-KEK-Peg3, [21 -carboxy-heneicosanoyl]-βAla-KEK-Peg3,
[13-carboxy-tridecanoyl]-isoGlu-KEK-Peg3-Peg3, [15-carboxy-Pentadecanoyl]-isoGlu- KEK-Peg3-Peg3, [17-carboxy-Heptadecanoyl]-isoGlu-KEK-Peg3-Peg3, [19-carboxy- Nonadecanoyl]-isoGlu-KEK-Peg3-Peg3, [21 -carboxy-heneicosanoyl]-isoGlu-KEK- Peg3-Peg3,
[13-carboxy-tridecanoyl]-βAla-KEK-Peg3-Peg3, [15-carboxy-Pentadecanoyl]-βAla- KEK-Peg3-Peg3, [17-carboxy-Heptadecanoyl]-βAla-KEK-Peg3-Peg3, [19-carboxy- Nonadecanoyl]-βAla-KEK-Peg3-Peg3, [21 -carboxy-heneicosanoyl]-βAla-KEK-Peg3- Peg3,
[13-carboxy-tridecanoyl]-isoLys-KEK-Peg3-Peg3, [15-carboxy-Pentadecanoyl]-isoLys- KEK-Peg3-Peg3, [17-carboxy-Heptadecanoyl]-isoLys-KEK-Peg3-Peg3, [19-carboxy- Nonadecanoyl]-isoLys-KEK-Peg3-Peg3, [21 -carboxy-heneicosanoyl]-isoLys-KEK- Peg3-Peg3,
[13-carboxy-tridecanoyl]-[4-aminobutanoyl]-KEK-Peg3-Peg3, [15-carboxy- Pentadecanoyl]-[4-aminobutanoyl]-KEK-Peg3-Peg3, [17-carboxy-Heptadecanoyl]-[4- aminobutanoyl]-KEK-Peg3-Peg3, [19-carboxy-Nonadecanoyl]-[4-aminobutanoyl]- KEK-Peg3-Peg3, [21 -carboxy-heneicosanoyl]-[4-aminobutanoyl]-KEK-Peg3-Peg3,
[13-carboxy-tridecanoyl]-isoGlu-KEK-Peg3-Peg3-Peg3, [15-carboxy-Pentadecanoyl]- isoGlu-KEK-Peg3-Peg3-Peg3, [17-carboxy-Heptadecanoyl]-isoGlu-KEK-Peg3-Peg3- Peg3, [19-carboxy-Nonadecanoyl]-isoGlu-KEK-Peg3-Peg3-Peg3, [21 -carboxy- heneicosanoyl]-isoGlu-KEK-Peg3-Peg3-Peg3,
[13-carboxy-tridecanoyl]- βAla-KEK-Peg3-Peg3-Peg3, [15-carboxy-Pentadecanoyl]- βAla-KEK-Peg3-Peg3-Peg3, [17-carboxy-Heptadecanoyl]- βAla-KEK-Peg3-Peg3- Peg3, [19-carboxy-Nonadecanoyl]- βAla-KEK-Peg3-Peg3-Peg3, [21 -carboxy- heneicosanoyl]- βAla-KEK-Peg3-Peg3-Peg3,
[13-carboxy-tridecanoyl]-isoLys-KEK-Peg3-Peg3-Peg3, [15-carboxy-Pentadecanoyl]- isoLys-KEK-Peg3-Peg3-Peg3, [17-carboxy-Heptadecanoyl]-isoLys-KEK-Peg3-Peg3- Peg3, [19-carboxy-Nonadecanoyl]-isoLys-KEK-Peg3-Peg3-Peg3, [21 -carboxy- heneicosanoyl]-isoLys-KEK-Peg3-Peg3-Peg3,
[13-carboxy-tridecanoyl]-[4-aminobutanoyl]-KEK-Peg3-Peg3-Peg3, [15-carboxy- Pentadecanoyl]-[4-aminobutanoyl]-KEK-Peg3-Peg3-Peg3, [17-carboxy- Heptadecanoyl]-[4-aminobutanoyl]-KEK-Peg3-Peg3-Peg3, [19-carboxy- Nonadecanoyl]-[4-aminobutanoyl]-KEK-Peg3-Peg3-Peg3, [21 -carboxy- heneicosanoyl]-[4-aminobutanoyl]-KEK-Peg3-Peg3-Peg3,
[13-carboxy-tridecanoyl]-KEK-isoGlu-Peg3, [15-carboxy-Pentadecanoyl]-KEK-isoGlu- Peg3, [17-carboxy-Heptadecanoyl]-KEK-isoGlu-Peg3, [19-carboxy-Nonadecanoyl]- KEK-isoGlu-Peg3, [21 -carboxy-heneicosanoyl]-KEK-isoGlu-Peg3,
[13-carboxy-tridecanoyl]-KEK-βAla-Peg3, [15-carboxy-Pentadecanoyl]-KEK-βAla- Peg3, [17-carboxy-Heptadecanoyl]-KEK-βAla-Peg3, [19-carboxy-Nonadecanoyl]- KEK-βAla-Peg3, [21 -carboxy-heneicosanoyl]-KEK-βAla-Peg3,
[13-carboxy-tridecanoyl]-KEK-[4-aminobutanoyl]-Peg3, [15-carboxy-Pentadecanoyl]- KEK-[4-aminobutanoyl]-Peg3, [17-carboxy-Heptadecanoyl]-KEK-[4-aminobutanoyl]- Peg3, [19-carboxy-Nonadecanoyl]-KEK-[4-aminobutanoyl]-Peg3, [21 -carboxy- heneicosanoyl]-KEK-[4-aminobutanoyl]-Peg3, [13-carboxy-tridecanoyl]-KEK-isoLys-Peg3, [15-carboxy-Pentadecanoyl]-KEK-isoLys- Peg3, [17-carboxy-Heptadecanoyl]-KEK-isoLys-Peg3, [19-carboxy-Nonadecanoyl]- KEK-isoLys-Peg3, [21 -carboxy-heneicosanoyl]-KEK-isoLys-Peg3,
[13-carboxy-tridecanoyl]-KEK-isoGlu-Peg3-Peg3, [15-carboxy-Pentadecanoyl]-KEK- isoGlu-Peg3-Peg3, [17-carboxy-Heptadecanoyl]-KEK-isoGlu-Peg3-Peg3, [19- carboxy-Nonadecanoyl]-KEK-isoGlu-Peg3-Peg3, [21 -carboxy-heneicosanoyl]-KEK- isoGlu-Peg3-Peg3,
[13-carboxy-tridecanoyl]-KEK-βAla-Peg3-Peg3, [15-carboxy-Pentadecanoyl]-KEK- βAla-Peg3-Peg3, [17-carboxy-Heptadecanoyl]-KEK-βAla-Peg3-Peg3, [19-carboxy- Nonadecanoyl]-KEK-βAla-Peg3-Peg3, [21 -carboxy-heneicosanoyl]-βAla-KEK-Peg3- Peg3,
[13-carboxy-tridecanoyl]-KEK-[4-aminobutanoyl]-Peg3-Peg3, [15-carboxy- Pentadecanoyl]-KEK-[4-aminobutanoyl]-Peg3-Peg3, [17-carboxy-Heptadecanoyl]- KEK-[4-aminobutanoyl]-Peg3-Peg3, [19-carboxy-Nonadecanoyl]-KEK-[4- aminobutanoyl]-Peg3-Peg3, [21 -carboxy-heneicosanoyl]-KEK-[4-aminobutanoyl]- Peg3-Peg3,
[13-carboxy-tridecanoyl]-KEK-isoLys-Peg3-Peg3, [15-carboxy-Pentadecanoyl]-KEK- isoLys-Peg3-Peg3, [17-carboxy-Heptadecanoyl]-KEK-isoLys-Peg3-Peg3, [19- carboxy-Nonadecanoyl]-KEK-isoLys-Peg3-Peg3, [21 -carboxy-heneicosanoyl]-KEK- isoLys-Peg3-Peg3,
[13-carboxy-tridecanoyl]-KEK-isoGlu-Peg3-Peg3-Peg3, [15-carboxy-Pentadecanoyl]- KEK-isoGlu-Peg3-Peg3-Peg3, [17-carboxy-Heptadecanoyl]-KEK-isoGlu-Peg3-Peg3- Peg3, [19-carboxy-Nonadecanoyl]-KEK-isoGlu-Peg3-Peg3-Peg3, [21 -carboxy- heneicosanoyl]-KEK-isoGlu-Peg3-Peg3-Peg3,
[13-carboxy-tridecanoyl]-KEK-βAla-Peg3-Peg3-Peg3, [15-carboxy-
Pentadecanoyl]KEK-βAla-Peg3-Peg3-Peg3, [17-carboxy-Heptadecanoyl]- βAla-KEK- Peg3-Peg3-Peg3, [19-carboxy-Nonadecanoyl]-KEK-βAla-Peg3-Peg3-Peg3, [21 - carboxy-heneicosanoyl]-KEK-βAla-Peg3-Peg3-Peg3,
[13-carboxy-tridecanoyl]-KEK-[4-aminobutanoyl]-Peg3-Peg3-Peg3, [15-carboxy- Pentadecanoyl]-KEK-[4-aminobutanoyl]-Peg3-Peg3-Peg3, [17-carboxy- Heptadecanoyl]-KEK-[4-aminobutanoyl]-Peg3-Peg3-Peg3, [19-carboxy- Nonadecanoyl]-KEK-[4-aminobutanoyl]-Peg3-Peg3-Peg3, [21 -carboxy- heneicosanoyl]-KEK-[4-aminobutanoyl]-Peg3-Peg3-Peg3, [13-carboxy-tridecanoyl]-KEK-isoLys-Peg3-Peg3-Peg3, [15-carboxy-Pentadecanoyl]- KEK-isoLys-Peg3-Peg3-Peg3, [17-carboxy-Heptadecanoyl]-KEK-isol_ys-Peg3-Peg3- Peg3, [19-carboxy-Nonadecanoyl]-KEK-isoLys-Peg3-Peg3-Peg3, [21 -carboxy- heneicosanoyl]-KEK-isoLys-Peg3-Peg3-Peg3.
Certain preferred substituents Z1- and Z1-Z2- include:
[HexadecanoyI], [OctadecanoyI], [17-Carboxy-heptadecanoyl], [19-Carboxy- nonadecanoyl],
[Hexadecanoyl]-isoGlu, [Octadecanoyl]-isoGlu,
[Hexadecanoyl]-βAla, [Octadecanoyl]-βAla,
[Hexadecanoyl]-isoGlu-Peg3,
[Hexadecanoyl]-βAla-Peg3,
[Hexadecanoyl]-isoGlu-Peg3-Peg3,
[Hexadecanoyl]-βAla-Peg3-Peg3,
[Hexadecanoyl]-βAla-Peg3-Peg3-Peg3,
[Hexadecanoyl]-isoLys,
[Hexadecanoyl]-[4-aminobutanoyl],
[Hexadecanoyl]-isoLys-Peg3,
[Hexadecanoyl]-[4-aminobutanoyl]-Peg3,
[Hexadecanoyl]-isoLys-Peg3-Peg3,
[Hexadecanoyl]-[4-aminobutanoyl]-Peg3-Peg3,
[Hexadecanoyl]-isoLys-Peg3-Peg3-Peg3,
[Hexadecanoyl]-[4-aminobutanoyl]-Peg3-Peg3-Peg3,
[17-carboxy-Heptadecanoyl]-isoGlu,
[19-carboxy-Nonadecanoyl]-isoGlu,
[17-carboxy-Heptadecanoyl]-βAla,
[19-carboxy-Nonadecanoyl]-βAla,
[17-carboxy-Heptadecanoyl]-isoGlu-Peg3,
[19-carboxy-Nonadecanoyl]-isoGlu-Peg3, [17-carboxy-Heptadecanoyl]-βAla-Peg3,
[19-carboxy-Nonadecanoyl]-βAla-Peg3,
[17-carboxy-Heptadecanoyl]-isoGlu-Peg3-Peg3,
[19-carboxy-Nonadecanoyl]-isoGlu-Peg3-Peg3,
[17-carboxy-Heptadecanoyl]-βAla-Peg3-Peg3,
[19-carboxy-Nonadecanoyl]-βAla-Peg3-Peg3,
[17-carboxy-Heptadecanoyl]-isoGlu-Peg3-Peg3-Peg3,
[19-carboxy-Nonadecanoyl]-isoGlu-Peg3-Peg3-Peg3,
[17-carboxy-Heptadecanoyl]-βAla-Peg3-Peg3-Peg3,
[19-carboxy-Nonadecanoyl]-βAla-Peg3-Peg3-Peg3,
[17-carboxy-Heptadecanoyl]-isoLys,
[19-carboxy-Nonadecanoyl]-isoLys,
[17-carboxy-Heptadecanoyl]-[4-aminobutanoyl],
[19-carboxy-Nonadecanoyl]-[4-aminobutanoyl],
[17-carboxy-Heptadecanoyl]-isoLys-Peg3,
[19-carboxy-Nonadecanoyl]-isoLys-Peg3,
[17-carboxy-Heptadecanoyl]-[4-aminobutanoyl]-Peg3,
[19-carboxy-Nonadecanoyl]- [4-aminobutanoyl]-Peg3,
[17-carboxy-Heptadecanoyl]-isoLys-Peg3-Peg3,
[19-carboxy-Nonadecanoyl]-isoLys-Peg3-Peg3,
[17-carboxy-Heptadecanoyl]-[4-aminobutanoyl]-Peg3-Peg3,
[19-carboxy-Nonadecanoyl]-[4-aminobutanoyl]-Peg3-Peg3,
[17-carboxy-Heptadecanoyl]-isoLys-Peg3-Peg3-Peg3,
[19-carboxy-Nonadecanoyl]-isoLys-Peg3-Peg3-Peg3,
[17-carboxy-Heptadecanoyl]-[4-aminobutanoyl]-Peg3-Peg3-Peg3,
[19-carboxy-Nonadecanoyl]-[4-aminobutanoyl]-Peg3-Peg3-Peg3.
More preferred substituents Z1-Z2- include:
[Hexadecanoyl]-isoGlu, [Hexadecanoyl]-βAla,
[Hexadecanoyl]-isoGlu-Peg3,
[Hexadecanoyl]-βAla-Peg3,
[Hexadecanoyl]-isoGlu-Peg3-Peg3,
[Hexadecanoyl]-isoLys,
[Hexadecanoyl]-isoLys-Peg3,
[Hexadecanoyl]-isoLys-Peg3-Peg3,
[17-carboxy-Heptadecanoyl]-isoGlu,
[19-carboxy-Nonadecanoyl]-isoGlu,
[17-carboxy-Heptadecanoyl]-isoGlu-Peg3,
[19-carboxy-Nonadecanoyl]-isoGlu-Peg3,
[17-carboxy-Heptadecanoyl]-isoGlu-Peg3-Peg3,
[19-carboxy-Nonadecanoyl]-isoGlu-Peg3-Peg3,
[17-carboxy-Heptadecanoyl]-isoGlu-Peg3-Peg3-Peg3, [19-carboxy-Nonadecanoyl]-isoGlu-Peg3-Peg3-Peg3,
[17-carboxy-Heptadecanoyl]-isoLys,
[19-carboxy-Nonadecanoyl]-isoLys,
[17-carboxy-Heptadecanoyl]-isoLys-Peg3,
[19-carboxy-Nonadecanoyl]-isoLys-Peg3,
[17-carboxy-Heptadecanoyl]-isoLys-Peg3-Peg3,
[19-carboxy-Nonadecanoyl]-isoLys-Peg3-Peg3,
[17-carboxy-Heptadecanoyl]-isoLys-Peg3-Peg3-Peg3,
[19-carboxy-Nonadecanoyl]-isoLys-Peg3-Peg3-Peg3.
Yet further preferred substituents Z1-Z2- include:
[Hexadecanoyl]-KEK, [Octadecanoyl]-KEK,
[Hexadecanoyl]-βAla-Peg3,
[Hexadecanoyl]-KEK-Peg3,
[Hexadecanoyl]-KEK-Peg3-Peg3, [Hexadecanoyl]-KEK-Peg3-Peg3-Peg3,
[17-carboxy-Heptadecanoyl]-KEK,
[19-carboxy-Nonadecanoyl]-KEK,
[17-carboxy-Heptadecanoyl]-KEK-Peg3,
[19-carboxy-Nonadecanoyl]-KEK-Peg3,
[17-carboxy-Heptadecanoyl]-KEK-Peg3-Peg3,
[19-carboxy-Nonadecanoyl]-KEK-Peg3-Peg3,
[17-carboxy-Heptadecanoyl]-isoGlu-KEK
[19-carboxy-Nonadecanoyl]-isoGlu-KEK,
[17-carboxy-Heptadecanoyl]-isoLys-KEK
[19-carboxy-Nonadecanoyl]-isoLys-KEK,
[17-carboxy-Heptadecanoyl]-βAla-KEK
[19-carboxy-Nonadecanoyl]-βAla-KEK, [17-carboxy-Heptadecanoyl]-KEK-Peg3- Peg3-Peg3,
[19-carboxy-Nonadecanoyl]-KEK-Peg3-Peg3-Peg3,
[17-carboxy-Heptadecanoyl]-[4-aminobutanoyl]-KEK,
[19-carboxy-Nonadecanoyl]-[4-aminobutanoyl]-KEK,
[17-carboxy-Heptadecanoyl]-[4-aminobutanoyl]-KEK-Peg3-Peg3-Peg3,
[19-carboxy-Nonadecanoyl]-[4-aminobutanoyl]-KEK-Peg3-Peg3-Peg3,
[17-carboxy-Heptadecanoyl]-[4-aminobutanoyl]-KEK-Peg3-Peg3,
[19-carboxy-Nonadecanoyl]-[4-aminobutanoyl]-KEK-Peg3-Peg3,
[Hexadecanoyl]-isoGlu-KEK-Peg3,
[Hexadecanoyl]-isoGlu-KEK-Peg3-Peg3,
[19-carboxy-Nonadecanoyl]-isoGlu-KEK,
[19-carboxy-Nonadecanoyl]-[4-aminobutanoyl]-KEK,
[17-carboxy-Heptadecanoyl]-[4-aminobutanoyl]-KEK-Peg3-Peg3-Peg3,
[17-carboxy-Heptadecanoyl]-[4-aminobutanoyl]-KEK-Peg3-Peg3,
[19-carboxy-NonadecanoylH4-aminobutanoyl]-KEK-Peg3-Peg3, [17-carboxy-Heptadecanoyl]-KEK-Peg3-Peg3,
[19-carboxy-Nonadecanoyl]-KEK-Peg3-Peg3,
[17-carboxy-Heptadecanoyl]-isoGlu-KEK-Peg3,
[19-carboxy-Nonadecanoyl]-isoGlu-KEK-Peg3,
[17-carboxy-Heptadecanoyl]-isoGlu-KEK-Peg3-Peg3,
[19-carboxy-Nonadecanoyl]-isoGlu-KEK-Peg3-Peg3.
Examples of Ψ comprising different substituents (fatty acids, FA), conjugated to the amino acid side-chain, optionally by a spacer, are illustrated below:
Figure imgf000054_0001
Figure imgf000055_0001
Figure imgf000056_0001
Figure imgf000057_0001
[K(Fatty acid- [3-aminopropanoyl])]
Figure imgf000057_0002
[K( [Fatty acid] -isoGlu-KEK-Peg3)]
Figure imgf000058_0001
Furthermore, the substituent [Hexadecanoyl]-isoGlu, conjugated to the side chain of a lysine residue, is illustrated below:
Figure imgf000058_0002
Thus, the side chain of the Lys residue is covalently attached to the side-chain carboxyl group of the isoGlu spacer -Z2- (-ZS1-) via an amide linkage. A
hexadecanoyi group (Z1) is covalently attached to the amino group of the isoGlu spacer via an amide linkage.
The substituent [4-Hexadecanoylamino-butanoyl]- conjugated to the side chain of a lysine residue, is illustrated below
Figure imgf000059_0001
The substituent [(Hexadecanoyl)iso-Lys]- conjugated to the side chain of a lysine residue, is illustrated below
Figure imgf000059_0002
The substituent [(Hexadecanoyl)β-Ala]- conjugated to the side chain of a lysine residue, is illustrated below
Figure imgf000059_0003
Some further specific examples of -Z2-Z1 combinations are illustrated below. In each case,— indicates the point of attachment to the side chain of the amino acid component of Ψ:
Figure imgf000060_0001
Figure imgf000061_0001
The skilled person will be well aware of suitable techniques for preparing the substituents employed in the context of the invention and conjugating them to the side chain of the appropriate amino acid in the dual agonist peptide. For examples of suitable chemistry, see WO98/08871 , WO00/55184, WO00/551 19, Madsen et al., J. Med. Chem. 50:6126-32 (2007), and Knudsen et al., J. Med Chem. 43:1664-1669 (2000), incorporated herein by reference.
Synthesis of dual agonists
It is preferred to synthesize dual agonists of the invention by means of solid-phase or liquid-phase peptide synthesis methodology. In this context, reference may be made to WO 98/1 1 125 and, among many others, Fields, G.B. et al., 2002, "Principles and practice of solid-phase peptide synthesis". In: Synthetic Peptides (2nd Edition), and the Examples herein. In accordance with the present invention, a dual agonist of the invention may be synthesized or produced in a number of ways, including for example, a method which comprises
(a) synthesizing the dual agonist by means of solid-phase or liquid-phase peptide synthesis methodology and recovering the synthesized dual agonist thus obtained; or
(b) expressing a precursor peptide sequence from a nucleic acid construct that encodes the precursor peptide, recovering the expression product, and modifying the precursor peptide to yield a compound of the invention.
The precursor peptide may be modified by introduction of one or more non- proteinogenic amino acids, e.g. Orn, Dap, or Dab, introduction of a lipophilic substituent Z1 or Z1 -Z2- at a residue Ψ, introduction of the appropriate terminal groups R1 and R2, etc.
Expression is typically performed from a nucleic acid encoding the precursor peptide, which may be performed in a cell or a cell-free expression system comprising such a nucleic acid.
It is preferred to synthesize the analogues of the invention by means of solid-phase or liquid-phase peptide synthesis. In this context, reference is made to WO 98/1 1 125 and, among many others, Fields, GB et al., 2002, "Principles and practice of solid- phase peptide synthesis". In: Synthetic Peptides (2nd Edition), and the Examples herein.
For recombinant expression, the nucleic acid fragments encoding the precursor peptide will normally be inserted in suitable vectors to form cloning or expression vectors. The vectors can, depending on purpose and type of application, be in the form of plasmids, phages, cosmids, mini-chromosomes, or virus, but also naked DNA which is only expressed transiently in certain cells is an important vector. Preferred cloning and expression vectors (plasmid vectors) are capable of autonomous replication, thereby enabling high copy-numbers for the purposes of high-level expression or high-level replication for subsequent cloning.
In general outline, an expression vector comprises the following features in the 5'→3' direction and in operable linkage: a promoter for driving expression of the nucleic acid fragment, optionally a nucleic acid sequence encoding a leader peptide enabling secretion (to the extracellular phase or, where applicable, into the periplasma), the nucleic acid fragment encoding the precursor peptide, and optionally a nucleic acid sequence encoding a terminator. They may comprise additional features such as selectable markers and origins of replication. When operating with expression vectors in producer strains or cell lines it may be preferred that the vector is capable of integrating into the host cell genome. The skilled person is very familiar with suitable vectors and is able to design one according to their specific requirements.
The vectors of the invention are used to transform host cells to produce the precursor peptide. Such transformed cells can be cultured cells or cell lines used for propagation of the nucleic acid fragments and vectors, and/or used for recombinant production of the precursor peptides.
Preferred transformed cells are micro-organisms such as bacteria [such as the species Escherichia (e.g. E. coli), Bacillus (e.g. Bacillus subtilis), Salmonella, or Mycobacterium (preferably non-pathogenic, e.g. M. bovis BCG), yeasts (e.g., Saccharomyces cerevisiae and Pichia pastoris), and protozoans. Alternatively, the transformed cells may be derived from a multicellular organism, i.e. it may be fungal cell, an insect cell, an algal cell, a plant cell, or an animal cell such as a mammalian cell. For the purposes of cloning and/or optimised expression it is preferred that the transformed cell is capable of replicating the nucleic acid fragment of the invention. Cells expressing the nucleic fragment can be used for small-scale or large-scale preparation of the peptides of the invention.
When producing the precursor peptide by means of transformed cells, it is
convenient, although far from essential, that the expression product is secreted into the culture medium.
Pharmaceutical Compositions and Administration
An aspect of the present invention relates to a composition comprising a dual agonist according to the invention, or a pharmaceutically acceptable salt or solvate thereof, together with a carrier. In one embodiment of the invention, the composition is a pharmaceutical composition and the carrier is a pharmaceutically acceptable carrier. The present invention also relates to a pharmaceutical composition comprising a dual agonist according to the invention, or a salt or solvate thereof, together with a carrier, excipient or vehicle. Accordingly, the dual agonist of the present invention, or salts or solvates thereof, especially pharmaceutically acceptable salts or solvates thereof, may be formulated as compositions or pharmaceutical compositions prepared for storage or administration, and which comprise a therapeutically effective amount of a dual agonist of the present invention, or a salt or solvate thereof.
Suitable salts formed with bases include metal salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium or magnesium salts; ammonia salts and organic amine salts, such as those formed with morpholine, thiomorpholine, piperidine, pyrrolidine, a lower mono-, di- or tri-alkylamine (e.g., ethyl-tert-butyl-, diethyl-, diisopropyl-, triethyl-, tributyl- or dimethylpropylamine), or a lower mono-, di- or tri-(hydroxyalkyl)amine (e.g., mono-, di- or triethanolamine). Internal salts may also be formed. Similarly, when a compound of the present invention contains a basic moiety, salts can be formed using organic or inorganic acids. For example, salts can be formed from the following acids: formic, acetic, propionic, butyric, valeric, caproic, oxalic, lactic, citric, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, phthalic, hydrochloric, hydrobromic, phosphoric, nitric, sulphuric, benzoic, carbonic, uric, methanesulphonic, naphthalenesulphonic, benzenesulphonic, toluenesulphonic, p-toluenesulphonic (i.e. 4-methylbenzene-sulphonic), camphorsulphonic, 2- aminoethanesulphonic, aminomethylphosphonic and trifluoromethanesulphonic acid (the latter also being denoted triflic acid), as well as other known pharmaceutically acceptable acids. Amino acid addition salts can also be formed with amino acids, such as lysine, glycine, or phenylalanine. In one embodiment, a pharmaceutical composition of the invention is one wherein the dual agonist is in the form of a pharmaceutically acceptable acid addition salt.
As will be apparent to one skilled in the medical art, a "therapeutically effective amount" of a dual agonist compound or pharmaceutical composition thereof of the present invention will vary depending upon, inter alia, the age, weight and/or gender of the subject (patient) to be treated. Other factors that may be of relevance include the physical characteristics of the specific patient under consideration, the patient's diet, the nature of any concurrent medication, the particular compound(s) employed, the particular mode of administration, the desired pharmacological effect(s) and the particular therapeutic indication. Because these factors and their relationship in determining this amount are well known in the medical arts, the determination of therapeutically effective dosage levels, the amount necessary to achieve the desired result of treating and/or preventing and/or remedying malabsorption and/or low-grade inflammation described herein, as well as other medical indications disclosed herein, will be within the ambit of the skilled person. As used herein, the term "a therapeutically effective amount" refers to an amount which reduces symptoms of a given condition or pathology, and preferably which normalizes physiological responses in an individual with that condition or pathology. Reduction of symptoms or normalization of physiological responses can be determined using methods routine in the art and may vary with a given condition or pathology. In one aspect, a therapeutically effective amount of one or more dual agonists, or pharmaceutical compositions thereof, is an amount which restores a measurable physiological parameter to substantially the same value (preferably to within 30%, more preferably to within 20%, and still more preferably to within 10% of the value) of the parameter in an individual without the condition or pathology in question.
In one embodiment of the invention, administration of a compound or pharmaceutical composition of the present invention is commenced at lower dosage levels, with dosage levels being increased until the desired effect of preventing/treating the relevant medical indication is achieved. This would define a therapeutically effective amount. For the dual agonists of the present invention, alone or as part of a pharmaceutical composition, such human doses of the active dual agonist may be between about 0.01 pmol/kg and 500 μηΊθΙ/kg body weight, between about 0.01 pmol/kg and 300 μηΊθΙ/kg body weight, between 0.01 pmol/kg and 100 μηΊθΙ/kg body weight, between 0.1 pmol/kg and 50 μηΊθΙ/kg body weight, between 1 pmol/kg and 10 μηΊθΙ/kg body weight, between 5 pmol/kg and 5 μηΊθΙ/kg body weight, between 10 pmol/kg and 1 μηΊθΙ/kg body weight, between 50 pmol/kg and 0.1 μηΊθΙ/kg body weight, between 100 pmol/kg and 0.01 μηΊθΙ/kg body weight, between 0.001 μηΊθΙ/kg and 0.5 μηΊθΙ/kg body weight, between 0.05 μηΊθΙ/kg and 0.1 μηΊθΙ/kg body weight. The therapeutic dosing and regimen most appropriate for patient treatment will of course vary with the disease or condition to be treated, and according to the patient's weight and other parameters. Without wishing to be bound by any particular theory, it is expected that doses, in the μg/kg range, and shorter or longer duration or frequency of treatment may produce therapeutically useful results, such as a statistically significant increase particularly in small bowel mass. In some instances, the therapeutic regimen may include the administration of maintenance doses appropriate for preventing tissue regression that occurs following cessation of initial treatment. The dosage sizes and dosing regimen most appropriate for human use may be guided by the results obtained by the present invention, and may be confirmed in properly designed clinical trials. An effective dosage and treatment protocol may be determined by conventional means, starting with a low dose in laboratory animals and then increasing the dosage while monitoring the effects, and systematically varying the dosage regimen as well. Numerous factors may be taken into consideration by a clinician when determining an optimal dosage for a given subject. Such considerations are known to the skilled person.
Medical Conditions
In a broad aspect, the present invention provides a dual agonist of the invention for use as a medicament.
In a further aspect, the present invention relates to a dual agonist of the invention for use in therapy.
The dual agonists described in this specification have biological activities of both GLP-1 and GLP-2. GLP-2 induces significant growth of the small intestinal mucosal epithelium via the stimulation of stem cell proliferation in the crypts and inhibition of apoptosis on the villi (Drucker et al. Proc Natl Acad Sci U S A. 1996, 93:791 1 -6). GLP-2 also has growth effects on the colon. GLP-2 also inhibits gastric emptying and gastric acid secretion (Wojdemann et al. J Clin Endocrinol Metab. 1999, 84:2513-7), enhances intestinal barrier function (Benjamin et al.Gut. 2000, 47:1 12-9.), stimulates intestinal hexose transport via the upregulation of glucose transporters (Cheeseman, Am J Physiol. 1997, R1965-71 ), and increases intestinal blood flow (Guan et al. Gastroenterology. 2003, 125, 136-47).
The beneficial effects of GLP-2 in the small intestine have raised considerable interest as to the use of GLP-2 in the treatment of intestinal disease or injury (Sinclair and Drucker, Physiology 2005: 357-65). Furthermore, GLP-2 has been shown to prevent or reduce mucosal epithelial damage in a wide number of preclinical models of gut injury, including chemotherapy-induced enteritis, ischemia-reperfusion injury, dextran sulfate-induced colitis and genetic models of inflammatory bowel disease (Sinclair and Drucker Physiology 2005: 357-65). The GLP-2 analogue teduglutide (Gly2- hGLP-2) is approved for treatment of short bowel syndrome under the trade names Gattex and Revestive. GLP-1 is a peptide hormone known for its important role in glucose homeostasis. When secreted from the gastrointestinal tract in response to nutrient ingestion, GLP-1 potentiates glucose-stimulated insulin secretion from the β-cells (Kim and Egan, 2008, Pharmacol. Rev. 470-512). Furthermore, GLP-1 or it analogues has been shown to increase somatostatin secretion and suppress glucagon secretion (Hoist JJ, 2007, Physiol Rev. 1409-1439).
Besides the primary actions of GLP-1 on glucose-stimulated insulin secretion, GLP-1 is also known as a key regulator of appetite, food intake, and body weight. Moreover, GLP-1 can inhibit gastric emptying and gastrointestinal motility in both rodents and humans, most likely through GLP-1 receptors present in the gastrointestinal tract
(Hoist JJ, 2007, Physiol Rev. 1409-1439; Hellstrom et al., 2008, Neurogastroenterol Motil. Jun; 20(6):649-659). In addition, GLP-1 seems to have insulin-like effects in major extrapancreatic tissues, participating in glucose homeostasis and lipid metabolism in tissues such as muscle, liver, and adipose tissues (Kim and Egan, 2008, Pharmacol. Rev. 470-512).
Thus the dual agonist compounds of the present invention may be used to increase intestinal mass, improve intestinal function (especially intestinal barrier function), increase intestinal blood flow, or repair intestinal damage or dysfunction (whether structural or functional), e.g. damage to the intestinal epithelium. They may also be used in the prophylaxis or treatment of conditions which may be ameliorated by these effects, and in reducing the morbidity related to gastrointestinal damage.
The dual agonists therefore find use in many gastrointestinal disorders. The term "gastrointestinal" is used here to include the entire gastrointestinal tract, including oesophagus, stomach, small intestine (duodenum, jejunum, ileum) and large intestine (cecum, colon, rectum), but especially the small intestine and colon.
Thus, conditions in which the dual agonists may be of benefit include malabsorption, ulcers (which may be of any aetiology, e.g., peptic ulcers, Zollinger-Ellison Syndrome, drug-induced ulcers, and ulcers related to infections or other pathogens), short-bowel syndrome, cul-de-sac syndrome, inflammatory bowel disease (Crohn's disease and ulcerative colitis), irritable bowel syndrome (IBS), pouchitis, celiac sprue (for example arising from gluten induced enteropathy or celiac disease), tropical sprue,
hypogammaglobulinemic sprue, and mucositis or diarrhea induced by chemotherapy or radiation therapy. The dual agonists may also find use in certain conditions which do not primarily affect gastrointestinal tissue but which may be caused or exacerbated by factors arising from intestinal dysfunction. For example, impaired intestinal barrier function (which may be referred to as "leakiness" of the intestine or gut) can lead to transit of materials from the lumen of the gut directly into the bloodstream and thus to the kidney, lung and/or liver. These materials may include food molecules such as fats, which contribute to conditions such as hepatitis and/or fatty liver diseases, including parenteral nutrition associated gut atrophy, PNALD (Parenteral Nutrition-Associated Liver Disease), NAFLD (Non-Alcoholic Fatty Liver Disease) and NASH (Non-Alcoholic Steatohepatitis).
The materials crossing into the bloodstream may also include pathogens such as bacteria, and toxins such as bacterial lipopolysaccharide (LPS), which may contribute to systemic inflammation (e.g. vascular inflammation). Such inflammation is often referred to as "low grade inflammation" and is a contributing factor to the
pathogenesis of metabolic endotoxemia (a condition seen in both diabetes and obesity, discussed further below), primary biliary cirrhosis and hepatitis. Entry of pathogens to the bloodstream may also result in conditions such as necrotising enterocolitis.
Low grade inflammation is not characterised by the normal symptoms of acute inflammation such as pain, fever and redness, but can be detected via the presence of inflammatory markers in the blood, such as C-reactive protein and proinflammatory cytokines including TNF-alpha (tumour necrosis factor alpha).
The dual agonists may also find use in conditions which primarily affect other tissues but have gastrointestinal side-effects. For example, inflammatory conditions such as pancreatitis result in elevated levels of circulating inflammatory mediators which may in turn induce intestinal damage or intestinal dysfunction, such as impairment of barrier function. In some circumstances, this may lead to more severe systemic inflammatory conditions such as sepsis, or to surgical procedures or mechanical injuries (volvulus) where blood supply to the intestine is interrupted, ultimately leading to ischaemia-reperfusion injuries.
Similarly, graft versus host disease (GVHD) may result in substantial tissue damage to the gastrointestinal tract, resulting in impaired barrier function and other side effects such as diarrhea. Thus, the dual agonists described may be useful for the
prophylaxis or treatment of intestinal dysfunction or damage caused by or associated with GVHD, as well as prophylaxis or treatment of side effects such as diarrhea caused by or associated with GVHD.
The dual agonist compounds described herein also find use, inter alia, in reducing or inhibiting weight gain, reducing rate of gastric emptying or intestinal transit, reducing food intake, reducing appetite, or promoting weight loss. The effect on body weight may be mediated in part or wholly via reducing food intake, appetite or intestinal transit.
Thus the dual agonists of the invention can be used for the prophylaxis or treatment of obesity, morbid obesity, obesity-linked gallbladder disease and obesity-induced sleep apnea.
Independently of their effect on body weight, the dual agonists of the invention may have a beneficial effect on glucose tolerance and/or glucose control. They may also be used to modulate (e.g. improve) circulating cholesterol levels, being capable of lowering circulating triglyceride or LDL levels, and increasing HDL/LDL ratio. Thus, they may be used for the prophylaxis or treatment of inadequate glucose control, glucose tolerance or dyslipidaemia (e.g. elevated LDL levels or reduced HDL/LDL ratio) and associated conditions, including diabetes (e.g. Type 2 diabetes, gestational diabetes), pre-diabetes, metabolic syndrome and hypertension.
Many of these conditions are also associated with obesity or overweight. The effects of the dual agonists on these conditions may therefore follow from their effect on body weight, in whole or in part, or may be independent thereof.
Effects on body weight may be therapeutic or cosmetic.
The dual agonist activity of the compounds described herein may be particularly beneficial in many of the conditions described, as the two activities may complement one another.
For example, malabsorption is a condition arising from abnormality in the absorption of water and/or food nutrients, such as amino acids, sugars, fats, vitamins or minerals, via the gastrointestinal (Gl) tract, leading to malnutrition and/or dehydration. Malabsorption may be a result of physical (e.g. traumatic) or chemical damage to the intestinal tract. Dual agonists as described in this specification may be capable of improving intestinal barrier function, reducing gastric empting, and increasing intestinal absorption while at the same time normalising intestinal transit time. This would not only help patients to increase the absorption of nutrients and liquid, but would also alleviate patients' social problems related to meal- stimulated bowel movements.
Furthermore, intestinal function and metabolic disorders may be closely inter-related, with each contributing to the development or symptoms of the other.
As mentioned above, obesity is linked with low grade inflammation (sometimes designated "obesity-linked inflammation"). It is also generally recognised that obesity (along with other syndromes) causes an increased vascular permeability which allows pathogens and toxins such as LPS to enter the cell wall of the intestinal tract and thereby initiate inflammation. The changes that result from the inflammatory response are essentially the same regardless of the cause and regardless of where the insult arises. The inflammatory response may be acute (short lived) or chronic (longer lasting).
It has been demonstrated that, e.g., obese mice (ob/ob and db/db mice) have a disrupted mucosal barrier function and exhibit increased low-grade inflammation
(Brun et al., 2007, Am. J. Physiol. Gastrointest. Liver Physiol., 292: G518-G525, Epub 5 Oct 2006). These observations were further extended to C57BL6/J mice maintained on a high-fat diet (Cani et al., 2008, Diabetes, vol. 57, 1470-1481 ) and to non-obese diabetic mice (Hadjiyanni et al., 2009, Endocrinology, 150(2): 592-599). Cani and colleagues (Gut; 2009, 58:1091 -1 103,) reported that in ob/ob mice, the modulation of the gut microbiota resulted in decreased intestinal barrier dysfunction and reduced systemic inflammation via a GLP-2 dependent pathway. Further, the increased intestinal permeability observed in obese and diabetic patients is likely to play a more vital role in the disease progression than previously anticipated.
Increased intestinal permeability leads to increased bacterial lipopolysaccharide (LPS) transport across the intestinal barrier. This increased LPS activates immune cells, such as circulating macrophages and macrophages residing in organs in the body, causing low-grade chronic inflammation that may be involved in the
pathogenesis of many diseases. This phenomenon is called metabolic endotoxemia (ME).
The inflammatory process may also play a role in causing metabolic dysfunction in obese individuals, such as insulin resistance and other metabolic disturbances. Thus the dual agonist compounds of the invention may be particularly useful for prophylaxis or treatment of low grade inflammation, especially in obese or overweight individuals, exerting beneficial effects via the GLP-1 agonist component of their activity and/or the GLP-2 component of their activity. The therapeutic efficacy of treatment with a dual agonist of the invention may be monitored by enteric biopsy to examine the villus morphology, by biochemical assessment of nutrient absorption, by non-invasive determination of intestinal permeability, by patient weight gain, or by amelioration of the symptoms associated with these conditions. In a further aspect there is provided a therapeutic kit comprising a dual agonist of the invention, or a pharmaceutically acceptable salt or solvate thereof.
The following examples are provided to illustrate preferred aspects of the invention and are not intended to limit the scope of the invention in any way.
Examples The following examples are provided to illustrate preferred aspects of the invention and are not intended to limit the scope of the invention.
MATERIAL AND METHODS
General Peptide Synthesis
List of abbreviations and suppliers are provided in the table below
Figure imgf000071_0001
Figure imgf000072_0001
Apparatus and synthetic strategy
Peptides were synthesized batchwise on a peptide synthesiser, such as a CEM Liberty Peptide Synthesizer or a Symphony X Synthesizer, according to solid phase peptide synthetic procedures using 9-fluorenylmethyloxycarbonyl (Fmoc) as N-o amino protecting group and suitable common protection groups for side-chain functionalities.
As polymeric support based resins, such as e.g. TentaGel™, was used. The synthesizer was loaded with resin that prior to usage was swelled in DMF. Coupling
CEM Liberty Peptide Synthesizer A solution of Fmoc-protected amino acid (4 equiv.) was added to the resin together with a coupling reagent solution (4 equiv.) and a solution of base (8 equiv.). The mixture was either heated by the microwave unit to 70-75°C and coupled for 5 minutes or coupled with no heat for 60 minutes. During the coupling nitrogen was bubbled through the mixture.
Symphony X Synthesizer
The coupling solutions were transferred to the reaction vessels in the following order: amino acid (4 equiv.), HATU (4 equiv.) and DIPEA (8 equiv.). The coupling time was 10 min at room temperature (RT) unless otherwise stated. The resin was washed with DMF (5 x 0,5 min). In case of repeated couplings the coupling time was in all cases 45 min at RT.
Deprotection
CEM Liberty Peptide Synthesizer The Fmoc group was deprotected using piperidine in DMF or other suitable solvents. The deprotection solution was added to the reaction vessel and the mixture was heated for 30 sec. reaching approx. 40°C. The reaction vessel was drained and fresh deprotection solution was added and subsequently heated to 70-75°C for 3 min. After draining the reaction vessel the resin was washed with DMF or other suitable solvents.
Symphony X Synthesizer
Fmoc deprotection was performed for 2,5 minutes using 40% piperidine in DMF and repeated using the same conditions. The resin was washed with DMF (5 x 0,5 min).
Side-chain acylation (optional)
A suitable trifunctional amino acid with an orthogonal side-chain protecting group according to Fmoc methodology is introduced at the position of the acylation. The N- terminal of the growing peptide chain is then Boc-protected using B0C2O or alternatively by using an N-a-Boc-protected amino acid in the last coupling. While the peptide is still attached to the resin, the orthogonal side chain protecting group is selectively cleaved using a suitable deprotection reagent. The lipophilic moiety is then coupled directly to the free side-chain functionality or alternatively via a linker in between according to suitable coupling protocols. Cleavage
The dried peptide resin was treated with TFA and suitable scavengers for
approximately 2 hours. The volume of the filtrate was reduced and the crude peptide was precipitated after addition of diethylether. The crude peptide precipitate was washed several times with diethylether and finally dried.
HPLC purification of the crude peptide
The crude peptide was purified by preparative reverse phase HPLC using a conventional HPLC apperatus, such as a Gilson GX-281 with 331/332 pump combination', for binary gradient application equipped with a column, such as 5 x 25 cm Gemini NX 5u C18 1 10A column, and a fraction collector using a flow 20-40 ml/min with a suitable gradient of buffer A (0.1 % Fomic acid, aq.) or A (0.1 % TFA, aq.) and buffer B (0.1 % Formic acid, 90% MeCN, aq.) or B (0.1 % TFA, 90% MeCN, aq.). Fractions were analyzed by analytical HPLC and MS and selected fractions were pooled and lyophilized. The final product was characterized by HPLC and MS. Analytical HPLC
Final purities were determined by analytic HPLC (Agilent 1 100/1200 series) equipped with auto sampler, degasser, 20 μΙ flow cell and Chromeleon software. The HPLC was operated with a flow of 1.2 ml/min at 40°C using an analytical column, such as Kinetex 2.6 μηη XB-C18 100A 100x4,6 mm column. The compound was detected and quantified at 215 nm. Buffers A (0.1 % TFA, aq.) and buffer B (0.1 % TFA, 90% MeCN, aq.).
Mass spectroscopy
Final MS analysis were determined on a conventionial mass spectroscopy, e.g.
Waters Xevo G2 Tof, equipped with electrospray detector with lock-mass calibration and MassLynx software. It was operated in positive mode using direct injection and a cone voltage of 15V (1 TOF), 30 V (2 TOF) or 45 V (3 TOF) as specified on the chomatogram. Precision was 5 ppm with a typical resolution of 15,000-20,000. GLP-1 and GLP-2 receptor potency assays
Peptides of the present invention act as both GLP-1 and GLP-2 agonists and thus activate the GLP-1 receptor and GLP-2 receptor, respectively. One useful in vitro assay for measuring GLP-1 receptor (GLP-1 R) and GLP-2 receptor (GLP-2 R) activation is quantification of cAMP, i.e. 3'-5'-cyclic adenosine monophosphate, which is a second messenger essential in many biological processes, and one of the most ubiquitous mechanisms for regulating cellular functions. An example is the cAMP AlphaScreen® assay from Perkin Elmer which has been used to quantify the cAMP response upon GLP-1 and GLP-2 receptor activation in HEK293 cells stably expressing GLP-1 R or GLP-2 R. Test compounds eliciting an increase in the intracellular level of cAMP can be tested in these assays and the response normalized relative to a positive and negative control (vehicle) to calculate the EC50 and maximal response from the concentration - response curve using the 4- parameter logistic (4PL) nonlinear model for curve fitting.
Pharmacokinetics (PK) measurements
C57BL/6J mice (males with a body weight of approximately 25 g) were given either a single subcutaneous (s.c.) bolus or a single intravenous (i.v.) bolus of each peptide to be tested.
Following s.c. or i.v. administration of the selected compounds (150 nmol/kg), blood samples were drawn at specific sampling time points post-dose. The dosing vehicle was either a phosphate buffer containing mannitol (pH 7.5) or a phosphate buffer containing NaCI (pH 7.4).
At each sampling time point, samples from the mice were drawn and plasma samples were analyzed after either solid phase extraction (SPE) or precipitation by liquid chromatography mass spectrometry (LC-MS/MS). Mean plasma concentrations were used for calculation of the pharmacokinetic parameters using the non-compartmental approach in Phoenix WinNonlin 7.0. Plasma terminal elimination half-life (T½) was determined as Ιη(2)/λζ where Iz is the magnitude of the slope of the log linear regression of the log concentration versus time profile during the terminal phase.
Bioavailability was determined as AUCinf (s.c.) / AUCinf (i.v.) x 100, where AUCinf is the area under the plasma concentration - time curve extrapolated to infinity (AUCinf = AUCIast + Clast/ λζ, where Clast is the last observed plasma concentration). Tmax is the post-dose time where the maximal plasma concentration was observed.
Example 1 : Synthesis of the compounds
Compounds Synthesised
The compounds of Table 1.1 were synthesized using the above techniques. Table 1.1: Compounds synthesized
Figure imgf000076_0001
Figure imgf000077_0001
Figure imgf000078_0001
For illustration purpose only, the synthesis of two selected compounds is described in detail below.
Synthesis of compound no 5 Hy-H[Aib]DGSFSSELATILD[K(Hexadecanoyl-isoGlu)]QAARDFIAWLIQQKITD-OH
Solid phase peptide synthesis was performed on a Symphony X Synthesizer using standard Fmoc chemistry. TentaGel S PHB Asp(tBu)Fmoc (1 ,13 g; 0.23 mmol/g) was swelled in DMF (10 ml) prior to use and the Fmoc-group was deprotected according to the procedure described above.
Coupling
Suitable protected Fmoc-amino acids according to the sequence were coupled as described above using HATU as coupling reagent. All couplings were performed at R.T. In order to facilitate the synthesis, a pseudoproline were used: in position 6 and 7 Fmoc-Phe-Ser(psi Me,Mepro)-OH. Acylation in position 16 was obtained according to the side-chain acylation procedure described above. The pseudoproline was coupled according to the standard procedure described above for Fmoc-amino acids.
Deprotection
Fmoc deprotection was performed according to the procedure described above. Cleavage of the peptide from the solid support
The peptide-resin was washed with EtOH (3 x 10 ml) and Et20 (3 x 10 ml) and dried to constant weight at room temperature (r.t). The peptide was cleaved from the resin by treatment with TFA TIS/H20 (95/2,5/2,5; 40 ml, 2 h; r.t.). The volume of the filtrate was reduced and the crude peptide was precipitated after addition of diethylether. The crude peptide precipitate was washed several times with diethylether and finally dried to constant weight at room temperature yield 710 mg crude peptide product (purity -40%).
HPLC purification of the crude peptide
The crude peptide was purified by preparative reverse phase HPLC using a Gilson GX-281with 331/332 pump combination for binary gradient application equipped with a 5 x 25 cm Gemini NX 5u C18 1 1 OA, column and a fraction collector and run at 35 ml/min with a gradient of buffer A (0.1 % TFA, aq.) and buffer B (0.1 % TFA, 90% MeCN, aq.) gradient from 30%B to 70%B in 47 min. Fractions were analyzed by analytical HPLC and MS and relevant fractions were pooled and lyophilized to yield 156,8 mg, with a purity of 86% as characterized by HPLC and MS as described above. Calculated monoisotopic MW = 4069,18, found 4069,28.
Example 2: GLP-1 R and GLP-2R EC5o measurements
Generation of cell line expressing human GLP-1 receptors
The cDNA encoding the human glucagon-like peptide 1 receptor (GLP-1 R) (primary accession number P43220) was cloned from the cDNA BC1 12126
(MGC:138331/IMAGE:8327594). The DNA encoding the GLP-1 -R was amplified by PCR using primers encoding terminal restriction sites for subcloning. The 5'-end primers additionally encoded a near Kozak consensus sequence to ensure efficient translation. The fidelity of the DNA encoding the GLP-1 -R was confirmed by DNA sequencing. The PCR products encoding the GLP-1 -R were subcloned into a mammalian expression vector containing a neomycin (G418) resistance marker. The mammalian expression vectors encoding the GLP-1 -R were transfected into HEK293 cells by a standard calcium phosphate transfection method. 48 hours post- transfection, cells were seeded for limited dilution cloning and selected with 1 mg/ml G418 in the culture medium. Following 3 weeks in G418 selection clones were picked and tested in a functional GLP-1 receptor potency assay as described below. One clone was selected for use in compound profiling.
Generation of cell line expressing human GLP-2 receptors
The hGLP2-R was purchased from MRC-geneservice, Babraham, Cambridge as an Image clone: 5363415 (1 1924-117). For subcloning into a mammalian expression vector, primers for subcloning were obtained from DNA-Technology, Risskov, Denmark. The 5' and 3' primers used for the PCR reaction include terminal restriction sites for cloning and the context of the 5' primer is modified to a Kozak consensus without changing the sequence of the product encoded by the ORF. A standard PCR reaction was run using Image clone 5363415 (1 1924-117) as a template with the above mentioned primers and Polymerase Herculase II Fusion in a total vol. of 50μΙ. The generated PCR product was purified using GFX PCR and Gel band purification kit, digested with restriction enzymes and cloned into the mammalian expression vector using Rapid DNA Ligation Kit. Ligation reaction was transformed to XL10 Gold Ultracompetent cells and colonies were picked for DNA production using Endofree Plasmid maxi kit. Subsequent sequence analysis was conducted by MWG Eurofins, Germany. The clone was confirmed to be the hGLP-2 (1 -33) receptor, splice variant rs17681684.
HEK293 cells were transfected using the Lipofectamine PLUS transfection method. The day before transfection, HEK293 cells were seeded in two T75 flasks at a density of 2x106 cells / T75 flask in cell culturing medium without antibiotics. On the day of transfection, cells were washed with 1x DPBS and medium was replaced with Optimem to a volume of 5 mL / T75 flask before addition of Lipofectamine-plasmid complexes were added gently and drop wise to the cells in T75 flasks and replaced with growth medium after 3 hours and again to growth medium supplemented with 50C^g/ml_ G418 after 24 hours. Following 4 weeks in G418 selection, clones were picked and tested in a functional GLP-2 receptor potency assay as described below. One clone was selected for use in compound profiling. GLP-1R and GLP-2 receptor potency assays
The cAMP AlphaScreen® assay from Perkin Elmer was used to quantitate the cAMP response to activation of the GLP1 and GLP2 receptor, respectively. Exendin-4 was used as reference compound for GLP1 receptor activation and Teduglutide as reference compound for GLP2 receptor activation. Data from test compounds eliciting an increase in the intracellular level of cAMP were normalized relative to the positive and negative control (vehicle) to calculate the ECso and maximal response from the concentration response curve. The results are listed in Table 2.1.
Table 2.1 ECso measurements
Figure imgf000081_0001
Figure imgf000082_0001
Figure imgf000083_0001
Example 3: Pharmacokinetics of selected compounds in mice dosed with a single administration The purpose of this study was to determine the half-life (T½) and clearance of the GLP-1/GLP-2 dual agonist after s.c. and i.v. administration to mice.
Method
C57BL/6J mice (males with a body weight of approximately 25 g) were given either a single subcutaneous (s.c.) bolus or a single intravenous (i.v.) bolus of each peptide to be tested.
Selected compounds were administered either s.c. or i.v., 150 nmol/kg, and blood samples were drawn at 10 min, 30 min, 2, 4, 8, 16, 24, 36, 48 and 72 hours post-dose following s.c. administration or 10 min, 30 min, 2, 4, 8, 16, 24, 36 and 48 hours post- dose following i.v. administration. Blood samples were drawn by orbital bleeding. The dosing vehicle was 50 mM Histidine pH 6 and 200 mM Mannitol.
At each sampling time point, samples from two mice were drawn, i.e. 20 mice were included for each compound s.c. and 18 mice for each compound i.v. The mice were euthanized immediately after blood sampling by cervical dislocation. Plasma samples were analyzed after either solid phase extraction (SPE) or precipitation by liquid chromatography mass spectrometry (LC-MS/MS). Mean plasma concentrations were used for calculation of the pharmacokinetic parameters using the non-compartmental approach in Phoenix WinNonlin 7.0. Plasma terminal elimination half-life (T½) was determined as Ιη(2)/λζ where λζ is the magnitude of the slope of the log linear regression of the log concentration versus time profile during the terminal phase. Bioavailability was determined as AUCinf (s.c.) / AUCinf (i.v.) x 100, where AUCinf is the area under the plasma concentration - time curve extrapolated to infinity (AUCinf = AUCiast + Ciast λζ, where Ciast is the last observed plasma concentration). Tmax is the post-dose time where the maximal plasma concentration was observed. See tables 3.1 . and 3.2.
Results Table 3.1
Figure imgf000084_0001
Table 3.2
Figure imgf000084_0002
Example 4: Effect on fasting glucose and intestinal wet weight in normal mice
Normal chow-fed C57BL/6J male mice were used. The mice were kept in standard housing conditions, light-, temperature-, and humidity-controlled room (12:12 h light- dark cycle, with lights on at 06.00-18.00 h; 20-22°C; 50-80% relative humidity). Each dosing group consisted of 6 animals. Mice were dosed once daily (compound 18 and compound 21 , or twice daily (compound 22) with 250 nmol/kg, or vehicle for 3 days (day 0-day 2) via subcutaneous administration. Mice were fasted and blood glucose levels measured after a single s.c. injection with peptides. Animals were sacrificed on day 3 after final dosing on day 2, and small intestinal wet weights were measured.
Results
All test compounds (250 nmol/kg) reduced fasting blood glucose levels compared to the vehicle-treated mice (Table 4).
All test compounds (250 nmol/kg) increased small intestine wet weight as compared to the vehicle-treated mice (Table 4). Table 4: Effects on fasting blood glucose levels and small intestinal wet weight.
Figure imgf000085_0001

Claims

1. A GLP-1/GLP-2 dual agonist represented by the formula:
R1-X*-U-R2
wherein:
R1 is hydrogen (Hy), C1-4 alkyl (e.g. methyl), acetyl, formyl, benzoyl or trifluoroacetyl; R2 is NH2 or OH;
X* is a peptide having the formula I:
Figure imgf000086_0001
wherein:
X2 is G or Aib;
X5 is S orT;
X7 is S orT;
X8isS, ΌorΨ;
X10 is L, V, M orΨ;
X11 is A; S orΨ;
X15isDorE;
X16isE, G, A or Ψ;
X17 is Q, E, K, L or Ψ;
X19 is A, VorS;
X20 is R or K;
X21 is L, D or E;
X27 is I, H,Q, Y, ΚorΨ;
X28 isQ, E, H, Y, L, K, RorA;
X29 is H, Q, Y, ΚorΨ;
X33 is D, E or is absent;
U is absent or a sequence of 1-15 residues each independently selected from K, k, E, A, T, I, Land Ψ;
the molecule contains a minimum of one and a maximum of two Ψ, wherein each Ψ is independently a residue of k, K, R, Orn, Dap or Dab in which the side chain is conjugated to a substituent having the formula -Z1 or-Z2-Z1,
wherein Z1- is CH3-(CH2)io-22-(CO)- or HOOC-(CH2)io-22-(CO)-; and
-Z2- is selected from
Figure imgf000087_0001
Figure imgf000087_0002
-ZS1- is isoGlu, β-Ala, isoLys, or 4-aminobutanoyl;
-ZS2- is -(Peg3)m- where m is 1 , 2, or 3; and
-ZS3- is a peptide sequence of 1-6 amino acid units independently selected from the group consisting of A, L, S, T, Y, Q, D, E, K, k, , H, F and G;
or a pharmaceutically acceptable salt or solvate thereof.
2. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to claim 1 wherein:
X2 is G or Aib;
X5 is S or T;
X8isS, Dor<+>;
X10 is Lor Ψ;
X11 is A; βorΨ;
X15isDorE;
X16 is E, G or Ψ;
X17 is Q, E, K or Ψ;
X19isA,VorS;
X21 is D or E;
X27 is I, H, Q, Y or Ψ;
X28 is Q, E or A;
X29 is H, Q, Y or Ψ; and
X33 is D, E or is absent.
3. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to claim 1 wherein: X2 is Aib;
X5 is S or T;
X8 is S or D;
X10 is Lor Ψ;
X11 is A or Ψ; X15 is D orE;
X16 is ΕorΨ;
X17 is Q or E;
X19 is A, V orS;
X21 is D or E;
X27 is I;
X28 is Q or E;
X29 isH.Q.YorM^and
X33 is D, E or is absent.
4. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to any of claims 1 to 3 wherein, if X33 is absent, U is also absent.
5. A GLP-1/GLP-2 dual agonist represented by the formula:
R1-X*-U-R2
wherein:
R1 is hydrogen (Hy), Ci-4 alkyl (e.g. methyl), acetyl, formyl, benzoyl or trifluoroacetyl; R2 is NH2 or OH;
X* is a peptide having the formula II:
H-X2-DG-X5-FS-X8-E-X10-X11 -TILD-X16-X17-A-X19-RDFIAWL-X27-X28-X29-KITD wherein:
X2 is G or Aib;
X5 is S orT;
X8 is S, D or Ψ;
XIOisLorHJ;
X11 is A; S orΨ;
X16isE, ΰorΨ;
X17 isQ, E, ΚorΨ;
X19 is A or S;
X27 is I, H, Q, Y or Ψ;
X28 is Q or A;
X29 is H, Q, Y or Ψ;
U is absent or a sequence of 1-15 residues independently selected from K, k and Ψ; the molecule contains one and only one Ψ, wherein Ψ is a residue of K, R, Orn, Dap or Dab in which the side chain is conjugated to a substituent having the formula -Z1 or -Z2-Z\
wherein
Z1- is CH3-(CH2)io-22-(CO)- or HOOC-(CH2)io-22-(CO)-; and
-Z2- is selected from -ZS1-, -ZS1-ZS2-, -ZS2-ZS1, and ZS2 wherein
-ZS1- is isoGlu, β-Ala, isoLys, or 4-aminobutanoyl;
-ZS2- is -(Peg3)m- where m is 1 , 2, or 3;
or a pharmaceutically acceptable salt or solvate thereof.
6. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to any one of the preceding claims wherein X27 is Q and X29 is H, Q or Y; or X27 is Q and X29 is H.
7. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to claim 1 wherein :
X16 is Ψ;
X2 is Aib and X17 is Q;
X27 is I and X28 is Q;
X2 is Aib, X5 is S and X17 is Q,
X27 is I, X28 is Q and X29 is H;
X8 is D and X10 is Ψ;
X8 is D and XH is Ψ;
X8 is S and X16 is Ψ;
X8 is D, X10 is Ψ and X29 is H;
X8 is D, X1 1 is Ψ and X29 is H;
X8 is S, X16 is Ψ and X29 is H;
X2 is Aib, X5 is S, X17 is Q, X27 is I, X28 is Q and X29 is H;
X2 is Aib, X8 is S, X17 is Q, X27 is I, X28 is Q and X29 is H;
X2 is Aib, X8 is D, X17 is Q, X27 is I, X28 is Q and X29 is H; or
X2 is Aib, X8 is S, X16 is Ψ, X19 is A and X29 is H.
8. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to claim 1 wherein X* is a peptide having the formula III:
Figure imgf000090_0001
wherein:
X2 is G or Aib;
X5 is S or T;
X8 is S, D or Ψ;
X10 is L, Ψ;
X11 isAorS;
X15isDorE;
X16isE, G or Ψ;
X17is Q, E or K;
X19isA,VorS;
X21 isDorE;
X27 is I or Ψ;
X28 is Q, E or A;
X29 is H, Q, Y or Ψ; and
X33 is D, E or absent.
9. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to claim 8 wherein:
X2 is Aib;
X5 is S or T;
X8 is S or D;
X10 is L, Ψ;
X11 is A;
X15isDorE;
X16 is ΕorΨ;
X17isQorE;
X19isA,VorS;
X21 is D or E;
X27 is I;
X28 is Q or E; X29 is H, Q, Y or Ψ; and
X33 is D, E or absent.
10. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to claim 1 wherein X* is a peptide having the formula IV:
Figure imgf000091_0001
wherein:
X2 is G or Aib;
X5 is S orT;
Χδίββ, ϋorΨ;
X10 is L, Ψ;
X11 is A or S;
ΧΙΘίβΕ, ΘorΨ;
X17 isQor K;
X19isAorS;
X27 is I or Ψ;
X28 is Q or A; and
X29 is H, Q, Y or Ψ.
11. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to claim 9 or claim 10 wherein X28 is Q and X29 is H, Q or Y; or X28 is Q and X29 is H.
12. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to any one of the preceding claims wherein :
X16 is Ψ;
X2 is Aib and X17is Q;
X27 is I and X28 is Q;
X8 is D and X10 is Ψ;
X8isDandX11 is Ψ;
X8 is S and X16 is Ψ;
X8 is D.XIOis^Fand X29 is H;
X8 is D.X11 is Ψ and X29 is H; X8 is S, X16 is Ψ and X29 is H;
X2 is Aib, X5 is S and X17 is Q,
X27 is I, X28 is Q and X29 is H;
X2 is Aib, X5 is S, X17 is Q, X27 is I, X28 is Q and X29 is H;
X2 is Aib, X8 is S, X17 is Q, X27 is I, X28 is Q and X29 is H;
X2 is Aib, X8 is D, X17 is Q, X27 is I, X28 is Q and X29 is H; or
X2 is Aib, X8 is S, X16 is Ψ, X19 is A and X29 is H.
13. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to any one of the preceding claims wherein:
X2 is Aib, X8 is D and X10 is Ψ;
X2 is Aib, X8 is D, X10 is Ψ, X16 is E and X24 is A;
X2 is Aib, X8 is D, X10 is Ψ, X16 is E and X29 is H;
X2 is Aib, X5 is S, X8 is D, X10 is Ψ, X1 1 is A, X16 is E, X17 is Q and X24 is A; X2 is Aib, X5 is S, X8 is D, X10 is Ψ, X1 1 is A, X16 is E, X17 is Q, X24 is A and X29 is H;
X16 is Ψ, X19 is A and X29 is H;
X2 is Aib, X8 is S, X16 is Ψ, X19 is A and X29 is H;
X2 is Aib, X8 is S, X16 is Ψ, X19 is A and X29 is H;
X2 is Aib, X5 is S, X8 is S, X10 is L, X1 1 is A, X16 is Ψ, X17 is Q, X24 is A and X29 is H; or
X2 is Aib, X5 is S, X24 is A and X29 is H.
14. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to any one of the preceding claims wherein:
X2 is Aib, X8 is S, X16 is Ψ, X19 is S and X29 is Y;
X2 is Aib, X8 is D, X16 is E, X24 is A, and X29 is Ψ;
X2 is Aib, X5 is S, X16 is E, X24 is A and X29 is Ψ; or
X8 is S, X16 is Ψ, X19 is S and X29 is Y.
15. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to any one of the preceding claims wherein the sequence of the peptide X* has no more than 5 amino acid changes, e.g. no more than 4, no more than 3, no more than 2 or no more than 1 change relative to the amino acid sequence
Figure imgf000093_0001
16. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to any one of the preceding claims wherein the peptide X* has the sequence
Figure imgf000093_0002
17. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to any one of the preceding claims wherein the peptide X* has the sequence
Figure imgf000093_0003
H[Aib]DGSFSSELATILD[K*]QAVRDFIAWLIQHKITD;
H[Aib]DGSFSSE[K*]ATILDEQAARDFIAWLIQHKITD;
H[Aib]DGSFSSELATILD[K*]QAARDFIAWLIQHKIT;
H[Aib]DGSFSSELATILD[K*]EAARDFIAWLIQHKITD;
H[Aib]DGSFSSELATILD[K*]QAARDFIAWLIEHKITD;
H[Aib]DGSFSSELATILD[K*]QAARDFIAWLIQHKITE;
H[Aib]DGSFSSELATILD[K*]QAAREFIAWLIQHKITD;
H[Aib]DGSFSSELATILE[K*]QAARDFIAWLIQHKITD;
H[Aib]DGSFSSELATILE[K*]QAAREFIAWLIQHKITE;
H[Aib]DGSFSSELATILE[K*]QAAREFIAWLIQHKITD; or
H[Aib]DGTFSSELATILD[K*]QAARDFIAWLIQHKITD.
wherein K* indicates a lysine residue in which the side chain is conjugated to the substituent Z1- or Z1-Z2-.
18. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to claim 1 or claim 5 wherein X* is a peptide having the formula V:
Figure imgf000094_0001
wherein:
X2 is G or Aib;
X8 is D or S;
X16 is E or G;
X17 is Q or K;
X29 is H, Q, K or Y.
19. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to claim 18 wherein:
X2 is Aib and X8 is D;
X2 is Aib, and X29 is H;
X2 is Aib and X16 is E;
X2 is Aib and X17 is Q, or
X16 is E and X17 is Q.
20. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to claim 18 or claim 19 wherein X* has no more than 5 amino acid changes, e.g. no more than 4, no more than 3, no more than 2 or no more than 1 change relative to the amino acid sequence:
H[Aib]DGSFSDELΨTILDEQAARDFIAWLIQHKITD.
21. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to claim 20 wherein X* has the sequence:
Figure imgf000095_0001
22. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to claim 21 wherein X* has the sequence:
Figure imgf000095_0003
wherein K* indicates a lysine residue in which the side chain is conjugated to the substituent Z1- or Z1-Z2-.
23. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to claim 1 wherein X* is a peptide having the formula VI:
Figure imgf000095_0002
wherein:
X2 is G or Aib;
X5 is S orT;
Χδίββ, ϋorΨ;
X10 is Lor Ψ;
X11 is A; S orΨ;
ΧΙθίβΕ, ΘorΨ;
X17 isQ, E, ΚorΨ;
X19isAorS;
X27 is I, Η,Ο,ΥorΨ;
X28 is Q or A;
X29 is H, Q, Y or Ψ;
U is a sequence of 1-15 residues independently selected from K, k and Ψ;
the molecule contains a minimum of one and a maximum of two Ψ, wherein each Ψ is independently a residue of k, K, R, Orn, Dap or Dab in which the side chain is conjugated to a substituent having the formula -Z1 or-Z2-Z1, and U contains at least one residue Ψ.
24. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to claim 23 wherein:
X2 is Aib;
X5 is S orT;
X8 is S or D; X10 is Ι_orΨ;
X11 is ΑorΨ;
X15 is DorE;
X16 is ΕorΨ;
X17 is Q or E;
X19 is A, VorS;
X21 is DorE;
X27 is I;
X28 is Q or E;
X29 is H, Q, Y or
X33 is DorE.
25. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to claim 23 or claim 24 wherein:
X2isAib;
X5 is S;
X8 is S;
X10 is Ι_orΨ;
X11 is A;
X15 is D;
X16 is ΕorΨ;
X17 is Q or E;
X19 is A;
X21 is D;
X27 is I;
X28 is Q;
X29 is H; and
X33 is D.
26. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to any one of claims 23 to 25 , containing one and only one Ψ at one position of sequence U.
27. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to any one of claims 1 to 25 containing a Ψ at a position of sequence U and Ψ at a position of X*.
28. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to any one of claims 23 to 27 wherein the sequence of the dual agonist has no more than 5 amino acid changes, e.g. no more than 4, no more than 3, no more than 2 or no more than 1 change relative to the amino acid sequence:
Figure imgf000097_0001
29. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to claim 28 wherein the peptide X*-U has the sequence:
Figure imgf000097_0002
30. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to claim 29 wherein the peptide X*-U has the sequence:
Figure imgf000097_0003
H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDAKEKE[K*];
H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDATILE[K*];
H[Aib]DGSFSSE[K*]ATILDEQAARDFIAWLIQHKITDEKEKE[K*];
H[Aib]DGSFSSELATILDEEAARDFIAWLIQHKITDkkkkk[k*]; or
H[Aib]DGSFSSELATILD[K*]QAARDFIAWLIQHKITDEKEKE[K*].
wherein K* indicates a lysine residue in which the side chain is conjugated to the substituent Z1 - or Z1 -Z2-.
31 . A dual agonist or pharmaceutically acceptable salt or solvate thereof according to any one of the preceding claims wherein Ψ is a Lys residue whose side chain is conjugated to the substituent Z1- or Z1-Z2-.
32. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to any one of the preceding claims wherein Z1- is dodecanoyl, tetradecanoyl, hexadecanoyl, octadecanoyl or eicosanoyl.
33. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to any one of claims 1 to 31 wherein Z1- is:
13-carboxytridecanoyl, i.e. HOOC-(CH2)i2-(CO)-;
15-carboxypentadecanoyl, i.e. HOOC-(CH2)i4-(CO)-;
17-carboxyheptadecanoyl, i.e. HOOC-(CH2)i6-(CO)-;
19-carboxynonadecanoyl, i.e. HOOC-(CH2)i8-(CO)-; or
21 -carboxyheneicosanoyl, i.e. HOOC-(CH2)20-(CO)-.
34. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to any one of the preceding claims wherein Z2 is absent.
35. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to any one of claims 1 to 33 wherein Z2 comprises ZS1 alone or in combination with ZS2 and/or ZS3.
36. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to claim 35 wherein:
-ZS1- is isoGlu, β-Ala, isoLys, or 4-aminobutanoyl; -ZS2-, when present, is -(Peg3)m- where m is 1 , 2, or 3; and -ZS3- is a peptide sequence of 1 -6 amino acid units independently selected from the group consisting of A, L, S, T, Y, Q, D, E, K, k, R, H, F and G, such as the peptide sequence KEK.
37. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to claim 35 or claim 36 wherein Z2 has the formula -ZS1-ZS3-ZS2-, where ZS1 is bonded to Z1 and ZS2 is bonded to the side chain of the amino acid component of Ψ.
38. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to any one of claims 35 to 37 wherein -Z2- is:
isoGlu(Peg3)o-3;
3-Ala(Peg3)0-3;
isoLys(Peg3)o-3; or
4-aminobutanoyl(Peg3)o-3; or
isoGlu-KEK-(Peg3)o-3.
39. Specific examples of the substituent Z1-Z2- are set out below. In some embodiments, Z1-Z2- is [17-carboxy-heptadecanoyl]-isoGlu). For example, Ψ may be K([17-carboxy-heptadecanoyl]-isoGlu).
40. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to any one of claims 35 to 39 wherein Z1- or Z1-Z2 - is:
[17-carboxy-heptadecanoyl]-[3-Aminopropanoyl]-;
Hexadecanoyl-[3-aminopropanoyl]-;
[17-carboxy-heptadecanoyl]-isoGlu-;
[19-carboxy-nonadecanoyl]-isoGlu-;
[19-Carboxy-nonadecanoyl]-isoGlu-KEK-;
[19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3-;
[19-Carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3-;
[19-Carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3-Peg3-;
Dodecanoyl-[3-Aminopropanoyl]-;
Eicosanoyl-[3-Aminopropanoyl]-;
Hexadecanoyl-[3-Aminopropanoyl]-;
Hexadecanoyl-isoGlu-
Hexadecanoyl-isoLys-; or
Octadecanoyl-[3-Aminopropanoyl]-.
41 . A dual agonist or pharmaceutically acceptable salt or solvate thereof according to claim 40 wherein Ψ is:
K([17-carboxy-heptadecanoyl]-isoGlu)
K([17-carboxy-heptadecanoyl]-[3-Aminopropanoyl]);
K(Hexadecanoyl-[3-aminopropanoyl]);
K([17-carboxy-heptadecanoyl]-isoGlu);
K([19-carboxy-nonadecanoyl]-isoGlu);
K([19-Carboxy-nonadecanoyl]-isoGlu-KEK);
K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3);
K([19-Carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3);
K([19-Carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3-Peg3);
K(Dodecanoyl-[3-Aminopropanoyl]);
K(Eicosanoyl-[3-Aminopropanoyl]);
K(Hexadecanoyl-[3-Aminopropanoyl]);
K(Hexadecanoyl-isoGlu);
K(Hexadecanoyl-isoLys); or
K(Octadecanoyl-[3-Aminopropanoyl]).
42. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to any one of the preceding claims wherein U is 1 -10 amino acids in length, 1 -7 amino acids in length, 3-7 amino acids in length, 1 -6 amino acids in length, or 3-6 amino acids in length.
43. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to any one of the preceding claims wherein U includes at least one charged amino acid , e.g. two or more charged amino acids.
44. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to claim 43 wherein U includes at least 1 positively charged amino acid and at least one negatively charged amino acid.
45. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to claim 43 or claim 44 wherein U is a chain of alternately positively and negatively charged amino acids.
46. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to any one of claims 43 to 45 wherein U comprises residues selected only from K, k, E and Ψ.
47. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to claim 34 wherein U is K3, K4, K5, Κβ , K7, k3, k4, k5, k6 or k7.
48. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to any one of claims 43 to 46 wherein U is KEK, EKEKEK, EkEkEk, AKAAEK, AKEKEK or ATILEK.
49. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to any one of claims 43 to 46 wherein U is Κι-ι4-Ψ, Ki-g-Ψ, Κι-β-Ψ, k-i.-u-Ψ, ki-g-Ψ, ki-6-Ψ, ΚΕΨ, ΕΚΕΚΕΨ, EkEkE<+" ΑΚΑΑΕΨ, ΑΚΕΚΕΨ or ΑΤΊΙ.ΕΨ.
50. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to any one of claims 1 to 41 wherein U is absent.
51 . A dual agonist or pharmaceutically acceptable salt or solvate thereof according to any one of the preceding claims wherein R1 is Hy and/or R2 is OH.
52. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to any one of the preceding claims wherein X* or X*-U has the sequence:
H[Aib]DGSFSDE[K(Dodecanoyl-[3-
Aminopropanoyl])]ATILDEQAARDFIAWLIQHKITD;
H[Aib]DGSFSDE[K(Hexadecanoyl-[3-
Aminopropanoyl])]ATILDEQAARDFIAWLIQHKITD;
H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]- isoGlu)]QAARDFIAWLIQHKITD;
H[Aib]DGSFSSELATILD[K(Hexadecanoyl-isoGlu)]QASRDFIAWLIQHKITD;
H[Aib]DGSFSSELATILD[K(Hexadecanoyl-isoGlu)]QAARDFIAWLIQQKITD;
H[Aib]DGSFSSELATILD[K(Hexadecanoyl-isoGlu)]QAARDFIAWLIQHKITD;
H[Aib]DGSFSSELATILD[K(Octadecanoyl-isoGlu)]QAARDFIAWLIQHKITD;
H[Aib]DGSFSDELATILDEQAARDFIAWLIQ[K(Dodecanoyl-[3- Aminopropanoyl])]KITD;
H[Aib]DGSFSSELATILD[K(Hexadecanoyl-isoGlu)]QASRDFIAWLIQYKITD;
H[Aib]DGSFSDEL[K(dodecanoyl-[3- aminopropanoyl])]TILDEQAARDFIAWLIQHKITD; H[Aib]DGSFSDEL[K(hexadecanoyl-[3- aminopropanoyl])]TILDEQAARDFIAWLIQHKITD;
H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDKKKKK[K(Hexadecanoyl- isoGlu)];
H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDkkkkk[k(19-carboxy- Nonadecanoyl]-isoGlu)];
H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDkkkkk[k(Hexadecanoyl- isoGlu)];
H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDkkkkk[k([17-carboxy- Heptadecanoyl]-isoGlu)];
H[Aib]DGSFSSELATILD[K(Hexadecanoyl-isoGlu)]QAVRDFIAWLIQHKITD;
H[Aib]DGSFSSELATILD[K([19-carboxy-nonadecanoyl]- isoGlu)]QAARDFIAWLIQHKITD;
H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]-[3- Aminopropanoyl])]QAARDFIAWLIQHKITD;
H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDkkkkk[k(Hexadecanoyl- [3-aminopropanoyl])];
H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDkkkkk[k(Hexadecanoyl- isoLys)];
H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]-[3-
Aminopropanoyl])]QAARDFIAWLIQHKITDkkkkk[K(Hexadecanoyl-[3- aminopropanoyl])];
H[Aib]DGSFSSE[K(Hexadecanoyl-[3-
Aminopropanoyl])]ATILDEQAARDFIAWLIQHKITDkkkkk[k(Hexadecanoyl-
[3-aminopropanoyl])];
H[Aib]DGSFSDE[K(Octadecanoyl-[3-
Aminopropanoyl])]ATILDEQAARDFIAWLIQHKITD;
H[Aib]DGSFSDE[K(Eicosanoyl-[3-
Aminopropanoyl])]ATILDEQAARDFIAWLIQHKITD;
H[Aib]DGSFSSE[K(Dodecanoyl-[3-
Aminopropanoyl])]ATILDEQAARDFIAWLIQHKITD;
H[Aib]DGSFSSE[K(Hexadecanoyl-[3-
Aminopropanoyl])]ATILDEQAARDFIAWLIQHKITD;
H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDkkkkk[k(Octadecanoyl-[3- aminopropanoyl])];
H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDkkkkk[k(Eicosanoyl-[3- aminopropanoyl])];
H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDEKEKE[K(Hexadecanoyl- isoGlu)];
H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDKKEEE[K(Hexadecanoyl- isoGlu)];
H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDAKAAE[K(Hexadecanoyl- isoGlu)];
H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDAKEKE[K(Hexadecanoyl- isoGlu)];
H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDATILE[K(Hexadecanoyl- isoGlu)];
H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDEKEKE[K([19-Carboxy- nonadecanoyl]-isoGlu)];
H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDEKEKE[K([19-Carboxy- nonadecanoyl]-isoGlu-Peg3-Peg3)];
H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDEKEKE[K([19-Carboxy- nonadecanoyl]-isoGlu-Peg3-Peg3-Peg3)];
H[Aib]DGSFSSE[K(Hexadecanoyl- isoGlu)]ATILDEQAARDFIAWLIQHKITDEKEKE[K(Hexadecanoyl-isoGlu)]; H[Aib]DGSFSSE[K(Hexadecanoyl- isoGlu)]ATILDEQAARDFIAWLIQHKITDEKEKE[K([19-Carboxy- nonadecanoyl]-isoGlu)];
H[Aib]DGSFSSELATILD[K([19-Carboxy-nonadecanoyl]-isoGlu-Peg3- Peg3)]QAARDFIAWLIQHKITD;
H[Aib]DGSFSSELATILD[K([19-Carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3- Peg3)]QAARDFIAWLIQHKITD;
H[Aib]DGSFSDE[K(Hexadecanoyl-isoGlu)]ATILDEQAARDFIAWLIQHKITD;
H[Aib]DGSFSSE[K(Hexadecanoyl-isoGlu)]ATILDEQAARDFIAWLIQHKITD;
H[Aib]DGSFSSE[K([19-Carboxy-nonadecanoyl]- isoGlu)]ATILDEQAARDFIAWLIQHKITD;
H[Aib]DGSFSSE[K([19-Carboxy-nonadecanoyl]-isoGlu-
KEK)]ATILDEQAARDFIAWLIQHKITD;
H[Aib]DGSFSSE[K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]ATILDEQAARDFIAWLIQHKITD;
H[Aib]DGSFSSELATILD[K([19-Carboxy-nonadecanoyl]-isoGlu- KEK)]QAARDFIAWLIQHKITD;
H[Aib]DGSFSSELATILD[K([19-Carboxy-nonadecanoyl]-isoGlu-KEK- Peg3)]QAARDFIAWLIQHKITD;
H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]- isoGlu)]QAARDFIAWLIQHKIT;
H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]- isoGlu)]EAARDFIAWLIQHKITD;
H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]- isoGlu)]QAARDFIAWLIEHKITD;
H[Aib]DGSFSSELATILDEEAARDFIAWLIQHKITDkkkkk[k([17-carboxy- Heptadecanoyl]-isoGlu)];
H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]- isoGlu)]QAARDFIAWLIQHKITE;
H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]- isoGlu)]QAAREFIAWLIQHKITD;
H[Aib]DGSFSSELATILE[K([17-carboxy-heptadecanoyl]- isoGlu)]QAARDFIAWLIQHKITD;
H[Aib]DGSFSSELATILE[K([17-carboxy-heptadecanoyl]- isoGlu)]QAAREFIAWLIQHKITE;
H[Aib]DGSFSSELATILE[K([17-carboxy-heptadecanoyl]- isoGlu)]QAAREFIAWLIQHKITD;
H[Aib]DGTFSSELATILD[K([17-carboxy-heptadecanoyl]- isoGlu)]QAARDFIAWLIQHKITD; or
H[Aib]DGSFSSELATILD[K([19-Carboxy-nonadecanoyl]- isoGlu)]QAARDFIAWLIQHKITDEKEKE[K(Hexadecanoyl-isoGlu)].
53. A dual agonist or pharmaceutically acceptable salt or solvate thereof according to any one of the preceding claims which is:
Cpd 1 Hy-H[Aib]DGSFSDE[K(Dodecanoyl-[3-
Aminopropanoyl])]ATILDEQAARDFIAWLIQHKITD-OH;
Cpd 2 Hy-H[Aib]DGSFSDE[K(Hexadecanoyl-[3-
Aminopropanoyl])]ATILDEQAARDFIAWLIQHKITD-OH;
Cpd 3 Hy-H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]- isoGlu)]QAARDFIAWLIQHKITD-OH; Cpd 4 Hy-H[Aib]DGSFSSELATILD[K(Hexadecanoyl- isoGlu)]QASRDFIAWLIQHKITD-OH;
Cpd 5 Hy-H[Aib]DGSFSSELATILD[K(Hexadecanoyl- isoGlu)]QAARDFIAWLIQQKITD-OH;
Cpd 6 Hy-H[Aib]DGSFSSELATILD[K(Hexadecanoyl- isoGlu)]QAARDFIAWLIQHKITD-OH;
Cpd 7 Hy-H[Aib]DGSFSSELATILD[K(Octadecanoyl- isoGlu)]QAARDFIAWLIQHKITD-OH;
Cpd 8 Hy-H[Aib]DGSFSDELATILDEQAARDFIAWLIQ[K(Dodecanoyl-[3-
Aminopropanoyl])]KITD-OH;
Cpd 9 Hy-H[Aib]DGSFSSELATILD[K(Hexadecanoyl- isoGlu)]QASRDFIAWLIQYKITD-OH;
Cpd 10 Hy-H[Aib]DGSFSDEL[K(dodecanoyl-[3- aminopropanoyl])]TILDEQAARDFIAWLIQHKITD-OH;
Cpd 1 1 Hy-H[Aib]DGSFSDEL[K(hexadecanoyl-[3- aminopropanoyl])]TILDEQAARDFIAWLIQHKITD-OH;
Cpd 12 Hy-
H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDKKKKK[K(Hexadecanoyl- isoGlu)]-[NH2];
Cpd 13 Hy-H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDkkkkk[k(19-carboxy-
Nonadecanoyl]-isoGlu)]-[NH2];
Cpd 14 Hy-
H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDkkkkk[k(Hexadecanoyl- isoGlu)]-[NH2];
Cpd 15 Hy-H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDkkkkk[k([17-carboxy- Heptadecanoyl]-isoGlu)]-[NH2];
Cpd. 16 Hy-H[Aib]DGSFSSELATILD[K(Hexadecanoyl- isoGlu)]QAVRDFIAWLIQHKITD-OH;
Cpd. 17 Hy-H[Aib]DGSFSSELATILD[K([19-carboxy-nonadecanoyl]- isoGlu)]QAARDFIAWLIQHKITD-OH;
Cpd. 18 Hy-H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]-[3-
Aminopropanoyl])]QAARDFIAWLIQHKITD-OH;
Cpd. 19 Hy-
H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDkkkkk[k(Hexadecanoyl- [3-aminopropanoyl])]-[NH2];
Cpd. 20 Hy-
H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDkkkkk[k(Hexadecanoyl- isoLys)]-[NH2];
Cpd. 21 Hy-H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]-[3-
Aminopropanoyl])]QAARDFIAWLIQHKITDkkkkk[K(Hexadecanoyl-[3- aminopropanoyl])]-[NH2];
Cpd. 22 Hy-H[Aib]DGSFSSE[K(Hexadecanoyl-[3- Aminopropanoyl])]ATILDEQAARDFIAWLIQHKITDkkkkk[k(Hexadecanoyl-
[3-aminopropanoyl])]-[NH2];
Cpd. 23 Hy-H[Aib]DGSFSDE[K(Octadecanoyl-[3-
Aminopropanoyl])]ATILDEQAARDFIAWLIQHKITD-OH;
Cpd. 24 Hy-H[Aib]DGSFSDE[K(Eicosanoyl-[3-
Aminopropanoyl])]ATILDEQAARDFIAWLIQHKITD-OH;
Cpd. 25 Hy-H[Aib]DGSFSSE[K(Dodecanoyl-[3-
Aminopropanoyl])]ATILDEQAARDFIAWLIQHKITD-OH;
Cpd. 26 Hy-H[Aib]DGSFSSE[K(Hexadecanoyl-[3-
Aminopropanoyl])]ATILDEQAARDFIAWLIQHKITD-OH;
Cpd. 27 Hy-
H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDkkkkk[k(Octadecanoyl-[3- aminopropanoyl])]-[NH2];
Cpd. 28 Hy-H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDkkkkk[k(Eicosanoyl-
[3-aminopropanoyl])]-[NH2];
Cpd. 29 Hy-
H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDEKEKE[K(Hexadecanoyl- isoGlu)]-[NH2];
Cpd. 30 Hy-
H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDKKEEE[K(Hexadecanoyl- isoGlu)]-[NH2];
Cpd. 31 Hy-
H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDAKAAE[K(Hexadecanoyl- isoGlu)]-[NH2];
Cpd. 32 Hy-
H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDAKEKE[K(Hexadecanoyl- isoGlu)]-[NH2];
Cpd. 33 Hy-
H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDATILE[K(Hexadecanoyl- isoGlu)]-[NH2];
Cpd. 34 Hy-H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDEKEKE[K([19-
Carboxy-nonadecanoyl]-isoGlu)]-[NH2];
Cpd. 35 Hy-H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDEKEKE[K([19-
Carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3)]-[NH2];
Cpd. 36 Hy-H[Aib]DGSFSSELATILDEQAARDFIAWLIQHKITDEKEKE[K([19-
Carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3-Peg3)]-[NH2];
Cpd. 37 Hy-H[Aib]DGSFSSE[K(Hexadecanoyl- isoGlu)]ATILDEQAARDFIAWLIQHKITDEKEKE[K(Hexadecanoyl-isoGlu)]-
[NH2];
Cpd. 38 Hy-H[Aib]DGSFSSE[K(Hexadecanoyl- isoGlu)]ATILDEQAARDFIAWLIQHKITDEKEKE[K([19-Carboxy- nonadecanoyl]-isoGlu)]-[NH2];
Cpd. 39 Hy-H[Aib]DGSFSSELATILD[K([19-Carboxy-nonadecanoyl]-isoGlu-Peg3-
Peg3)]QAARDFIAWLIQHKITD-0H;
Cpd. 40 Hy-H[Aib]DGSFSSELATILD[K([19-Carboxy-nonadecanoyl]-isoGlu-Peg3-
Peg3-Peg3)]QAARDFIAWLIQHKITD-OH;
Cpd. 41 Hy-H[Aib]DGSFSDE[K(Hexadecanoyl- isoGlu)]ATILDEQAARDFIAWLIQHKITD-OH;
Cpd. 42 Hy-H[Aib]DGSFSSE[K(Hexadecanoyl- isoGlu)]ATILDEQAARDFIAWLIQHKITD-OH;
Cpd. 43 Hy-H[Aib]DGSFSSE[K([19-Carboxy-nonadecanoyl]- isoGlu)]ATILDEQAARDFIAWLIQHKITD-OH;
Cpd. 44 Hy-H[Aib]DGSFSSE[K([19-Carboxy-nonadecanoyl]-isoGlu-
KEK)]ATILDEQAARDFIAWLIQHKITD-OH;
Cpd. 45 Hy-H[Aib]DGSFSSE[K([19-Carboxy-nonadecanoyl]-isoGlu-KEK- Peg3)]ATILDEQAARDFIAWLIQHKITD-OH;
Cpd. 46 Hy-H[Aib]DGSFSSELATILD[K([19-Carboxy-nonadecanoyl]-isoGlu-
KEK)]QAARDFIAWLIQHKITD-OH;
Cpd. 47 Hy-H[Aib]DGSFSSELATILD[K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]QAARDFIAWLIQHKITD-0H;
Cpd. 48 Hy-H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]- isoGlu)]QAARDFIAWLIQHKIT-OH;
Cpd. 49 Hy-H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]- isoGlu)]EAARDFIAWLIQHKITD-OH;
Cpd. 50 Hy-H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]- isoGlu)]QAARDFIAWLIEHKITD-OH;
Cpd. 51 Hy-H[Aib]DGSFSSELATILDEEAARDFIAWLIQHKITDkkkkk[k([17-carboxy-
Heptadecanoyl]-isoGlu)]-[NH2];
Cpd. 52 Hy-H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]- isoGlu)]QAARDFIAWLIQHKITE-OH;
Cpd. 53 Hy-H[Aib]DGSFSSELATILD[K([17-carboxy-heptadecanoyl]- isoGlu)]QAAREFIAWLIQHKITD-OH;
Cpd. 54 Hy-H[Aib]DGSFSSELATILE[K([17-carboxy-heptadecanoyl]- isoGlu)]QAARDFIAWLIQHKITD-OH;
Cpd. 55 Hy-H[Aib]DGSFSSELATILE[K([17-carboxy-heptadecanoyl]- isoGlu)]QAAREFIAWLIQHKITE-OH;
Cpd. 56 Hy-H[Aib]DGSFSSELATILE[K([17-carboxy-heptadecanoyl]- isoGlu)]QAAREFIAWLIQHKITD-OH;
Cpd. 57 Hy-H[Aib]DGTFSSELATILD[K([17-carboxy-heptadecanoyl]- isoGlu)]QAARDFIAWLIQHKITD-OH; or
Cpd. 58 Hy-H[Aib]DGSFSSELATILD[K([19-Carboxy-nonadecanoyl]- isoGlu)]QAARDFIAWLIQHKITDEKEKE[K(Hexadecanoyl-isoGlu)]-[NH2].
54. A composition comprising a dual agonist according to any one of claims 1 to 53, or a pharmaceutically acceptable salt or solvate thereof, in admixture with a carrier.
55. A composition according to claim 54 wherein the composition is a
pharmaceutical composition and the carrier is a pharmaceutically acceptable
56. A pharmaceutical composition comprising a dual agonist according to any one claims 1 to 53, or a pharmaceutically acceptable salt or solvate thereof, in admixture with a pharmaceutically acceptable carrier, excipient or vehicle.
57. A dual agonist according to any one of claims 1 to 53 for use in therapy.
58. A dual agonist according to any one of claims 1 to 53 for use in a method of increasing intestinal mass, improving intestinal function, increasing intestinal blood flow, or repairing intestinal damage or dysfunction.
59. A dual agonist according to any one of claims 1 to 53 for use in a method of prophylaxis or treatment of malabsorption, ulcers, short-bowel syndrome, cul-de-sac syndrome, inflammatory bowel disease, irritable bowel syndrome, pouchitis, celiac sprue, tropical sprue, hypogammaglobulinemic sprue, mucositis induced by chemotherapy or radiation therapy, diarrhea induced by chemotherapy or radiation therapy, low grade inflammation, metabolic endotoxemia, necrotising enterocolitis, primary biliary cirrhosis, hepatitis, fatty liver disease, or gastrointestinal side-effects of inflammatory conditions.
60. A dual agonist according to any one of claims 1 to 53 for use in a method of reducing or inhibiting weight gain, reducing gastric emptying or intestinal transit, reducing food intake, reducing appetite, or promoting weight loss.
61 . A dual agonist according to any one of claims 1 to 53 for use in a method of prophylaxis or treatment of obesity, morbid obesity, obesity-linked gallbladder disease, obesity-induced sleep apnea, inadequate glucose control, glucose tolerance, dyslipidaemia, diabetes, pre-diabetes, metabolic syndrome or hypertension.
62. A method of increasing intestinal mass, improving intestinal function, increasing intestinal blood flow, or repairing intestinal damage or dysfunction in a subject in need thereof, the method comprising administering a dual agonist according to any one of claims 1 to 53 to the subject.
63. A method of prophylaxis or treatment of malabsorption, ulcers, short-bowel syndrome, cul-de-sac syndrome, inflammatory bowel disease, irritable bowel syndrome, pouchitis, celiac sprue, tropical sprue, hypogammaglobulinemic sprue, mucositis induced by chemotherapy or radiation therapy, diarrhea induced by chemotherapy or radiation therapy, low grade inflammation, metabolic endotoxemia, necrotising enterocolitis, primary biliary cirrhosis, hepatitis, fatty liver disease, or gastrointestinal side-effects of inflammatory conditions in a subject in need thereof, the method comprising administering a dual agonist according to any one of claims 1 to 53 to the subject.
64. A method of reducing or inhibiting weight gain, reducing gastric emptying or intestinal transit, reducing food intake, reducing appetite, or promoting weight loss in a subject in need thereof, the method comprising administering a dual agonist according to any one of claims 1 to 53 to the subject.
65. A method of prophylaxis or treatment of obesity, morbid obesity, obesity-linked gallbladder disease, obesity-induced sleep apnea, inadequate glucose control, glucose tolerance, dyslipidaemia, diabetes, pre-diabetes, metabolic syndrome or hypertension in a subject in need thereof, the method comprising administering a dual agonist according to any one of claims 1 to 53 to the subject.
66. Use of a dual agonist according to any one of claims 1 to 53 in the preparation of a medicament for use in increasing intestinal mass, improving intestinal function, increasing intestinal blood flow, or repairing intestinal damage or dysfunction.
67. Use of a dual agonist according to any one of claims 1 to 53 in the preparation of a medicament for use in prophylaxis or treatment of malabsorption, ulcers, short- bowel syndrome, cul-de-sac syndrome, inflammatory bowel disease, irritable bowel syndrome, pouchitis, celiac sprue, tropical sprue, hypogammaglobulinemic sprue, mucositis induced by chemotherapy or radiation therapy, diarrhea induced by chemotherapy or radiation therapy, low grade inflammation, metabolic endotoxemia, necrotising enterocolitis, primary biliary cirrhosis, hepatitis, fatty liver disease, or gastrointestinal side-effects of inflammatory conditions.
68. Use of a dual agonist according to any one of claims 1 to 53 in the preparation of a medicament for reducing or inhibiting weight gain, reducing gastric emptying or intestinal transit, reducing food intake, reducing appetite, or promoting weight loss.
69. Use of a dual agonist according to any one of claims 1 to 53 in the preparation of a medicament for prophylaxis or treatment of obesity, morbid obesity, obesity- linked gallbladder disease, obesity-induced sleep apnea, inadequate glucose control, glucose tolerance, dyslipidaemia, diabetes, pre-diabetes, metabolic syndrome or hypertension.
PCT/EP2017/082284 2016-12-09 2017-12-11 Acylated glp-1/glp-2 dual agonists Ceased WO2018104558A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201600755 2016-12-09
DKPA201600755 2016-12-09

Publications (1)

Publication Number Publication Date
WO2018104558A1 true WO2018104558A1 (en) 2018-06-14

Family

ID=60812044

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/082284 Ceased WO2018104558A1 (en) 2016-12-09 2017-12-11 Acylated glp-1/glp-2 dual agonists

Country Status (1)

Country Link
WO (1) WO2018104558A1 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020249782A1 (en) * 2019-06-14 2020-12-17 Zealand Pharma A/S Pharmaceutical parenteral composition of dual glp1/2 agonist
US10905745B2 (en) 2016-12-09 2021-02-02 Zealand Pharma A/S Acylated GLP-1/GLP-2 dual agonists
WO2021174048A1 (en) 2020-02-28 2021-09-02 Kallyope, Inc. Gpr40 agonists
WO2021186166A1 (en) * 2020-03-16 2021-09-23 Heptares Therapeutics Limited Glp receptor agonists
WO2021186169A1 (en) * 2020-03-16 2021-09-23 Heptares Therapeutics Limited Oral glp receptor agonists
WO2021198195A1 (en) * 2020-03-30 2021-10-07 Zealand Pharma A/S Agonist combination
WO2021198196A1 (en) * 2020-03-30 2021-10-07 Zealand Pharma A/S Glp-1/glp-2 dual agonists
US11279702B2 (en) 2020-05-19 2022-03-22 Kallyope, Inc. AMPK activators
US11407768B2 (en) 2020-06-26 2022-08-09 Kallyope, Inc. AMPK activators
WO2022175410A1 (en) * 2021-02-18 2022-08-25 Zealand Pharma A/S Composition for treating short bowel syndrome
US11512065B2 (en) 2019-10-07 2022-11-29 Kallyope, Inc. GPR119 agonists
WO2022268029A1 (en) * 2021-06-21 2022-12-29 广东东阳光药业有限公司 Triple agonist for glp-1, gcg and gip receptors
WO2023031380A1 (en) * 2021-09-03 2023-03-09 Zealand Pharma A/S Dosage regime
IT202200015204A1 (en) * 2022-07-20 2024-01-20 Bioinnova S R L S GLP-2 EXPRESSING MICROALGAE AND RELATED USES
RU2815643C2 (en) * 2019-06-14 2024-03-19 Зилэнд Фарма А/С Pharmaceutical parenteral composition of double agonist glp1/2
CN118146350A (en) * 2024-03-13 2024-06-07 北京泽勤生物医药有限公司 Preparation method and application of GLP-2 peptide analogue

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008871A1 (en) 1996-08-30 1998-03-05 Novo Nordisk A/S Glp-1 derivatives
WO1998011125A1 (en) 1996-09-09 1998-03-19 Zealand Pharmaceuticals A/S Improved solid-phase peptide synthesis and agent for use in such synthesis
WO2000055184A1 (en) 1999-03-15 2000-09-21 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides with an organic modifier in the elution step
WO2000055119A1 (en) 1999-03-17 2000-09-21 Novo Nordisk A/S Method for acylating peptides and novel acylating agents
WO2006117565A2 (en) * 2005-05-04 2006-11-09 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
EP1767545A1 (en) * 2005-09-22 2007-03-28 Biocompatibles UK Limited GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance
WO2011006497A1 (en) * 2009-07-13 2011-01-20 Zealand Pharma A/S Acylated glucagon analogues
WO2011143335A2 (en) * 2010-05-11 2011-11-17 Nps Pharmaceuticals, Inc. Methods for treatment or prophylaxis of kidney or liver dysfunction
WO2013164484A1 (en) 2012-05-03 2013-11-07 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
WO2015067715A2 (en) * 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
WO2016066818A1 (en) 2014-10-31 2016-05-06 Gubra Aps Compositions and peptides having dual glp-1r and glp-2r agonist activity

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008871A1 (en) 1996-08-30 1998-03-05 Novo Nordisk A/S Glp-1 derivatives
WO1998011125A1 (en) 1996-09-09 1998-03-19 Zealand Pharmaceuticals A/S Improved solid-phase peptide synthesis and agent for use in such synthesis
WO2000055184A1 (en) 1999-03-15 2000-09-21 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides with an organic modifier in the elution step
WO2000055119A1 (en) 1999-03-17 2000-09-21 Novo Nordisk A/S Method for acylating peptides and novel acylating agents
WO2006117565A2 (en) * 2005-05-04 2006-11-09 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
EP1767545A1 (en) * 2005-09-22 2007-03-28 Biocompatibles UK Limited GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance
WO2011006497A1 (en) * 2009-07-13 2011-01-20 Zealand Pharma A/S Acylated glucagon analogues
WO2011143335A2 (en) * 2010-05-11 2011-11-17 Nps Pharmaceuticals, Inc. Methods for treatment or prophylaxis of kidney or liver dysfunction
WO2013164484A1 (en) 2012-05-03 2013-11-07 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
WO2015067715A2 (en) * 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
WO2016066818A1 (en) 2014-10-31 2016-05-06 Gubra Aps Compositions and peptides having dual glp-1r and glp-2r agonist activity

Non-Patent Citations (25)

* Cited by examiner, † Cited by third party
Title
ALTSCHUL ET AL., METHODS IN ENZYMOLOGY, vol. 266, 1996, pages 460 - 480
BENJAMIN ET AL., GUT, vol. 47, 2000, pages 112 - 119
BENJAMIN ET AL., GUT, vol. 47, 2000, pages 112 - 9
BRUN ET AL., AM. J. PHYSIOL. GASTROINTEST. LIVER PHYSIOL., vol. 292, 2007, pages G518 - G525
CANI ET AL., DIABETES, vol. 57, 2008, pages 1470 - 1481
CHEESEMAN, AM J PHYSIOL., 1997, pages R1965 - 71
CHEESEMAN, AM. J. PHYSIOL., 1997, pages R1965 - 71
DACAMBRA M P ET AL: "Structural determinants for activity of glucagon-like peptide-2", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 39, no. 30, 1 August 2000 (2000-08-01), pages 8888 - 8894, XP002293748, ISSN: 0006-2960, DOI: 10.1021/BI000497P *
DRUCKER ET AL., PROC NATL ACAD SCI USA., vol. 93, 1996, pages 7911 - 6
DRUCKER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 7911 - 7916
FIELDS, G.B ET AL.: "Synthetic Peptides", 2002, article 2ND ED.: "Principles and practice of solid-phase peptide synthesis"
FIELDS, GB ET AL.: "Synthetic Peptides", 2002, article 2ND ED.: "Principles and practice of solid-phase peptide synthesis"
GUAN ET AL., GASTROENTEROLOGY, vol. 125, 2003, pages 136 - 147
GUAN ET AL., GASTROENTEROLOGY, vol. 125, 2003, pages 136 - 47
GUT, vol. 58, 2009, pages 1091 - 1103
HADJIYANNI ET AL., ENDOCRINOLOGY, vol. 150, no. 2, 2009, pages 592 - 599
HELLSTROM ET AL., NEUROGASTROENTEROL MOTIL., vol. 20, no. 6, June 2008 (2008-06-01), pages 649 - 659
HOLST JJ, PHYSIOL REV., 2007, pages 1409 - 1439
KIM; EGAN, PHARMACOL.REV., 2008, pages 470 - 512
KNUDSEN ET AL., J. MED CHEM., vol. 43, 2000, pages 1664 - 1669
MADSEN ET AL., J. MED. CHEM., vol. 50, 2007, pages 6126 - 32
PEARSON ET AL., GENOMICS, vol. 46, 1997, pages 24 - 36
TOLESSA ET AL., DIG. DIS. SCI., vol. 43, no. 10, 1998, pages 2284 - 90
WOJDEMANN ET AL., J CLIN ENDOCRINOL METAB., vol. 84, 1999, pages 2513 - 7
WOJDEMANN ET AL., J. CLIN. ENDOCRINOL. METAB., vol. 84, 1999, pages 2513 - 2517

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10905745B2 (en) 2016-12-09 2021-02-02 Zealand Pharma A/S Acylated GLP-1/GLP-2 dual agonists
US11395847B2 (en) 2016-12-09 2022-07-26 Zealand Pharma A/S Acylated GLP-1/GLP-2 dual agonists
RU2828220C2 (en) * 2019-06-14 2024-10-08 Зилэнд Фарма А/С Pharmaceutical parenteral composition of double agonist glp1/2
CN113966226A (en) * 2019-06-14 2022-01-21 西兰制药公司 Pharmaceutical parenteral compositions of dual GLP1/2 agonists
RU2815643C2 (en) * 2019-06-14 2024-03-19 Зилэнд Фарма А/С Pharmaceutical parenteral composition of double agonist glp1/2
WO2020249778A1 (en) * 2019-06-14 2020-12-17 Zealand Pharma A/S Pharmaceutical parenteral composition of dual glp1/2 agonist
WO2020249782A1 (en) * 2019-06-14 2020-12-17 Zealand Pharma A/S Pharmaceutical parenteral composition of dual glp1/2 agonist
CN113966225A (en) * 2019-06-14 2022-01-21 西兰制药公司 Pharmaceutical parenteral compositions of dual GLP1/2 agonists
US11512065B2 (en) 2019-10-07 2022-11-29 Kallyope, Inc. GPR119 agonists
WO2021174048A1 (en) 2020-02-28 2021-09-02 Kallyope, Inc. Gpr40 agonists
US12264171B2 (en) 2020-02-28 2025-04-01 Kallyope, Inc. GPR40 agonists
RU2838225C1 (en) * 2020-03-16 2025-04-14 НКСЕРА ФАРМА Юкей ЛИМИТЕД Glp receptor agonists
WO2021186169A1 (en) * 2020-03-16 2021-09-23 Heptares Therapeutics Limited Oral glp receptor agonists
CN115666623A (en) * 2020-03-16 2023-01-31 赫普泰雅治疗有限公司 Oral GLP receptor agonists
WO2021186166A1 (en) * 2020-03-16 2021-09-23 Heptares Therapeutics Limited Glp receptor agonists
JP2023517766A (en) * 2020-03-16 2023-04-26 ヘプタレス セラピューティクス リミテッド oral GLP receptor agonist
WO2021198195A1 (en) * 2020-03-30 2021-10-07 Zealand Pharma A/S Agonist combination
WO2021198196A1 (en) * 2020-03-30 2021-10-07 Zealand Pharma A/S Glp-1/glp-2 dual agonists
US11851429B2 (en) 2020-05-19 2023-12-26 Kallyope, Inc. AMPK activators
US11279702B2 (en) 2020-05-19 2022-03-22 Kallyope, Inc. AMPK activators
US11407768B2 (en) 2020-06-26 2022-08-09 Kallyope, Inc. AMPK activators
WO2022175410A1 (en) * 2021-02-18 2022-08-25 Zealand Pharma A/S Composition for treating short bowel syndrome
WO2022268029A1 (en) * 2021-06-21 2022-12-29 广东东阳光药业有限公司 Triple agonist for glp-1, gcg and gip receptors
WO2023031380A1 (en) * 2021-09-03 2023-03-09 Zealand Pharma A/S Dosage regime
IT202200015204A1 (en) * 2022-07-20 2024-01-20 Bioinnova S R L S GLP-2 EXPRESSING MICROALGAE AND RELATED USES
WO2024018037A1 (en) * 2022-07-20 2024-01-25 Bioinnova S.R.L.S. Microalgae expressing glp-2 and uses thereof
CN118146350A (en) * 2024-03-13 2024-06-07 北京泽勤生物医药有限公司 Preparation method and application of GLP-2 peptide analogue

Similar Documents

Publication Publication Date Title
US11395847B2 (en) Acylated GLP-1/GLP-2 dual agonists
EP3551652B1 (en) Glp-1/glp-2 dual agonists
WO2018104558A1 (en) Acylated glp-1/glp-2 dual agonists
WO2018103868A1 (en) Acylated glp-1/glp-2 dual agonists
WO2018104559A1 (en) Glp-1/glp-2 dual agonists
HK40111792A (en) Acylated glp-1/glp-2 dual agonists
CA3043151C (en) Acylated glp-1/glp-2 dual agonists
HK40007709A (en) Acylated glp-1/glp-2 dual agonists
HK40007709B (en) Acylated glp-1/glp-2 dual agonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17821520

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17821520

Country of ref document: EP

Kind code of ref document: A1